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 The objective of this doctoral dissertation research was to develop novel strategies to 
predict and evaluate drug interactions with hepatic bile acid transporters. Sandwich-cultured 
hepatocytes (SCH) and mechanistic pharmacokinetic modeling were employed. Altered 
disposition of the model bile acid taurocholate (TCA) in human SCH due to inhibition of 
multiple transporters was predicted based on the potency of inhibitors [e.g., inhibition constant 
(Ki)] and kinetic parameters of TCA using pharmacokinetic modeling. The accuracy of 
predictions using total and unbound inhibitor concentrations was assessed. The effect of 
bosentan and telmisartan (model inhibitors) was predicted adequately by using intracellular 
unbound concentrations of the inhibitors. In subsequent studies, a simulation-based method was 
proposed to determine the relevant inhibitor concentration when predicting the effect of hepatic 
efflux transporter inhibition. For inhibitors with high plasma protein binding and/or high relative 
inhibition potency, using intracellular unbound rather than total inhibitor concentrations was 
optimal. The utility of this method was evaluated using experimental data from human SCH. To 
circumvent the limitations of individual transporter Ki data, a model-based approach was 
proposed to obtain overall Ki values against each efflux clearance pathway (i.e., biliary and 
basolateral efflux clearance) of TCA in rat SCH. The study design was optimized using 
modeling and simulation to estimate Ki values of troglitazone sulfate (the model inhibitor). 
Using this study design, Ki estimation in different hepatocyte lots, and limitations on the 
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accuracy, were evaluated using simulated data. In addition to inhibition, transporter induction by 
Farnesoid X Receptor agonists was investigated in human SCH. Basolateral efflux and biliary 
clearance values for TCA, determined by pharmacokinetic modeling, were significantly 
increased by the Farnesoid X Receptor agonists, obeticholic acid and chenodeoxycholic acid. 
These studies provided direct functional evidence for transporter induction. Immunoblot analysis 
results suggested that organic solute transporter alpha/beta may be the primary transporter 
responsible for the increase in the basolateral efflux clearance of TCA.   
This research leveraged pharmacokinetic modeling and simulation to integrate and 
interpret in vitro bile acid transport data. The approaches developed and the results detailed in 
this dissertation will improve the accuracy of predictions and mechanistic understanding of drug-
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CHAPTER 1. Introduction 1 
1. General Introduction to the Dissertation 
1.1 Importance of Drug Transporters in Clinical Pharmacology and Drug Development 
Transport proteins (hereafter transporters) are membrane-bound proteins that move 
endogenous compounds (e.g., bile acids) and xenobiotics (e.g., drugs) across biological 
membranes. Transporters can have clinically relevant effects on the pharmacokinetics (PK) and 
pharmacodynamics of a drug in various organs by affecting the absorption, distribution, and 
elimination (Giacomini et al., 2010; Giacomini and Huang, 2013). Transporters are ubiquitously 
expressed in various tissues such as the liver, kidneys, intestine, and blood brain barrier and, 
therefore, play a key role in determining the efficacy and toxicity of drugs in different tissues. 
For example, hepatic uptake transporters determine the exposure of statins in the liver, which is 
the therapeutic target organ (Farmer, 2001). Conversely, drugs can modulate the expression and 
function of transporters through various mechanisms (e.g., inhibition and induction), resulting in 
altered disposition of transporter substrates (Farmer, 2001; Jackson et al., 2016; Zhang et al., 
2017). Because of potential drug-drug interaction (DDI) liability mediated by transporters, 
regulatory agencies in the US (FDA), Europe (EMA), and Japan (PMDA) recommend 
performing in vitro transport assays and even running clinical DDI studies to evaluate 
interactions with transporters for investigational drugs acting as either a substrate or perpetrator. 
                                                          
1Section 4 of this chapter has been published as part of the review by Yang K, Guo C (contributed 
equally), Woodhead JL, St Claire RL 3rd, Watkins PB, Siler SQ, Howell BA, Brouwer KLR. Sandwich-
cultured hepatocytes as a tool to study drug disposition and drug-induced liver injury. J. Pharm. Sci. 2016 




Accordingly, an increasing percentage of new drugs approved between 2003 and 2011 had 
transporter information in the package inserts (Agarwal et al., 2013).  
1.2 Bile Acids and Hepatic Bile Acid Transporters  
The liver is a major organ where transporters are expressed. The liver determines the 
homeostasis of many endogenous compounds, such as bile acids, by regulating their metabolism 
and transport. Bile acids are important components of the bile, and act as lipid solubilizers and 
cell signaling molecules that modulate bile acid homeostasis, hepatic inflammation (Allen et al., 
2011), etc. Bile acids can be cytotoxic at high concentrations (Hofmann, 1999). The hydrophobic 
bile acids, such as lithocholic acid (LCA), chenodeoxycholic acid (CDCA), and deoxycholic acid 
are more cytotoxic than less hydrophobic bile acids, such as cholic acid and ursodeoxycholic 
acid. Bile acids are synthesized primarily in the liver from cholesterol by Cytochrome P450 
cholesterol 7alpha-hydroxylase (CYP7A1), followed by hydroxylation by Cytochrome P450 
sterol 12α-hydroxylase (CYP8B1) (Zhang and Chiang, 2001). Alternatively, bile acids can be 
synthesized in extrahepatic tissues by Cytochrome P450 oxysterol 7α-hydroxylase (CYP27A1) 
followed by hydroxylation by CYP7A1 in the liver (Norlin and Wikvall, 2007). Bile acids 
undergo further conjugation, primarily with taurine or glycine in human (Falany et al., 1994), 
and to a lesser extent, with glucuronide or sulfate moieties. Eventually, bile acids are secreted via 
the bile duct into the small intestine. The most abundant bile acids in serum are 
glycochenodeoxycholic acid, chenodeoxycholic acid (CDCA), and deoxycholic acid in humans 
(Trottier et al., 2011; Ferslew et al., 2015), while hyodeoxycholic acid, cholic acid, alpha or beta-
muricholic acid, and CDCA are most abundant in rat serum(Garcia-Canaveras et al., 2012; Xie et 
al., 2013) Although taurocholic acid (TCA) is not the major bile acid, it is used most commonly 
as a substrate to study bile acid transporters.  
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Hepatic bile acid uptake transporters are expressed on the basolateral membrane 
transporting bile acids from the sinusoidal blood into hepatocytes. The clinically relevant hepatic 
uptake transporters are Solute Carrier (SLC) transporters, including sodium taurocholate 
cotransporting polypeptide (NTCP; encoded by SLC10A1) and organic anion-transporting 
polypeptides (OATPs; SLCOs). Although hepatic uptake usually is the predominating transport 
pathway under normal conditions, bile acids can be effluxed from the hepatocyte into the 
sinusoids through basolateral efflux transporters under cholestatic conditions. These transporters 
include multidrug resistance-associated protein 3 (MRP3; ABCC3) and MRP4 (ABCC4), as well 
as organic solute transporter α/β (OSTα/β; SLC51). Although OSTα/β was reported to be a 
bidirectional transporter in vitro (Ballatori et al., 2005), this transporter primarily acts as an 
efflux transporter in hepatocytes in vivo due to the extracellular and intracellular fluid sodium 
and potassium gradients in hepatocytes (Soroka et al., 2010). Biliary transporters expressed on 
the canalicular membrane of hepatocytes are responsible for bile acid excretion into the bile. The 
bile salt export pump (BSEP, ABCB11) excretes the majority of bile acid species, while  MRP2 
(ABCC2) is responsible for the excretion of sulfated bile acids (Dawson et al., 2009)(Figure 1.1). 
Novel bile acid transporters are still being identified.  
Bile acid transporter-mediated drug interactions have important implications in drug 
safety. Inhibition of efflux transporters is acknowledged as a risk factor for drug-induced liver 
injury (DILI) (Kock et al., 2014). Inhibition of BSEP was one of the mechanisms for 
troglitazone- and bosentan-induced liver toxicity, which led to the withdrawal of troglitazone 
from the market (Yang et al., 2014b) and a black box warning for bosentan (Woodhead JL et al., 
2014). Patients with mutations in the ABCB11 gene that result in impaired BSEP function 
develop liver injury due to hepatic accumulation of toxic bile acids (Jansen and Muller, 2000). In 
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addition, an in vitro study involving more than 600 drugs provided direct evidence for an 
association between BSEP inhibition and hepatotoxicity (Morgan et al., 2013). Simultaneous 
inhibition of basolateral efflux transporters and BSEP is also a contributing factor for the 
development of DILI (Kock et al., 2014). In contrast, inhibition or downregulation of uptake 
transporters serves as a protective mechanism in response to cholestasis (Leslie et al., 2007; 
Meng et al., 2015). Due to the importance of hepatic bile acid transporters, scientific publications 
in this area have been constantly increasing over the past few decades (Figure 1.2).  
1.3 Tools to Study Transporters: In Vitro and In Silico 
Multiple in vitro tools with various levels of throughput and physical relevance can be 
used to study transport kinetics. They can be divided into two general categories: (i) expression 
systems, including inside-out membrane vesicles and cell lines transfected with specific uptake 
or efflux transporters; (ii) whole cells including polarized cell lines, such as Caco-2, and primary 
hepatocytes in suspension or in sandwich culture.   
Transfected cell lines can be used to directly estimate kinetic/inhibition parameters for 
the overexpressed transporter. However, the results of these assays are confounded by the 
expression of endogenous transporters (Ahlin et al., 2009) and may not be suitable for 
compounds with low permeability. Inside-out membrane vesicles are used primarily to study 
efflux transporters, and are suitable for low-permeability compounds. The uptake buffer can 
represent the cytoplasm, and therefore uptake, rather than efflux, of the drug is measured. One 
caveat of this system is relatively high background noise for highly lipophilic compounds as a 
result of nonspecific binding to the membranes (Lai, 2013).  
In contrast, cellular systems can be used to estimate kinetic parameters for specific 
clearance pathways, such as uptake, metabolism, or efflux, as well as the interplay of multiple 
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processes. Primary hepatocytes are more physiologically relevant than other systems for studying 
hepatic transporters. Suspended hepatocytes have been considered the “gold standard” for 
studying hepatic uptake, while sandwich-cultured primary hepatocytes are more suitable for 
studying vectorial transport due to the maintenance of in vivo polarity. A more detailed 
introduction regarding sandwich-cultured hepatocytes will be discussed in the following 
sections.  
Some empirical methods have been developed to predict the role of transporters in the 
interplay with metabolism. The Biopharmaceutics Drug Disposition Classification System 
(BDDCS) are used to predict the role of transporters in PK and DDIs in the context of transport 
and metabolism interplay (Benet, 2009; Shugarts and Benet, 2009; Broccatelli et al., 2012). The 
Extended Clearance Classification System (ECCS) is used to identify major clearance pathways 
using in vitro and physicochemical properties (El-Kattan et al., 2016; Varma et al., 2016).  
Computational models have been developed to predict putative inhibitors and substrates 
of transporters (Ekins et al., 2007; Ali et al., 2017). In general, two approaches have been used, 
including indirect ligand-based methods, such as pharmacophore and quantitative structure–
activity relationship (QSAR) modeling, and direct structure-based approaches, which require 
crystallographic data of the transport protein (Chang et al., 2006). These models are useful in 
screening large numbers of compounds at an early stage.  
PK modeling is a useful tool to analyze, interpret, and integrate transport data. 
Physiologically-based PK (PBPK) models may offer a platform to quantitatively evaluate the 
role of drug transporters and its interplay with metabolism and passive diffusion (Li et al., 2014a; 
Varma and El-Kattan, 2016). Although PBPK modeling and simulations have been successfully 
applied to predict metabolism-based DDIs, the confidence in predicting transporter-mediated 
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drug disposition and DDIs using PBPK models is considered low (Pan et al., 2016). The 
relatively poor model performance could be due to the uncertainty or ambiguity of in vitro 
transporter kinetic parameters, and limited knowledge concerning key factors, such as basic 
transport mechanisms (Pan et al., 2016). To improve the quality of in vitro data analysis, 
mechanistic PK modeling has unique advantages compared to empirical approaches and has 
gained lots of interest. Simcyp In Vitro Analysis Toolkit was developed to analyze in vitro 
transport data using modeling approaches. In addition, application of physiologically-relevant 
whole cell systems will be crucial for generating quality data that can be translated to in vivo. 
2. Challenges in the Estimation of Transport Parameters using Expression Systems  
2.1 Challenges in Estimating Inhibitory Potency 
The inhibitory potency of a compound, which is represented by the half maximal 
inhibitory concentration (IC50) or inhibition constant (Ki), is an important parameter for 
predicting DDIs.  Large variability around this parameter has been reported, raising concerns 
about the predictability of clinical DDIs based on in vitro IC50 data. For example, the IC50 for 
digoxin transport showed up to ~800-fold difference across different labs (Lee et al., 2014).  
A few factors have contributed to the large variability in IC50 data. First, substrate-
dependent inhibition due to multiple binding sites has been reported for P-gp (Martin et al., 
2000), BCRP (Giri et al., 2009), OATP1B1, OATP1B3, and OATP2B1 (Noe et al., 2007; Izumi 
et al., 2013; Shirasaka et al., 2014). In addition, IC50 or Ki values can be dependent on the 
experimental system (Bentz et al., 2013). False positive results have been reported due to 
cytotoxicity using transfected cell lines (Zheng et al., 2010). The actual concentration of the 
compound might be much lower than the nominal concentration due to non-specific binding to 
the incubation apparatus and/or lipid membranes, especially for highly lipophilic compounds. In 
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some cases, Ki values estimated from overexpression systems can be biased by the transporter 
expression level and the substrate affinity (Balakrishnan et al., 2007). In addition, the 
contribution of passive diffusion to the overall transport clearance of the substrate also makes it 
challenging to estimate the true IC50 related to the active uptake/efflux. Conventional methods to 
estimate IC50 using the efflux ratio in Caco-2 cells may introduce bias because the substrates 
inside the cell (intracellular concentrations) interact with efflux transporter while extracellular 
concentrations are measured. Therefore, the efflux ratio does not necessarily represent the efflux 
transporter function. In contrast, model-based approaches can directly reflect the efflux 
transporter function, and therefore provide more accurate estimations (Kishimoto et al., 2016). 
2.2 Challenges in Estimating Transport Clearance Parameters 




      (1) 
where v, [S], and Vmax represents the velocity of transport, the substrate concentration, and the 
maximal velocity, respectively. Km represents the Michaelis-Menten constant, which is the 
substrate concentration at half Vmax. High variability in Vmax and Km have been reported 
(Shirasaka et al., 2008), which may be attributed to the data analysis method and the limitation of 
experimental systems as described below.  
When transfected cell lines are used to estimate kinetic parameters, flux rate across the 
monolayer reflects both uptake and efflux, and does not follow the principles of the Michaelis-
Menten equation. However, traditional methods used the flux rate to estimate Vmax and the 
concentration in the donor chamber (extracellular) to estimate Km. In a study that used different 
monolayers, the Km value for P-gp varied by > 25-fold based on extracellular concentrations 
(Shirasaka et al., 2008), but were within ~2-fold when this data set was analyzed using a 
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compartmental PK model and intracellular concentrations (Tachibana et al., 2010). In addition, 
since Vmax is related to the expression level of the transporter, Vmax generated from different 
experimental systems are not comparable (Harwood et al., 2016).  
2.3 Mechanisms of Inhibition  
Although most DDI predictions assume competitive inhibition, drugs may interact with 
transporters through other reversible mechanisms, such as noncompetitive inhibition, 
uncompetitive inhibition, and mixed inhibition. In addition, there are other types of interaction, 
such as induction (Williamson et al., 2013a), time-dependent inhibition (Shitara et al., 2009), and 
allosteric modulation (Sterz et al., 2009). Generally, the site of interaction is from the same side 
of the membrane domain (cis-inhibition). For example, efflux transporters are inhibited by drugs 
from the cytoplasmic side rather than the extracellular side of the membrane. In contrast, trans-
inhibition has been reported where the transporters are inhibited by drugs from the opposite 
membrane domain. This effect could result from reversible or irreversible mechanisms (Vallejo 
et al., 2006). More details about reversible cis-inhibition are introduced below, and additional 
information about induction will be introduced later. 
Competitive inhibition is most common due to the overlapping substrate and inhibitor 
specificity of transporters. The basic rule is that the binding of the substrate or the inhibitor is 
mutually exclusive. In the presence of inhibitor, the apparent Km of the reaction increases while 
the Vmax remains the same. The relationship can be described in Eq. 2, where [I] represents the 
inhibitor concentration and Ki (also known as the inhibition constant) represents the dissociation 
constant of free transporter and inhibitor from the transporter-inhibitor complex. Noncompetitive 
inhibitors do not affect the binding of substrate to the transporter, meaning Km is not affected, 
but the overall effect is a decrease in the amount of functional transporter, shown as a reduction 
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of Vmax. The relationship is described in Eq. 3. In mixed-type inhibition (Eq. 4), the inhibitor 
decreases Vmax while it may increase or decrease Km. When α=1, mixed inhibition is the same as 
noncompetitive inhibition. Uncompetitive inhibitors only bind to transporter-substrate 
complexes, and are the least common mechanism of reversible inhibition. The overall effect is a 


































                 (5) 
In order to estimate Ki and identify the inhibition mechanism, the system will be 
incubated with at least five different substrate levels that bracket the Km in the presence of at 
least five different inhibitor concentrations that cover the Ki. An incubation time within the linear 
range must be used. Traditionally, the inhibition mechanism is differentiated by visualizing the 
transformed data in a Lineweaver-Burk plot, with 1/[S] and 1/v on the x- and y-axis, 
respectively. Alternatively, models representing different inhibition mechanisms are fit to the 
data using nonlinear regression analysis. The best-fit model is selected based on the goodness-of-
fit, represented by the lowest Akaike’s Information Criteria (AIC) value.  
2.4 Protein Binding and the Implications for Drug-Drug Interactions  
Importance of Unbound Concentration 
Based on the free drug hypothesis, it is generally assumed that only unbound drug 
molecules interact with their protein targets, including transporters (Schmidt et al., 2010). 
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Therefore, knowing the unbound concentration is important. An analysis of >180 drugs approved 
by FDA between 2003 and 2013 showed that the plasma protein binding of one-quarter of the 
drugs were > 99% (Liu et al., 2014). Usually, unbound concentration is calculated as the product 
of the unbound fraction (fu) and the total drug concentration.  
In the blood, drugs bind to various proteins including human serum albumin (HSA), 
alpha 1-acid glycoprotein (AAG), and lipoproteins. Lipophilic and acidic drugs tend to bind to 
HSA (with concentration around 670 µM); basic drugs tend to bind to AAG (with concentration 
around 16 µM). Measurement of plasma fu is relatively straightforward and has been reviewed 
previously (Di et al., 2017). Inside the cell, drugs can partition into the plasma membrane or 
organelle membranes or bind to intracellular proteins including cytosolic fatty acid binding 
protein (Z-fraction), 3a-hydroxy-steroid dehydrogenase (Y-protein), and glutathione-S-
transferase B (ligandin) (Levi and Arias, 1969; Burczynski et al., 1999). In addition, many drugs 
show preferential subcellular organelle sequestration, particularly in lysosomes and mitochondria 
(Zheng et al., 2011). The lysosomal pH is relatively low (~4-5), which is maintained by a Mg2+ 
ATP-dependent proton pump, so lysosomal trapping mostly affects compounds with a basic 
center (pKa>8) (Kaufmann and Krise, 2007). In mitochondria, the electrochemical gradient is the 
main driving force for sequestration as mitochondria exhibit a negative membrane potential of 
~160mV, which attracts the accumulation of lipophilic cations. The accumulation of delocalized 
lipophilic cations in the mitochondria could be 1000-fold higher than that in cytosol (Duvvuri 
and Krise, 2005). In summary, the distribution of drugs in the cell is not homogenous.  
Despite the free drug hypothesis, there is no consensus on which inhibitor concentration 
to use for comparison with IC50 in order to predict DDI potential. For example, with hepatic 
uptake transporters, the  2012 FDA draft guidance suggested using 10×[I]max,total (FDA/CDER, 
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2012), instead of 10×[I]max,unbound, which was proposed in the 2010 ITC whitepaper. [I]max,total and 
[I]max,unbound represent total and unbound maximum systemic plasma concentrations, respectively. 
The EMA guidance published in 2012 recommends using 25×[I]u,inlet,max (EMA, 21 June 2012); 
the FDA guidance published in 2017 recommends using 10×[I]u,inlet,max (FDA/CDER, 2017), 
where [I]u,inlet,max represents unbound maximum plasma concentration at the inlet to the liver. For 
hepatic efflux transporters, the unbound hepatocellular concentration is more relevant than the 
plasma concentration, but no regulatory recommendations are available yet. 
Current Methods to Measure Intracellular Unbound Concentration 
Intracellular unbound drug concentrations are critical determinants of drug interactions 
with therapeutic targets, enzymes, and efflux transporters. The measurement or estimation of 
intracellular unbound concentrations has been reviewed by the ITC (Chu et al., 2013). In general, 
the methods most commonly used to measure or model intracellular unbound concentration are: 
1) homogenization method; 2) temperature method; 3) prediction based on physicochemical 
properties; 4) cytosol isolation method; and 5) compartmental PK modeling. In addition, a new 
technology based on mass spectrometry imaging techniques has been used to measure 
intracellular drug concentrations in vivo (Dollery, 2013), but this method is limited by equipment 
requirements and the high cost.  
In Method 1, the compounds are mixed with homogenized hepatocytes or liver tissue 
followed by equilibrium dialysis, which is the most common practice to obtain fu (Mateus et al., 
2013). Although this method is high throughput and commonly used, it assumes homogenous 
intracellular distribution of drugs without considering subcellular sequestration. In Method 2, 
hepatocytes are incubated with compounds at 4°C for 60 min; intracellular fu is calculated as the 
medium unbound concentration divided by total cellular concentration, assuming complete 
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inactivation of uptake transporters at 4°C and that concentration equilibrium of the unbound drug 
is reached between the medium and hepatocytes(Shitara et al., 2013). In Method 3, the empirical 
relationship between logD7.4 and fu in hepatocytes has been reported by different groups (Austin 
et al., 2005; Yabe et al., 2011). In Method 4, drugs are incubated with hepatocytes to mimic the 
drug distribution process. Then the cytosol is isolated by differential centrifugation of cell lysate 
that has been gently homogenized to avoid breaking subcellular organelles. Following that, the 
total amount and fu of drugs in the cytosol are measured (Pfeifer et al., 2013b). In Method 5, 
compartmental PK models are used to describe the transport process and membrane partitioning 
of transporter substrates, and intracellular unbound concentrations are estimated. This PK 
modeling approach has been applied to analyze data obtained from isolated perfused rat livers 
and MDCK cell lines. Although this method might be more accurate due to its mechanistic 
nature, it is very time-consuming and laborious to generate time-course data for modeling.  
Although Method 1 is high-throughput, a comparison of a data set consisting of 18 
diverse compounds revealed that the fu in human hepatocytes measured using Method 1 was 
generally lower and correlated poorly with that measured by Methods 2 and 3 (Riede et al., 
2017). Although Method 2 and 4 consider subcellular distribution and possibly are more 
accurate, they are not widely utilized due to the resource-intensive nature of these methods.   
To understand the importance of intracellular binding, the distribution of intracellular 
unbound fraction for 29 compounds measured using human or rat primary hepatocytes 
(fu,hepatocyte) was obtained from the literature (Gardiner and Paine, 2011; Mateus et al., 2013; 
Pfeifer et al., 2013b; Treiber et al., 2014; Guo et al., 2016). All the fu,hepatocyte data were measured 
using Method 1 or 4. Measured fu,hepatocyte ranged from 0.00076 to 0.93. The distribution of 
fu,hepatocyte is presented as a histogram in Figure S3.1; 17% (5 out of 29) of the compounds had 
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fu,hepatocyte values smaller than 0.01, whereas 31% (9 out of 29) and 52% (15 out of 29) of the 
compounds had fu,hepatocyte values of 0.01-0.5 and 0.5-1, respectively.  
3.  Indirect Modulation of Hepatic Bile Acid Transporters 
In addition to direct inhibition, transporter function could be modulated through indirect 
mechanisms, such as induction or alteration in localization. Hepatic bile acid transporters are 
regulated by various signaling pathways and nuclear receptors (NRs), with farnesoid X receptor 
(FXR) being the main NR for bile acids (Halilbasic et al., 2013).  
NTCP transcription is regulated by bile acids, cytokines, liver injury/disease, and 
hormones. Although FXR does not bind with the NTCP promoter directly, it induces the 
expression of other factors that repress NTCP expression (Kosters and Karpen, 2008). Other NRs 
involved in NTCP regulation are small heterodimer partner, retinoic acid receptor alpha:retinoid 
X receptor alpha (RARα:RXRα), hepatocyte nuclear factor 4α, and glucocorticoid receptor. A 
FXR-responsive element in the BSEP promoter area has been identified (Ananthanarayanan et 
al., 2001). BSEP expression is upregulated by FXR agonists, and downregulated by 
inflammatory injury and estrogens [reviewed in (Stieger, 2011)]. In addition, RXR and 
membrane lipid composition also affect BSEP function (Paulusma et al., 2009). MRP3 is 
regulated by constitutive androstane receptor (CAR), pregnane X receptor (PXR), vitamin D 
receptor and peroxisome proliferator-activated receptor alpha (PPARα), while MRP4 is induced 
by CAR and PPARα (Wagner et al., 2010). The expression of heterodimeric transporters 
OSTα/OSTβ is induced via FXR and LXR (Dawson et al., 2009). Besides transcriptional 
regulation, transporter trafficking also plays a role in determining the amount of functional 
transporters expressed on the plasma membrane. Trafficking of transporters to and from the 
membrane may involve phosphoinositide 3-kinase, protein kinase C (PKC), and cyclic AMP 
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(Chandra et al., 2005; Stieger et al., 2007; Park et al., 2012). This short-term regulation enables 
hepatocytes to quickly adapt to increased cellular bile acids as a protective mechanism. 
It is challenging to study the induction of transporters due to limited knowledge of 
quantitative relationships between function and mRNA expression. In fact, mRNA expression 
data are highly variable and poorly correlated with the protein expression and function of 
transporters (Ahlin et al., 2009; Thompson et al., 2017). Furthermore, in vivo evidence for 
induction of transporter function is limited, and further studies are warranted.  
4. Sandwich-Cultured Hepatocytes as a Tool to Study Drug Disposition and Drug-Induced 
Liver Injury 
4.1 Introduction of Sandwich-Cultured Hepatocytes (SCH) 
Among many in vitro and in vivo model systems, primary hepatocytes remain the gold 
standard to assess hepatic drug metabolism and transport. Hepatocytes can be isolated from the 
species of interest, including humans, to address species differences in hepatic disposition of 
drugs. Primary hepatocytes express multiple metabolic enzymes and transporters, enabling 
assessment of overall hepatobiliary drug disposition. However, hepatocytes in suspension or 
under conventional culture conditions quickly lose cell polarity and viability, which limits their 
utility (Borlak and Klutcka, 2004; Swift et al., 2010). Culturing hepatocytes between two layers 
of gelled collagen (sandwich configuration) improves morphology and viability of hepatocytes, 
and maintains function for longer periods of time in culture (Dunn et al., 1991; Dunn et al., 
1992). In addition, sandwich-cultured hepatocytes (SCH) regain polarity, allowing proper 
localization of basolateral and canalicular transporters as well as formation of functional bile 
networks (Figure 1.1) (LeCluyse et al., 1994; Liu et al., 1998).  
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When properly cultured, the expression and function of basolateral uptake transporters 
including NTCP and OATPs are maintained over time in human SCH (Hoffmaster et al., 2004; 
Kotani et al., 2011; Bi et al., 2012), whereas down-regulation of Ntcp and Oatp has been 
reported for rat SCH (Liu et al., 1998; Kotani et al., 2011). Upon isolation, hepatocytes lose 
biliary excretory function due to internalization of canalicular efflux transporters (Bow et al., 
2008).  However, canalicular transport proteins [e.g., BSEP/Bsep, P-glycoprotein (P-gp), breast 
cancer resistance protein (BCRP/Bcrp), and MRP/Mrp2] properly localize over time and regain 
excretory function in human and rat SCH (Liu et al., 1998). A schematic representation of 
hepatic transporters in SCH is shown in Figure 1.1. Phase I [e.g., cytochrome P450 (CYP)] and 
phase II [e.g., UDP-glucuronosyltransferase (UGT), sulfotransferase (SULT)] metabolizing 
enzymes also are expressed in SCH, although some enzymes exhibit decreased expression and/or 
function over time in SCH compared to freshly isolated hepatocytes, depending on the culture 
conditions and medium composition (Li et al., 2010; Jacobsen et al., 2011; Tchaparian et al., 
2011). The influence of culture conditions and culture time on the expression and/or function of 
enzymes and transporters in the SCH system have been reviewed in detail elsewhere and is not 
the main focus of this chapter (Swift et al., 2010; De Bruyn et al., 2013; Godoy et al., 2013). 
SCH provide a unique tool to estimate biliary excretion of compounds. Substances 
excreted into bile and accumulated in the canalicular network can be quantified by modulating 
tight junctions using buffer with and without calcium (Liu et al., 1999a; Liu et al., 1999b). 
Therefore, SCH have been used widely to assess hepatobiliary disposition of drugs and 
metabolites, and potential DDIs. Transcriptional and post-translational regulatory machinery are 
well-maintained in SCH, which makes it a suitable model for studying induction and feedback 
regulation of enzymes and transporters in response to compounds or other interventions (Dunn et 
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al., 1992; Jackson et al., 2009). Metabolically competent SCH also have been employed to study 
the pharmacology and toxicology of drugs and hepatically-generated metabolites. Because of the 
essential role of the liver in drug elimination, hepatocytes are often a target of drug-induced 
toxicity. SCH have been used in the assessment of direct cytotoxicity and in mechanistic studies 
to determine perturbations of biological processes and to better understand underlying 
mechanisms of DILI.  
In this chapter, applications of SCH in studying hepatobiliary drug disposition are 
reviewed. First, use of the SCH system to characterize hepatic drug metabolism and transport is 
discussed. Predictions of in vivo drug disposition and clinical DDIs using SCH data combined 
with mechanistic and/or PBPK modeling also are reviewed.  
4.2 Use of SCH in Studying Metabolism 
During drug discovery and development, assessment of metabolism and transport of new 
chemical entities is important to predict clinical exposure and potential DDIs. In this section, the 
use of SCH to study drug disposition is reviewed with a focus on metabolism and hepatobiliary 
transport of compounds and DDIs, and enzyme-transporter interplay. This section also highlights 
the estimation of enzyme- and transporter-mediated intrinsic clearance values using mechanistic 
PK modeling in addition to empirical methods. In vitro-in vivo extrapolation of intrinsic 
clearance and incorporation into PBPK modeling is discussed.  
Metabolism 
SCH have been used to study drug disposition, including hepatic uptake, metabolism and 
biliary excretion. Although human liver microsomes (HLMs), S9 subcellular fractions, and 
primary hepatocytes cultured in monolayers (without extracellular matrix overlay) are used more 
commonly in metabolism studies, SCH are used often when extended incubation times (>24 hr) 
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are needed, after which the viability and function of primary hepatocytes cultured in monolayers 
begin to deteriorate (Swift et al., 2010). The metabolic clearance values of the low clearance 
drugs tolbutamide and warfarin, as well as the high clearance compound 7-ethoxycoumarin, were 
estimated using mathematical modeling after co-incubation with human SCH for 48 hr. (Treijtel 
et al., 2004) (Treijtel et al., 2005). The calculated intrinsic clearance was in accordance with 
literature reports. The advantage of using SCH was demonstrated in another study where DB829, 
the active metabolite of an antitrypanosomal prodrug, was detected only in trace amounts in 
HLMs at the end of the 180-min incubation, but was detected readily in human SCH throughout 
the 24-hr incubation (Generaux et al., 2013). 
Metabolism-Mediated DDIs  
Both inhibition- and induction-mediated DDIs have been studied using SCH. The CYP 
substrates used in these studies generally are selected to penetrate the hepatocytes via passive 
diffusion to eliminate the confounding effect of transporters. Although CYP inhibition has been 
studied primarily using HLMs, a few studies using SCH have been reported. The inhibitory 
effect of tritolide on CYP3A was evaluated by Shen et al (Shen et al., 2014). Both the expression 
and activity (measured by midazolam hydroxylation) of CYP3A in rat SCH were reduced after 
exposure to tritolide for up to 24 hr. Bi et al. reported that the intracellular accumulation of 
buprenorphine and midazolam in human SCH was increased by rifamycin SV due to inhibition 
of CYP3A4 and UGT1A1, which mediate the metabolism of these two victim substrates (Bi et 
al., 2012). SCH allow for longer exposure time, making them suitable for CYP induction studies. 
For example, the activity of CYP3A was assessed in human SCH after incubation with 




4.3 Use of SCH in Studying Hepatobiliary Transport  
Mechanisms of Hepatobiliary Disposition 
Under appropriate culture conditions, SCH express key transporters that are properly 
localized, and therefore, SCH are uniquely advantageous to study the mechanisms of 
hepatobiliary transport of a compound as well as the effects of a compound on hepatobiliary 
transporters. SCH isolated from naturally occurring genetically deficient rodents [e.g., Mrp2-
deficient Wistar rats (TR- rats), Eisai-hyperbilirubinemic Sprague-Dawley rats (EHBR rats)] or 
genetically modified animals with loss-of-function of a specific transporter can be used to 
elucidate the role of that transporter in disposition of the compound (Yue et al., 2011; Zamek-
Gliszczynski et al., 2012). Knockdown of Bcrp using RNA interference in SCH isolated from 
wild-type rats elucidated the role of Bcrp in drug hepatobiliary disposition (Yue et al., 2009; 
Yang et al., 2014a). With human SCH, the role of individual transporters may be evaluated by 
using “specific” transporter inhibitors if they are available, or by modifying the experimental 
conditions (e.g., uptake study in the absence and presence of sodium). However, highly specific 
transport inhibitors and substrates are often lacking. Furthermore, genetically modified animals 
are only available for a few transporters, and loss of function of one transporter may result in 
compensatory changes in other pathways. Therefore, a multi-experimental approach integrating 
SCH data, transfected systems and membrane vesicles can be used to characterize the 
involvement of multiple transporters (Lepist et al., 2014). Understanding the transport 
mechanism(s) could facilitate identification of potential DDIs involving uptake and efflux 
transporters. Previous reviews have discussed the utility of SCH for these types of studies (Swift 
et al., 2010; De Bruyn et al., 2013), and recent reports are discussed below.  
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Yanni et al. (Yanni et al., 2010) identified the hepatic transporters involved in micafungin 
disposition by co-incubation of micafungin with an NTCP inhibitor [taurocholic acid (TCA)], an 
OATP inhibitor (rifampin), BSEP inhibitors (TCA and nefazodone), a BCRP inhibitor 
(GF120918), as well as a P-gp and MRP2 inhibitor (cyclosporine A). Mohamed et al. (Mohamed 
and Kaddoumi, 2014) reported that the disposition of tacrine, which was approved for treatment 
of Alzheimer’s disease, was mediated by Octs, Mrp2 and P-gp by using rat SCH and chemical 
inhibitors. A similar approach to elucidate the responsible hepatobiliary transporters for 17α-
hydroxyprogesterone caproate and its effect on BA transporters has been reported (Sharma et al., 
2013). One caveat with this type of approach is that these “specific” inhibitors may have other 
effects on metabolism and/or transport. To overcome this issue, transporter assays using 
transfected cells can be used to confirm findings from the SCH studies. For example, disposition 
of a natural product timosaponin b2 (TB2) was characterized using rat SCH and involvement of 
specific transporters was confirmed using human OATP1B1- and OATP1B3-expressing HEK-
293 cells and membrane vesicles isolated from cells expressing human MRP2 and BCRP (Sheng 
et al., 2015). 
In addition to drugs, the disposition of endogenous compounds has been studied using 
SCH. For example, amyloid-β (Aβ) hepatic disposition was studied in human SCH since Aβ 
accumulation contributes to Alzheimer's disease (Mohamed and Kaddoumi, 2013). Aβ was 
found to be taken up primarily by low-density lipoprotein receptor-related protein-1 (LRP), and 
effluxed by P-gp. This finding indicates that enhancement of Aβ hepatic clearance via LRP1 and 
P-gp induction could be a novel therapeutic approach for the prevention and treatment of 
Alzheimer’s disease. Toxic compounds such as arsenic also have been studied in human SCH. 
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The results suggest that arsenic basolateral efflux prevails over biliary excretion, and is mediated 
at least in part by MRPs, most likely MRP4 (Roggenbeck et al., 2015). 
Estimation of Transport Clearance 
In the estimation of uptake clearance, hepatocytes in suspension generally are preferred 
due to the ease of use (De Bruyn et al., 2011; Williamson et al., 2013b) and concerns regarding 
down-regulation of uptake transporters in rat SCH (Kotani et al., 2011). Uptake transporter 
function in human SCH, however, appears to be well maintained under appropriate culture 
conditions (Kotani et al., 2011; Bi et al., 2012). Recent evidence suggests that cryopreserved 
hepatocytes cultured in sandwich configuration are a more feasible research tool to evaluate in 
vitro transport parameters than suspended hepatocytes, which may be affected by membrane 
leakage caused by cryopreservation (Kimoto et al., 2012). To distinguish active uptake from 
passive diffusion, hepatocytes can be co-incubated with an OATP inhibitor if the active uptake is 
mediated mainly by OATP. For example, rifampicin SV (100 µM) was reported to block OATP 
function in OATP-transfected cell lines and human SCH without affecting the passive diffusion 
(Vavricka et al., 2002; Bi et al., 2012). Alternatively, active uptake in SCH can be determined by 
the difference in uptake in the absence and presence of sodium if the active uptake is governed 
primarily by NTCP. Or uptake can be measured at low temperatures (e.g., 4°C compared to 
37°C). However, reduced uptake at 4°C might be an artificial effect of a more rigid cell 
membrane, and thus, active uptake using this approach may be overestimated (Webborn et al., 
2007). 
In SCH, the biliary efflux clearance and biliary excretion index (BEI) can be calculated 
using B-CLEAR® technology and Equations 6-8 (Liu et al., 1999a). A detailed description of B-
CLEAR® technology, including an overview of the advantages and limitations, has been 
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published by Swift et al (Swift et al., 2010). Essentially, the accumulation of compound in 
cells+bile canaliculi and the accumulation of compound in cells can be differentiated by 
modulating the tight junctions using Ca2+-containing and Ca2+-free Hank's balanced salt solution 
(HBSS), respectively. The utility of SCH data for extrapolation from in vitro biliary clearance to 












×100%                  (8) 
CLb, app, in vitro and CLb, int, in vitro represent in vitro apparent biliary clearance and in vitro intrinsic 
biliary clearance, respectively. BEI represents biliary excretion index, which is the fraction of 
compound accumulated in the bile compartment relative to the total accumulation in cells plus 
bile.  
Use of the SCH assay to categorize compounds as low, intermediate or high biliary 
clearance was first reported by Liu et al.(Liu et al., 1999b), and has been confirmed by numerous 
investigators and reviewed by De Bruyn et al. and Swift et al.(Swift et al., 2010; De Bruyn et al., 
2013). Pan et al.(Pan et al., 2012) evaluated the biliary clearance of 110 compounds from 
Novartis exhibiting different permeability properties using the rat SCH model. The predicted 
biliary clearance from rat SCH correlated well with in vivo rat data, except for underestimation 
of biliary clearance for compounds with extremely low passive permeability and metabolism. 
The rank order of biliary clearance from human SCH data corresponded with clinical data for 
compounds with low to high biliary clearance (Ghibellini et al., 2007), despite modest 
underestimation of the absolute values (by 50-80%). The underestimation might be due to the 
decreased activity of uptake transporters depending on the culture conditions, and use of 
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compound concentrations in the medium (Eq. 6) instead of the intracellular concentrations (Eq. 
7) to predict biliary clearance. A more recent paper compared the human SCH estimated biliary 
clearance with clinical data and showed good agreement for drugs with no significant active 
hepatic uptake (absolute average fold error [AAFE] = 1.6). For drugs showing significant active 
uptake in human SCH, the predictability of biliary clearance was improved when scaled based on 
the extended clearance term (AAFE = 2.0), which incorporated sinusoidal uptake along with a 
global scaling factor for active uptake and the canalicular efflux clearance (Kimoto et al., 2017). 
More precise estimates of biliary clearance parameters for in vitro-in vivo scaling are discussed 
in greater detail in the “Mechanistic and PBPK Modeling” section.  
To improve the precision of biliary clearance predictions using both rat and human SCH, 
the following approaches have been reported. The correlation between in vitro and in vivo biliary 
clearance is improved by using unbound plasma concentrations in the estimation of in vivo 
biliary clearance (Fukuda et al., 2008). Moreover, the difference between in vivo intrinsic biliary 
clearance and predicted intrinsic biliary clearance from the SCH data using Eq. 7 is smaller than 
the difference between in vivo apparent biliary clearance and predicted apparent biliary clearance 
from SCH data based on Eq. 6 (Nakakariya et al., 2012). Therefore, in vitro intrinsic biliary 
clearance (calculated based on intracellular concentrations instead of medium concentrations) is 
more reflective of in vivo biliary clearance (Nakakariya et al., 2012). In addition, quantitative 
proteomic approaches have been applied to improve biliary clearance predictions, as discussed in 
detail in the “Mechanistic and PBPK Modeling” section. 
Basolateral efflux clearance can be estimated by preloading SCH with a substrate, and 
measuring the medium concentration at the end of the efflux phase. Ferslew et al. estimated 
basolateral efflux clearance of enalaprilat (generated in hepatocytes after incubation of rat SCH 
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with enalapril) based on the cumulative amount of enalaprilat effluxed into the medium and 
intracellular enalaprilat concentrations over the efflux period (Ferslew et al., 2014). The 
functional importance of MRP4 in the basolateral efflux of enalaprilat was demonstrated by 
using the pan-MRP inhibitor MK-571 in rat SCH, and confirmed in membrane vesicles prepared 
from HEK-293 cells overexpressing human MRP4. Of note, direct estimation of basolateral 
efflux clearance using this approach was possible because biliary excretion of enalaprilat is 
negligible. For compounds that undergo extensive biliary excretion, mechanistic modeling is 
necessary to deconvolute basolateral efflux, biliary excretion, and flux from the bile 
compartment to the medium, as discussed in the “Mechanistic and PBPK Modeling” section. 
Transporter-Mediated DDIs 
Transporter-based drug-drug and drug-bile acid interactions may have significant 
toxicological implications. SCH are a physiologically representative, organ-specific, whole-cell 
system that is well suited to elucidate the relative contribution of individual transporters to 
overall clearance, and to estimate the net effect of inhibition/induction at multiple sites. Both 
acute (direct and indirect) and long-term effects on transporters have been studied in SCH.  
Pfeifer et al. elucidated the sites and mechanisms of DDIs between ritonavir (perpetrator) 
and 99mTc–mebrofenin (victim substrate) using human SCH coupled with modeling and 
simulation of clinical data (Bi et al., 2012; Pfeifer et al., 2013a). Ritonavir decreased 99mTc–
mebrofenin uptake without changing the BEI of 99mTc–mebrofenin, despite the fact that ritonavir 
had been reported to inhibit MRP2, which mediates the biliary excretion of 99mTc–mebrofenin. 
These in vitro findings were consistent with the clinical observation that single or multiple doses 
of ritonavir increased 99mTc–mebrofenin systemic exposure without significantly changing 
biliary recovery of 99mTc–mebrofenin. SCH data revealed that intracellular ritonavir 
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concentrations after clinical doses were not high enough to inhibit MRP2 based on data 
generated in membrane vesicles for 99mTc–mebrofenin transport by MRP2. 
Unlike direct inhibition of transporters, indirect modulation of transporters is under-
appreciated and the relevant studies using SCH are still limited. Powell et al. reported post-
translational regulation of OATP1B3 by the PKC activator, phorbol-12-myristate-13-acetate 
(PMA). This mechanism was revealed by the fact that pre-treatment of SCH with PMA inhibited 
OATP1B3 function while co-incubation with PMA did not (Powell et al., 2014). Kruglov et al. 
reported that the type II inositol 1,4,5-trisphosphate receptor modulates Bsep activity in rat SCH 
through post-translational regulation (Kruglov et al., 2011). The important role of N-
glycosylation of ATP-binding cassette transporters on transport activity was established using rat 
SCH (Zhang et al., 2005; Draheim et al., 2010). The induction of transporters after long-term 
incubation (>24 hr) also was studied in SCH (Annaert et al., 2001; Turncliff et al., 2004; Lee et 
al., 2008), and has been reviewed in (Swift et al., 2010). More recent examples studied the effect 
of nuclear receptors on transporter induction. Up-regulation of transporter mRNA expression in 
response to prototypical activators of PXR, aryl hydrocarbon receptor, and CAR were reported in 
mouse SCH (Noel et al., 2013). It was reported that dexamethasone treatment induced the 
expression and function of Mrp2 in rat SCH. Studies using human SCH showed that FXR 
agonists up-regulated the mRNA expression of bile acid efflux transporters (Jackson et al., 2016; 
Zhang et al., 2017).  
4.4 Use of SCH in Studying Enzyme-Transporter Interplay 
The complexity of DDI predictions may be increased further by the interplay between 
enzymes and transporters. Many compounds interact with enzymes and transporters 
simultaneously. For example, cyclosporine inhibits CYP3A4, and multiple transporters including 
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P-gp and OATP1B1. Gemfibrozil and gemfibrozil glucuronide inhibit CYP2C8 and OATP1B1 
(Neuvonen et al., 2006). Moreover, the parent compound and derived metabolites may have 
similar or opposite effects on transporters and enzymes. For drugs that are metabolized 
extensively, the presence of metabolic capacity in SCH enables the simultaneous evaluation of 
parent and metabolite effects without prior knowledge regarding the metabolites. This capability 
is very beneficial, especially in the early stages of drug discovery when metabolite identification 
has not been conducted and purified metabolites are not available. A few examples are discussed 
below.  
For drugs that are rapidly metabolized and the metabolites are not transporter inhibitors, 
the intracellular concentration of the parent compound might not be high enough to inhibit efflux 
transporters. For example, cilexetil (CIL) exhibited potent BSEP inhibition based on membrane 
vesicle assays.  However, BSEP inhibition by CIL was not observed in human SCH after 120-
min exposure, which might be due to the metabolic elimination of CIL in SCH (Fukuda et al., 
2014). In this case, the membrane vesicle data led to a false positive prediction of BSEP 
inhibition. Sometimes metabolites are more potent inhibitors of transporters, such as troglitazone 
sulfate compared to troglitazone. In this case, data from a metabolism-deficient system could 
lead to false-negative results (Yang et al., 2014b). The interplay between formation and excretion 
of troglitazone metabolites was studied in rat SCH lacking Bcrp and Mrp2 by Yang et al. using 
RNA interference techniques to knock down Bcrp in SCH prepared from TR- rats which are 
Mrp2 deficient (Yang et al., 2014a). In some cases, only the metabolites are transporter 
inhibitors.  For example, although estradiol and bilirubin do not inhibit MRP2, pre-exposure of 
rat SCH to estradiol and bilirubin decreased the biliary excretion of 5-(and 6)-carboxy-2',7'-
26 
 
dichlorofluorescein, a MRP2 substrate, which could be attributed to inhibition by the generated 
metabolites of estradiol and bilirubin (Nakanishi et al., 2012). 
4.5 Use of SCH Data in Mechanistic and PBPK Modeling   
PBPK modeling is a useful tool to predict the PK of novel compounds in the systemic 
circulation and target organs. Successful PBPK models depend on reliable estimates of 
compound-specific information (e.g., clearance, tissue partition coefficients, and the rate and 
extent of absorption). SCH have been used to estimate clearance values that are incorporated into 
PBPK models. The methods to estimate in vitro clearance using SCH, and to extrapolate from in 
vitro to in vivo clearance values are discussed below.  
In vitro intrinsic uptake and efflux clearance values have been estimated using empirical 
methods, as described in the previous sections. The apparent clearance value determined from 
SCH data may be comprised of more than one clearance pathway. Despite this limitation, 
estimated clearance values generated by empirical/static approaches can represent useful prior 
information to guide the experimental design for mechanistic modeling and simulation, and 
generally requires a relatively small number of data points.  
Mechanistic PK models have been developed to deconvolute apparent uptake and efflux 
clearance values and obtain more accurate estimates. Linear kinetics are assumed and the 
clearance terms (rather than Vmax and Km) are used because a single, low concentration of 
substrate typically is studied. To estimate the kinetic parameters, multiple time points during 
both the uptake and efflux phase are required. Depending on the permeability of the substrate, 
passive diffusion clearance could be estimated solely from 37°C data. The kinetic parameters 
estimated could be used to perform sensitivity analyses and Monte Carlo simulations, which can 
help identify key model input parameters. Depending on the model structure and complexity, the 
27 
 
published mechanistic PK models are classified into three categories. The model structures and 
exemplar experimental protocols are shown in Figure 1.3; the model output parameters, 
assumptions and applications of each model are summarized in Table 1.1. 
Model I 
This model is the simplest for the SCH system (Figure 1.3A). Three compartments 
represent the medium, cell, and bile, with passive diffusion, active uptake, biliary efflux, and 
metabolism processes included. Key kinetic parameters include intrinsic passive diffusion 
clearance (CLint, pass); intrinsic uptake clearance (CLint, uptake), and intrinsic biliary clearance (CLint, 
bile). Basolateral efflux is assumed to be negligible. When significant metabolism is observed, 
intrinsic metabolic clearance (CLint, met) is set to the unbound intrinsic clearance value determined 
in HLMs. To generate the experimental data, SCH are first pre-incubated with standard Hank’s 
balanced salt solution (HBSS), Ca2+-free HBSS, or standard HBSS containing rifamycin SV, 
followed by incubation with the substrate. Substrate uptake is terminated at different time points, 
and the intracellular and medium concentrations of the substrate are measured. This model has 
been applied to estimate the in vitro intrinsic clearance for OATP substrates (Jones et al., 2012; 
Jones et al., 2013; Li et al., 2014b).  
Model II  
Unlike Model I where CLint, met is fixed to a pre-determined value, CLint, met is fitted to 
metabolite(s) concentration-time data in Model II. In addition, intrinsic basolateral efflux 
clearance of metabolite (CLint, BL, metabolite) is included rather than assuming passive diffusion. 
Kflux, metabolite, which accounts for the “flux” of metabolite from the canalicular compartment into 
the buffer, also is incorporated (Oshio and Phillips, 1981; Phillips et al., 1982; Boyer et al., 
1988). In this model, it is assumed that only metabolites undergo efflux into bile or medium. 
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(Figure 1.3B). The experimental protocol is similar to that of Model I except that the pre-
incubation phase only consists of two conditions (HBSS and Ca2+-free HBSS), and both parent 
and metabolite(s) concentrations are measured. Lee et al. fitted this model to concentration-time 
data for troglitazone and metabolites [troglitazone sulfate, glucuronide, and quinone] in rat and 
human SCH (Lee et al., 2010). This model has been used to characterize the contribution of 
individual clearance pathways to the disposition of mycophenolic acid (MPA) and MPA 
glucuronide (MPAG) (Matsunaga et al., 2014), and the inhibitory potency of cyclosporine on 
each pathway in human SCH (Matsunaga et al., 2015). The modeling results suggest that 
cyclosporine A inhibits both basolateral uptake and biliary efflux clearance of MPAG without 
changing the conversion of MPA to MPAG.  This mechanism explains the cyclosporine A-
mediated decrease in enterohepatic circulation of MPAG and lower systemic exposure of MPA 
and MPAG in humans.  
Model III  
Model III is more suitable for compounds with minimal passive diffusion that are not 
extensively metabolized (Figure 1.3C), such as rosuvastatin (RSV) and TCA. To obtain an 
accurate estimate of basolateral efflux, a novel uptake and efflux protocol is used, which includes 
an uptake phase followed by an efflux phase where serial samples are obtained. Uptake, biliary, 
and basolateral efflux clearance values for RSV, 3H-TCA, and d8-TCA were estimated from rat 
and human SCH data (Pfeifer et al., 2013c; Yang et al., 2015; Guo et al., 2016).  The impact of 
impaired clearance of RSV and 3H-TCA were simulated, and predicted perpetrator effects on d8-
TCA disposition were compared with experimental observations.  
In this experimental design, a few practical factors need to be considered for determining 
the maximum incubation time. Most of the time, the uptake phase is extended beyond the linear 
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range to attain steady-state intracellular conditions, which reduces the error in certain parameter 
estimates observed with shorter incubation times. However, exposure to Ca2+-free HBSS for 
more than 30 min increases cytotoxicity (Swift et al., 2010). Therefore, after pre-incubation with 
Ca2+-containing or Ca2+-free HBSS for 10 min, SCH are incubated with Ca2+-containing HBSS 
during the uptake phase. The uptake phase should be limited to 20 min in Ca2+-containing HBSS 
to avoid resealing of tight junctions in SCH pre-incubated with Ca2+-free HBSS (Pfeifer et al., 
2013c).  
Scaling Methods 
In vivo intrinsic clearance is a key parameter for PBPK models that can be extrapolated 
from in vitro clearance using the following scaling methods. The simplest and most 
straightforward approach for scaling up is based on hepatocellularity and liver weight as 
described previously (Houston, 1994) and reviewed by Poulin and Haddad (Poulin and Haddad, 
2013). Scaling with physiological parameters works well for metabolic clearance. However, this 
approach leads to an underprediction of CLint, uptake and an overprediction of CLint, bile using 
human SCH (Jones et al., 2012). Underprediction of uptake may occur when CLint, BL is 
disregarded in the model, or when uptake transporters are down-regulated in vitro compared to in 
vivo (Jacobsen et al., 2011). Overprediction of CLint, bile may occur due to the absence of 
enterohepatic recirculation, and/or ignoring Kflux in the mechanistic model (Jones et al., 2012). 
Clearly, over-simplification of the model structure can lead to over- or under-prediction of 
parameters. To address the misprediction of in vivo parameters, Jones et al. determined 
compound-specific scaling factors (SFs) by comparing in vivo clearance to in vitro clearance 
data from human SCH (Jones et al., 2012); geometric mean SFs for intrinsic unbound uptake 
clearance (CLint, u, uptake), intrinsic unbound biliary clearance (CLint, u, bile) and intrinsic unbound 
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passive diffusion clearance (CLint, u, pass) of seven OATP substrates were reported as 58, 0.061, 
and 1, respectively (Jones et al., 2012). These SFs have been used in the in vitro-in vivo 
extrapolation of other OATP substrates such as telmisartan (Jones et al., 2012; Li et al., 2014b). 
A similar approach has been applied to estimate SFs for CLint, uptake of glyburide, pravastatin, and 
repaglinide (Varma et al., 2012; Varma et al., 2013b; Varma et al., 2014). Li et al. developed a 
single set of empirical SFs by simultaneously modeling data for the same seven OATP 
substrates; these authors reported SFs of 55 for CLint, u, uptake, 0.019 for CLint, u, bile, and 0.092 for 
CLint, u, pass (Li et al., 2014c). The difference in the estimated SF for CLint, u, pass between the two 
studies (1 vs. 0.092) could be due to different approaches for model fitting [the SF for intrinsic 
unbound metabolic clearance (CLint, u, met) was not estimated by Jones et al. because CLint, u, met 
was not identifiable, but this SF was fitted in the work of Li et al.] 
The approach described above relies on intravenous PK data to estimate empirical SFs. If 
intravenous data are not available, the in vitro-in vivo extrapolation could be facilitated by 
information regarding transporter abundance. Absolute quantification of transporter expression 
by mass spectrometry was first reported by Terasaki and colleagues based on the assumption that 
all expressed protein is localized on the membrane and, therefore, functional (Shawahna et al., 
2011; Agarwal et al., 2012; Sakamoto et al., 2013; Uchida et al., 2013; Sakamoto et al., 2015). 
This technique has been advanced by the work of Lai et al.(Kimoto et al., 2012) (Li et al., 2009; 
Li et al., 2010; Bi et al., 2012), Unadkat et al. (Shawahna et al., 2011; Agarwal et al., 2012), and 
more recently by Artursson et al. (Vildhede et al., 2015), and Galetin et al. (Badee et al., 2015). 
Intrinsic clearance values estimated using the approaches detailed above can be used 
directly in PBPK models (Jamei et al., 2009). Alternatively, the overall intrinsic clearance values 
can be combined with liver blood flow and protein binding data to estimate hepatic clearance 
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based on the well-stirred or parallel-tube models of hepatic disposition (Wilkinson, 1987). PK 
profiles have been predicted successfully for numerous compounds including statins, sartans, 
mebrofenin, pafuramidine, glyburide, and repaglinide using PBPK models that incorporated 
clearance values estimated from SCH (Bi et al., 2012; Jones et al., 2012; Varma et al., 2012; 
Pfeifer et al., 2013c; Jamei et al., 2014; Li et al., 2014a; Varma et al., 2014) (Yan et al., 2012) 
(Jones et al., 2013; Varma et al., 2013a; Li et al., 2014a). 
5. Project Rationale and Specific Aims  
The objective of this dissertation research was to develop in vitro and in silico approaches 
to increase our ability to predict and evaluate drug-bile acid interactions mediated by inhibition 
or induction of hepatic transporters. This work provided frameworks and innovative approaches 
to improve the prediction of transporter-mediated disposition of drugs and bile acids, which has 
important implications for safe and efficacious pharmacotherapy. To achieve this goal, 
mechanistic PK modeling combined with data generated in SCH were used. 
5.1 Rationale for Aim #1  
Transporter inhibition assays have been adopted by the pharmaceutical industry and 
included in regulatory guidelines to predict DDIs. However, many false negative or positive 
predictions have been reported using routine assay methods (Vaidyanathan et al., 2016). 
Explanations for inaccurate predictions include simultaneous inhibition of multiple transporters, 
inaccurate estimation of inhibitor concentrations at the site of action (due to protein binding and 
subcellular distribution), and uncertainty in Ki or IC50 measurements.   
Many drugs are dual inhibitors of uptake and efflux transporters, such as telmisartan and 
bosentan (Morgan et al., 2013). The net effect of inhibition of multiple transporters depends on 
the relative contribution of each transporter to the overall clearance in addition to the inhibitory 
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potency. Mechanistic PK modeling of data from human SCH is useful in assessing the relative 
contribution of each clearance pathway to overall drug disposition (Pfeifer et al., 2013c; 
Matsunaga et al., 2014; Yang et al., 2015), and predicting transporter-mediated disposition and 
DDIs in vivo (Jones et al., 2012; Jones et al., 2013; Li et al., 2014b). However, none of these 
publications have combined inhibition data from transfected systems with kinetic data from 
human SCH to predict the net effects of an inhibitor.  
Currently, there is no consensus on which inhibitor concentration is the most relevant and 
effective data input for predicting the interaction with hepatic efflux transporters. A comparison 
of prediction accuracy using various types of intracellular inhibitor concentrations, including 
total or unbound concentration in cell or cytosol, will be needed. In addition, a classification 
system would be helpful to determine a priori the benefit of measuring intracellular unbound 
fraction (fu,cell,inhibitor) for accurate predictions. Therefore, Aim #1 (Chapter 2 and 3) focused on 
developing frameworks to predict altered bile acid disposition due to the inhibition of multiple 
transporters, and to assess the relevant inhibitor concentration for hepatic efflux transporters. 
TCA was chosen as the model bile acid since TCA is the standard substrate for most bile acid 
transporter inhibition assays.   
5.2 Rationale for Aim #2 
Inhibition constants (such as Ki or IC50) for individual transporters are important 
parameters in predicting DDIs and DILI. Generally, inhibition constants are obtained from 
expression systems. Despite their ease of use, the quality of these data are limited by a few 
factors: transporter expression levels may not be physiologically relevant and membrane 
composition of these systems may not be ideal; the relative contribution of each transporter to 
the overall substrate clearance is often unknown for most substrates. These issues could be 
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avoided by using a physiologically-relevant holistic system, SCH, combined with PK modeling. 
Mechanistic PK modeling of SCH data allows for the assessment of inhibition potency against 
each clearance pathways (e.g., biliary and basolateral efflux), which represents the inhibition 
potency against multiple transporters in the same clearance pathway. The mechanism of 
inhibition is another critical factor that influences the impact of inhibition. Noncompetitive 
inhibition may lead to greater bile acid accumulation and an increased potential for toxicity 
compared to competitive inhibition, as shown by the troglitazone sulfate example (Woodhead JL 
et al., 2014). To identify the inhibition mechanism using expression systems, multiple substrate 
and inhibitor concentrations are needed, which is resource intensive. Since the intracellular 
concentrations of the substrate and inhibitor change over time in SCH, it is possible to identify 
the inhibition mechanism against the biliary clearance by using fewer concentrations of the 
substrate and inhibitor. To achieve this goal, sufficient data input is needed to allow for accurate 
parameter estimation. The purpose of Aim #2 (Chapter 4) was to provide an optimized study 
design for, and assess the practicality of, estimating the inhibition potency and identifying 
inhibition mechanism against multiple transport pathways using PK modeling and data from 
SCH. Troglitazone sulfate was chosen as the model inhibitor, which exhibits multiple inhibition 
mechanisms towards different bile acid efflux transporters. TCA was employed as the model 
substrate. 
5.3 Rationale for Aim #3 
Intracellular bile acids can bind with FXR, which increases gene transcription to enhance 
bile acid efflux and decrease bile acid uptake by the liver (Ananthanarayanan et al., 2001; Lee et 
al., 2006). FXR is a promising novel drug target to treat metabolic and chronic liver diseases 
because of its role in regulating bile acid homeostasis. Obeticholic acid (OCA), an analogue of 
34 
 
CDCA, is the first-in-class FXR agonist, and has been approved for the treatment of primary 
biliary cholangitis. Studies using human SCH showed that OCA and CDCA treatment for 72 hr 
increased mRNA expression of the basolateral efflux transporter OSTα/β and the canalicular 
transporter BSEP. Plasma bile acid concentrations in cholestatic patients are increased (Keppler, 
2011; Chen et al., 2013), which may be due to increased hepatic basolateral efflux or decreased 
hepatic uptake and/or biliary excretion of bile acids. However, direct functional evidence for the 
induction of bile acid efflux transporters (i.e., OSTα/β and BSEP) by FXR agonists is lacking 
both in vitro and in vivo. This information will provide mechanistic rationale for FXR as a 
therapeutic target for the treatment of cholestatic diseases by reducing bile acid burden in 
hepatocytes. In addition, exploration of the molecular mechanism will corroborate the observed 
alterations in function. Studies outlined in Aim #3 (Chapter 5) were designed to evaluate the 
changes in the function and expression of hepatic bile acid transporters by FXR agonists, OCA 
and CDCA. TCA again was chosen as the substrate to study bile acid transporter function.  
Aim #1. Develop an integrated approach to accurately predict the effect of hepatic 
transporter inhibition on the hepatobiliary disposition of bile acids.  
Hypothesis: Altered bile acid disposition due to inhibition of multiple transporters can be 
predicted by integrating experimental and mechanistic PK modeling approaches. Total or 
unbound concentrations in the cell or cytosol may lead to different prediction results. For certain 
inhibitors, it is optimal to measure intracellular unbound fraction of inhibitor (fu,cell,inhibitor) and 
use intracellular unbound inhibitor concentration rather than total concentration when predicting 
their inhibitory effects. This benefit can be determined a priori based on the PK characteristics of 
the inhibitor and victim substrate. 
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1.a. Characterize the hepatobiliary disposition (basolateral uptake and efflux, canalicular efflux) 
of taurocholate in protein-containing medium using human sandwich-cultured hepatocyte 
data and mechanistic PK modeling.  
1.b. Predict the effect of bosentan and telmisartan on taurocholate disposition by integrating 
individual IC50 data and the relevant inhibitor concentrations into a mechanistic PK model.  
1.c. Assess the impact of changes in fu,cell,inhibitor on the prediction of efflux transporter-mediated 
drug-bile acid interactions for various theoretical inhibitors using simulation; validate the 
simulation results with experimental data. 
Aim #2. Estimate inhibition constants against bile acid efflux clearance values using PK 
modeling of data from sandwich-cultured hepatocytes.    
Hypothesis: Using PK modeling of sandwich-cultured hepatocyte data and a single dose of 
inhibitor and substrate, Ki values of the inhibitor against the biliary and basolateral efflux 
clearance pathways of the substrate can be estimated simultaneously, and the inhibition 
mechanism can be identified. Modeling and simulation can assist the development of an optimal 
study design for this purpose.  
2.a. Develop an optimal study design to estimate the Ki of the model inhibitor, troglitazone 
sulfate, against biliary and basolateral efflux clearance pathways of taurocholate in rat 
sandwich-cultured hepatocytes using mechanistic PK modeling and simulation. Distinguish 
the inhibition mechanism of troglitazone sulfate against the biliary clearance based on the 
best-fit model of the kinetic data.  
2.b. Assess the practicality of using this optimal study design in different lots of rat hepatocytes.  
Aim #3. Evaluate the induction of bile acid efflux transporters in human sandwich-cultured 
hepatocytes by FXR agonists. 
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Hypothesis: Treatment of FXR agonists, obeticholic acid and chenodeoxycholic acid, for 72 hr 
increases the function and protein expression of bile acid efflux transporters. The functional 
changes can be reflected by taurocholate clearance values estimated by mechanistic PK 
modeling.  
3.a. Assess the hepatobiliary disposition (basolateral uptake and efflux, canalicular efflux) of 
taurocholate in human sandwich-cultured hepatocytes after 72-hr treatment with obeticholic 
acid and chenodeoxycholic acid using mechanistic PK modeling.  
3.b. Quantify the protein expression of bile acid transporters in human sandwich-cultured 
hepatocytes after 72-hr treatment with obeticholic acid and chenodeoxycholic acid.  
Chapters 2-5 focus on the use of mechanistic PK modeling and simulation as tools to 
elucidate and predict drug interactions mediated by the inhibition and induction of hepatic bile 
acid transporters using sandwich-cultured hepatocytes. Chapter 6 summarizes findings from this 
dissertation research and proposes a number of future directions for the projects. The outcomes 
of this dissertation research will facilitate the prediction of drug-drug interactions and drug-











Table 1.1. Output parameters, assumptions, and applications of mechanistic PK modeling to 












 No basolateral efflux 
 No Kflux 
 CLint, met same as estimated from HLMs 
Applications: 
 Substrates without basolateral efflux 
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 No passive diffusion 
 Only metabolites effluxed into bile 
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protocol 
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Kflux, first-order rate constant for flux from bile networks into buffer; CLint, uptake, intrinsic uptake 
clearance;  CLint, pass, intrinsic passive diffusion clearance; CLint,bile, intrinsic biliary clearance; 
CLint,met, intrinsic metabolic clearance; CLint, BL, intrinsic basolateral efflux clearance; CLint, uptake, 
parent, intrinsic uptake clearance of parent;  CLint, uptake, metabolite, intrinsic uptake clearance of 
metabolite; CLint,bile, metabolite, intrinsic biliary clearance of metabolite; CLint, BL, metabolite, intrinsic 
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basolateral efflux clearance of metabolite; Kflux, metabolite, first-order rate constant for flux from 

























Figure 1.1. Scheme illustrating the polarized expression of transporters in human sandwich-
cultured human hepatocytes.  
Three adjacent hepatocytes with interconnecting canalicular spaces sealed by tight junctions (red 
rectangles) are shown. Important ATP-binding cassette (ABC) transport proteins are depicted by 
blue solid arrows denoting the direction of transport. Solute carrier (SLC) transporters are 
depicted with black double arrows. Uptake transporters in the basolateral (sinusoidal) membrane 
include sodium taurocholate co-transporting polypeptide (NTCP); organic anion transporter 2 
(OAT2) and OAT7; organic cation transporter 1 (OCT1); and organic anion transporting 
polypeptide 1B1 (OATP1B1), OATP1B3 and OATP2B1. The heteromeric organic solute 
transporter (OSTα/β) is also depicted on the basolateral membrane.  Efflux transporters 
expressed in the hepatocyte basolateral membrane include multidrug resistance-associated 
protein 3 (MRP3), MRP4 and MRP6. Canalicular (apical) efflux pumps include MRP2, breast 
cancer resistance protein (BCRP), bile-salt export pump (BSEP), MDR1 P-glycoprotein (P-gp), 



















Figure 1.2. Number of PubMed publications with “hepatic” and “bile acid transporter” in the 






















































Figure 1.3. Schematic diagram depicting the mechanistic pharmacokinetic models (left) and 
experimental protocols (right) in sandwich-cultured hepatocytes. (A) Model I, uptake studies 
were conducted in the presence of standard HBSS, Ca2+-free HBSS, or standard HBSS 
containing rifamycin SV. (B) Model II, uptake studies were conducted in the presence of 
standard HBSS or Ca2+-free HBSS. (C) Model III, uptake and efflux studies were conducted in 
the presence of standard HBSS or Ca2+-free HBSS.  
In the model schemes (left), dashed boxes represent the sampling compartments. X, V, and C 
denote the mass of substrate, compartmental volume, and substrate concentration, respectively. 
Subscripts on mass, volume, and concentration terms denote the corresponding compartment in 
the model scheme, superscripts represent the presence or absence of Ca2+ in the pre-incubation 
and efflux buffer. X in parentheses represents experimental measurements. Output parameters 
include: intrinsic uptake clearance (CLint, uptake), intrinsic passive diffusion clearance (CLint, pass), 
intrinsic biliary clearance (CLint, bile), intrinsic metabolic clearance (CLint, met), intrinsic basolateral 
efflux clearance (CLint, BL), first-order rate constant for flux from bile networks into buffer (Kflux), 
intrinsic uptake clearance of parent (CLint, uptake, parent),  intrinsic uptake clearance of metabolite 
(CLint, uptake, metabolite), intrinsic biliary clearance of metabolite (CLint,bile, metabolite), intrinsic 
basolateral efflux clearance of metabolite (CLint, BL, metabolite), and first-order rate constant for flux 
from bile networks into buffer of metabolite (Kflux, metabolite). 
In the experimental protocols diagram, the white boxes represent incubation with Ca2+-free or 
standard HBSS. Grey shaded boxes represent inclusion of the substrate in standard HBSS during 
the uptake phase. Black boxes represent a 1-min wash with Ca2+-free or standard HBSS. The 
sampling times and incubation length are shown in this diagram as an example, but need to be 
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CHAPTER 2. Prediction of Altered Bile Acid Disposition due to Inhibition of Multiple 
Transporters: An Integrated Approach using Sandwich-Cultured Hepatocytes, 
Mechanistic Modeling and Simulation 2 
Introduction 
Transporters play a critical role in the absorption, distribution, and elimination of many 
drugs and endogenous compounds, such as bile acids. Transporter-mediated drug-bile acid 
interactions may have significant toxicological implications, such as troglitazone- and bosentan-
induced hepatotoxicity due to inhibition of the bile salt export pump (BSEP) (Woodhead JL et 
al., 2014; Yang et al., 2014). Transporter inhibition assays have been adopted by the 
pharmaceutical industry or included in the recent regulatory guidelines to predict drug-drug 
interactions (FDA/CDER, 2012). However, the static method, based on the ratio of total plasma 
maximum concentration (Cmax) and 50% inhibitory concentration (IC50) or inhibition constant 
(Ki) of the inhibitor, may not accurately predict the hepatic disposition of victim substrates. 
Limitations associated with the static method may explain the lack of cholestatic liability of 
some MRP2 and BSEP inhibitors (Dawson et al., 2012; Pfeifer et al., 2013a). To accurately 
translate transporter inhibition data (i.e. IC50 or Ki) to the prediction of hepatocellular exposure 
of victim substrates, a number of factors should be considered.  
                                                          
2This chapter has been published as C Guo, K Yang, KR Brouwer, RL St. Claire, and KLR Brouwer (2016) 
Prediction of Altered Bile Acid Disposition Due to Inhibition of Multiple Transporters: An Integrated Approach 
Using Sandwich-Cultured Hepatocytes, Mechanistic Modeling, and Simulation, J Pharmacol Exp Ther, 358(2):324-
333; DOI: https://doi.org/10.1124/jpet.116.231928. Reprinted with permission of the American Society for 
Pharmacology and Experimental Therapeutics and is presented in the style of that journal. All rights reserved.   
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First, hepatic bile acid exposure is regulated by hepatic uptake transporters [e.g. sodium 
taurocholate co-transporting polypeptide (NTCP) and organic anion-transporting polypeptides 
(OATPs)], as well as canalicular (e.g. BSEP) and basolateral efflux transporters [e.g. multidrug 
resistance-associated protein 3 (MRP3) and MRP4]. Often, inhibitors of efflux transporters also 
inhibit uptake transporters, which may exert protective effects (Leslie et al., 2007). However, the 
static model based on inhibition data from over-expression systems considers uptake and efflux 
as isolated processes. To overcome this limitation, mechanistic pharmacokinetic modeling 
coupled with data from sandwich-cultured hepatocytes have been used to deconvolute the 
relative contribution of various clearance pathways to the disposition of rosuvastatin, 
mycophenolic acid, and 3H-TCA (Pfeifer et al., 2013c; Matsunaga et al., 2014; Yang et al., 
2015). Transporters are expressed and properly localized in the sandwich-cultured hepatocyte 
system, which can be used to assess the function of multiple transporters (Yang et al., 2016). 
Thus, this cellular model is uniquely suited to evaluate the interplay of multiple transport 
pathways and predict the net effect due to inhibition of multiple transporters on the hepatic 
disposition of victim substrates. 
Secondly, the presence of protein in plasma is an important physiological factor. 
However, albumin at physiological concentrations (e.g., 4% bovine serum albumin; BSA) 
(Doherty et al., 2006; Wolf et al., 2008) has not been added routinely into in vitro experimental 
systems, such as membrane vesicles, to study transporter-based interactions and assess IC50 or Ki 
values. In addition, according to the “free drug hypothesis”, the inhibitory effect is driven by the 
local unbound concentration of inhibitor, which is the cytosolic unbound inhibitor concentration 
([I]u,cyt) for efflux transporters, and the medium unbound inhibitor concentration ([I]u,med) for 
uptake transporters (Smith et al., 2010). Some high-throughput methods have been used to 
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measure cellular total and unbound inhibitor concentrations ([I]t,cell and [I]u,cell, respectively) 
(Mateus et al., 2013). However, the isolation of cytosol and measurement of cytosolic total and 
unbound inhibitor concentrations ([I]t,cyt and [I]u,cyt, respectively) adds complexity (Pfeifer et al., 
2013b). Thus, [I]t,cyt or [I]u,cyt has not been adopted routinely into the prediction of efflux 
transporter-based drug interactions. The necessity of measuring the cellular unbound fraction of 
inhibitor (fu,cell,inhibitor)  and/or the cytosolic unbound fraction of inhibitor (fu,cyt,inhibitor) needs to be 
assessed.  
The purpose of this study was to develop an integrated approach to predict altered bile 
acid disposition mediated by inhibition of multiple transporters in sandwich-cultured human 
hepatocytes (SCHH), with a focus on taurocholic acid (TCA), a prototypical bile acid. TCA is 
generally not metabolized and is commonly used in BSEP and NTCP assays since its transport 
mechanism is well characterized. First, the hepatobiliary disposition of deuterium-labeled TCA 
(d8-TCA) was characterized in the presence of 4% BSA and pharmacokinetic parameters were 
estimated using mechanistic pharmacokinetic modeling. Total hepatocellular concentrations 
(Ct,Cells) were identified as the most sensitive model output according to sensitivity analysis. The 
effect of model inhibitors, i.e. telmisartan and bosentan, on TCA Ct,Cells was predicted based on 
medium and intracellular inhibitor concentrations (i.e., [I]t,cell, [I]u,cell, [I]t,cyt and [I]u,cyt, 
separately) and bile acid transporter inhibition data. The predictive performance of the model 
was evaluated by comparing the simulation results with experimental data and calculating the 
average fold error (AFE). To determine the necessity of measuring fu,cell,inhibitor for future studies, 
sensitivity analyses of fu,cell,inhibitor values for the model inhibitors and a set of theoretical 
inhibitors were performed. Based on the simulation results, a framework was proposed to help 
guide future study design.  
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Materials and Methods 
Materials 
All chemicals were purchased from Sigma-Aldrich (St. Louis, MO) unless otherwise 
stated. BioCoatTM cell culture plates and Matrigel® were obtained from BD Biosciences (San 
Jose, CA). QualGroTM Seeding Medium and QualGroTM Hepatocyte Culture Medium were 
obtained from Qualyst Transporter Solutions (Durham, NC). d8-TCA, d4-TCA (internal standard 
for d8-TCA), telmisartan, d3-telmisartan (internal standard for telmisartan), bosentan, and 
ambrisentan (internal standard for bosentan) were obtained from Toronto Research Chemicals 
(ON, Canada). OmniPur® Bovine Serum Albumin (BSA; Fraction V, Heat Shock Isolation) was 
purchased from Thomas Scientific (Swedesboro, NJ). Pierce bicinchoninic acid Protein Assay 
was obtained from Thermo Fisher Scientific Inc. (Rockford, IL) and the LDH Cytotoxicity 
Detection Kit was purchased from Roche Diagnostics (Indianapolis, IN).  
Sandwich-Cultured Human Hepatocytes (SCHH) 
B-CLEAR®-HU Transporter CertifiedTM cryopreserved human hepatocytes (Lot 
numbers: HUM4045, HUM4061B, and HUM4059 purchased from Triangle Research Labs, 
Durham, NC) were seeded in QualGroTM Seeding Medium at a density of 0.4×106 cells/well in 
24-well BioCoatTM plates and 1.75×106 cells/well in 6-well BioCoatTM plates, and cultured in a 
sandwich configuration (overlaid with Matrigel®) in QualGroTM Hepatocyte Culture Medium as 
previously reported (Swift et al., 2010).  Donors included one Caucasian male, one Caucasian 
female and one Hispanic female ranging in age from 2 to 44 years old with a body mass index 





Uptake and Efflux Studies of d8-TCA in SCHH 
Uptake and efflux studies of d8-TCA were performed in SCHH as reported previously 
with minor modifications (Pfeifer et al., 2013c). Briefly, on day 6 of culture, SCHH seeded in 
24-well plates were pre-incubated with standard (Ca2+-containing) or Ca2+-free (Ca2+/Mg2+-free 
buffer containing EGTA) Hanks’ balanced salt solution (HBSS) for 10 min. Incubation with 
standard HBSS maintains the integrity of the tight junctions, while incubation with Ca2+-free 
HBSS disrupts the tight junctions, allowing the contents in the bile canaliculi to be washed into 
the medium (B-CLEAR® technology, Qualyst Transporter Solutions, Durham, NC). Following 
pre-incubation, the uptake phase was initiated by treating the SCHH with dosing solution (1 μM 
d8-TCA in 0.3 mL/well standard HBSS, with 4% BSA) for up to 20 min. At the end of the uptake 
phase, the dosing solution was removed, and the SCHH were washed twice with standard or 
Ca2+-free HBSS at 37°C for 1 min, and incubated with the third application of buffer for a 15-
min efflux. Accumulation of d8-TCA in Cells+Bile (standard HBSS) and Cells (Ca
2+-free HBSS) 
during uptake (2, 5, 10, and 20 min) and efflux (2, 5, 10, and 15 min) phases was determined by 
terminal sampling of triplicate wells at each time point. During the efflux phase, incubation 
buffer also was collected at 2, 5, 10, and 15 min. At the end of incubation, the hepatocytes were 
washed with ice-cold standard HBSS three times and the samples were stored at −80 °C for 
future analysis.  
Determination of Kinetic Parameters for d8-TCA using Mechanistic Modeling 
A model scheme incorporating linear uptake and efflux clearance was adopted (Pfeifer et 
al., 2013c; Yang et al., 2015) and was fit to d8-TCA Cells+Bile, Cells, and incubation medium 
total mass-time data from three individual SCHH experiments (Fig. 2.1A). The model fitting was 
performed with Phoenix WinNonlin, v6.3 (Certara, St. Louis, MO) using the stiff estimation 
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method and a power model to account for residual error. Differential Equations 1 to 5 describe 
the changes in the amount of TCA in the different compartments in this model.  






 + KFlux×Xt,Bile − CLUptake×Ct,Buffer
+ − KWash×Xt,Buffer
+      XBuffer
+        ° = Xdose 
(1) 




 = (CLBL+ CLBile)×Ct,Cells
− − CLUptake×Ct,Buffer
− − KWash×Xt,Buffer
−              XBuffer
−        ° = Xdose 
(2)  





+or−  −  (CLBL+ CLBile)×Ct,Cells
+or−                                                  XCell
+or− ° = 0   (3) 
Mass in Bile (standard HBSS): 
dXt,Bile
dt
 = CLBile×Ct,Cells 
+ −  KFlux×Xt,Bile                                                                               XBile
       ° = 0   (4) 










                                                                                          XCells+Bile
° = 0   (5) 
where Ct,Cells represents the total intracellular concentration, and was calculated as XCells/VCells; 
VCells was calculated and fixed using the protein content of each preparation and a value of 7.4 
μL/mg protein (Pfeifer et al., 2013c; Yang et al., 2015); “+” and “-“ refer to Ca2+-containing 
(standard HBSS) and Ca2+-free HBSS, respectively; Xt,Cells represents the total amount in Cells; 
Xt,Cells+Bile represents the total amount in Cells+Bile; Xt,Bile represents the total amount in Bile; 
Ct,Buffer represents the total Buffer concentration; VBuffer was set as a constant (0.3 mL); CLUptake 
represents total uptake clearance; CLBL represents total basolateral efflux clearance; CLBile 
represents total biliary clearance; and KFlux represents the first-order rate constant that describes 
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the flux from bile networks into the medium due to periodic contraction of the bile canalicular 
networks (Pfeifer et al., 2013c)(Oshio and Phillips, 1981; Phillips et al., 1982; Lee et al., 2010). 
Clearance units (µL/min/mg protein) were converted to mL/min/g liver based on the protein 
content in liver tissue (90 mg protein/g liver) (Sohlenius-Sternbeck, 2006). To represent the 1-
min wash step, Kwash was activated for 1min at the end of the 20-min uptake phase using an if-
then statement. Kwash was fixed at 1x10
4 min-1, which was sufficient to eliminate the d8-TCA 
from the buffer compartment based on simulations. Initial parameter estimates were obtained 
from previous reports for 3H-TCA (Yang et al., 2015).  
Sensitivity Analyses of Model Output 
Sensitivity analyses were conducted using Berkeley-Madonna v.8.3.11 to identify the 
most sensitive SCHH model output with respect to changes in clearance (CL). Different model 
outputs measured in the SCHH experiment, including the (A) total concentration of TCA in Cells 
(Ct,Cells), (B) total amount in Cells+Bile (Xt,Cells+Bile), (C) total amount in Bile (Xt,Bile), (D) ratio of 
the total amount of TCA in Cells to the total amount of TCA in Cells+Bile (Xt,Cells/Xt,Cells+Bile), 
(E) ratio of the total amount of TCA in Bile to the total amount of TCA in Cells (Xt,Bile/Xt,Cells), 
and (F) ratio of the total amount in Bile to the total amount in Cells+Bile (Xt,Bile/Xt,Cells+Bile), were 
simulated throughout the time course assuming CLUptake and CLEfflux were inhibited by 0- to 0.99-
fold. CLEfflux was defined as CLBile+CLBL, assuming CLBile and CLBL were impaired to the same 
extent. The simulated fold-changes of the model output values at steady state (120 min) were 
plotted against the fraction of inhibition of CLUptake and CLEfflux in a 3-D fashion using SigmaPlot 
v.11, Systat Software Inc (San Jose, California). The fraction of inhibition was calculated as 
(CL-CLinhibitor)/CL, where CL and CLinhibitor represent the clearance in the absence and presence 
of inhibitor, respectively. A higher fraction of inhibition means more potent inhibition.  
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Determination of Cellular and Cytosolic Total and Unbound Concentrations of Inhibitors 
([I]t,cell, [I]t,cyt, [I]u,cell, and [I]u,cyt, respectively) 
SCHH seeded in 6-well plates were pre-incubated with Ca2+-free HBSS for 10 min, 
followed by a 20-min incubation with dosing solution of model inhibitors (1 and 10 μM of 
telmisartan, or 0.8 and 8 μM of bosentan in standard HBSS with 4% BSA). After the incubation, 
cells were washed with ice-cold HBSS three times and stored at −80°C for future analysis. All 
the incubations in this study were performed at 37°C.  
Cells were fractionated as reported previously with minor modification (Pfeifer et al., 
2013b). Briefly, hepatocytes from the same treatment group were pooled and homogenized by 
passing the cells in fractionation buffer through a 27g needle 20 times to disrupt the cell 
membranes. The resultant cell lysate was subject to 10,000g centrifugation for 10 min at 4°C to 
isolate cytosol (supernatant) from other cell debris. The protein content of cell lysate was 
determined by Pierce biocinchoninic acid Protein Assay. The LDH activity of each fraction (i.e. 
cell lysate, cytosol and suspended pellet) was measured using an LDH cytotoxicity detection kit 
to reflect LDH recovery from cytosol. Glucose-6-phosphatase, succinate dehydrogenase, and 
acid phosphatase activity of each fraction were measured to assess microsomal, mitochondrial, 
and lysosomal contamination, respectively. The percentage of the organelle-specific enzyme 
activity measured in each fraction was calculated in comparison to the whole lysate to assess 
recovery. The unbound fraction (fu) was determined by equilibrium dialysis as previously 
reported (Pfeifer et al., 2013b). Briefly, triplicate aliquots of samples (dosing solution, cell lysate 
and cytosol) were loaded into a 96-well equilibrium dialysis apparatus (HTDialysis, LLC; Gales 
Ferry, CT) and incubated at 37°C for 8 hours with shaking, which was sufficient to achieve 
equilibrium for most compounds (Banker et al., 2003). The fu was back-calculated based on 
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Equation 6 to account for dilution during the homogenization and fractionation process as 







         (6) 
where D represents the dilution factor. 
The total mass of inhibitors in cell lysate and cytosol samples was measured. Cellular 
concentrations were calculated by dividing the mass by the estimated cellular volume of 7.4 
μL/mg protein (Pfeifer et al., 2013c; Yang et al., 2015); cytosolic concentrations were calculated 
by dividing the mass by the estimated cytosolic volume, assuming cytosolic volume represents 
70% of cellular volume (Grunberg et al., 2009). Unbound inhibitor concentrations ([I]u) were 
calculated as the product of total inhibitor concentration ([I]t) and fu. 
Simulation of Inhibitor Effects on TCA Disposition and Comparison with Experimental 
Results 
d8-TCA Ct,Cells were measured after the following treatments: a 10-min pre-incubation of 
SCHH with telmisartan (1 or 10 μM) or bosentan (0.8 or 8 μM) in Ca2+-free HBSS with 4% 
BSA, followed by a 10-min co-incubation with d8-TCA (1 μM) and telmisartan or bosentan in 
standard HBSS with 4% BSA. TCA Ct,Cells after 10-min uptake were simulated using Equations 




⁄ )+ 0.3×CLUptake (1+
[I]u,med
IC50,OATP1B1 












⁄ )                                                                                             (10) 
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where CLUptake,Inhibitor, CLBL,inhibitor, and CLBile,inhibitor represent the CLUptake, CLBL, and CLBile of 
TCA in the presence of inhibitors, respectively; [I]u,med represents the unbound concentration of 
inhibitor in the medium; [I]cell represents the cellular inhibitor concentration, and different types 
of cellular concentration were used in the simulation, including [I]t,cell, [I]u,cell, [I]t,cyt, [I]u,cyt 
(obtained as described in the previous section; values are shown in Table 2.3). The mean IC50 
values for each transporter in Table 2.1 were used with the assumptions that NTCP and OATPs 
contribute 70% and 30%, respectively, to CLUptake (Shitara et al., 2003; De Bruyn et al., 2014), 
BSEP mediates CLBile (Noe et al., 2002; Chandra and Brouwer, 2004; Hayashi et al., 2005), and 
CLBL is governed by MRP3 (Zhang et al., 2003) or MRP4 (Rius et al., 2006). Since the relative 
contribution of MRP3 and MRP4 is unknown, two extremes were simulated assuming MRP3 
(Equation 8) or MRP4 (Equation 9) contributes 100% to CLBL. Monte Carlo simulations of 40 
individuals were performed 10 times using parameter estimates and the associated variance 
(Table 2.2); clearance was assumed to be normally distributed. The fold changes in the TCA 
Ct,Cells in the presence vs. the absence of inhibitors were calculated and compared between 
predicted and observed results. Arithmetic mean and 95% confidence intervals of the fold 
changes were reported.  The precision of the prediction was evaluated using the average fold 






Number of predictions         (11) 
Sensitivity Analyses of Model Input 
The sensitivity of fu,cell,inhibitor, a compound-specific parameter for telmisartan and 
bosentan, on model output (TCA Ct,Cells) was evaluated. Monte Carlo simulations were 
performed to predict the fold changes in the TCA Ct,Cells at steady state (120 min) using 
parameters and the associated variance in Table 2.2, and Equations 1-5 and 7, 8, 10, where 
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[I]cell=[I]t,cell×fu,cell,inhibitor. Different fu,cell,inhibitor values (0.02-1) were used in the simulations. 
[I]t,cell and [I]u,med in SCHH incubated with telmisartan (1 or 10 μM) and bosentan (0.8 or 8 μM) 
were obtained from Table 2.3, as described above.  
           Furthermore, to generalize the sensitivity analysis of fu,cell,inhibitor to a broader range of 
inhibitors, TCA Ct,Cells at steady state (120 min) in the presence of theoretical inhibitors with 
different ([I]t,cell/IC50) values (ranging from 0.5 to 60) were simulated assuming fu,cell,inhibitor=1 or 
0.02, respectively. In these simulations, IC50 represented the inhibitory potency against efflux 
transporters, and CLBL and CLBile were assumed to be inhibited to the same extent. All 
simulations were performed with and without 50% inhibition of CLUptake.  
Bioanalysis 
Lysis solution [500 µL of 70% methanol/30% water containing internal standard (25 nM 
d4-TCA, d3-telmisartan, or ambrisentan)] was added to each well of previously frozen 24-well or 
6-well plates containing study samples. Plates were shaken for ~15 min and the cell lysate 
solution was filtered, evaporated to dryness and reconstituted. Medium samples (100 µL) were 
extracted with 300 µL of 100% methanol containing internal standard, filtered, evaporated, and 
reconstituted. Standards and quality control samples were prepared by adding a known amount 
of standards into a blank cell plate or medium followed by the same sample processing methods 
with test samples. d8-TCA samples were reconstituted in 60% methanol/40% water containing 10 
mM ammonium acetate and analysed by liquid chromatography with triple quadrupole mass 
spectrometry (LC-MS/MS) using a Shimadzu binary high performance liquid chromatography 
(HPLC) system (Columbia, MD) and Thermo Electron TSQ® Quantum Discovery MAX TM 
(Waltham, MA) with an Ion Max ESI source using negative electrospray ionization mode. 
Samples (10 μL) were injected onto a 100×1.0mm Hypersil GoldTM C18 column (Thermo 
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Scientific, Bellefonte, PA). The mobile phase was methanol/water with 0.5 mM ammonium 
acetate at a flow rate of 50 μL/min. The transitions monitored (parent m/z > product m/z) were 
522 > 128 and 518 > 124 for d8-TCA and d4-TCA. The calibration curve range was 0.5-100 
pmol/well. Telmisartan samples were reconstituted in 70% methanol/30% water with 0.1% 
formic acid and analysed by the same LC-MS/MS system using positive electrospray ionization 
mode. The mobile phase was methanol/water with 0.1% formic acid at a flow rate of 50 μL/min. 
The transitions monitored were 515.2 > 276.2 and 518.2 > 279.2 for telmisartan and d3-
telmisartan, respectively. The calibration curve range was 0.01-10 pmol/well.  Bosentan samples 
were reconstituted in 60% methanol/30% water with 0.1% formic acid and analysed by LC-
MS/MS using a Shimadzu binary HPLC system (Columbia, MD) and Applied Biosystems API-
3000 mass spectrometer operated in positive electrospray ionization mode. Samples (10 μL) 
were loaded onto a 100×1.0 mm Hypersil GoldTM C18 column (Thermo Scientific, Bellefonte, 
PA). The mobile phase was acetonitrile/water with 0.2% formic acid. The transitions monitored 
were 522.3 > 202.2 for bosentan and 379.1 > 303.1 for ambrisentan. The calibration curve range 
was 0.05-50 pmol/well. Acceptance criteria for % accuracy of back calculated values was 15-
20%. TCA accumulation in cell lysate was corrected for nonspecific binding to the BioCoatTM 
plate without cells.  
Results 
Hepatobiliary Disposition of d8-TCA in SCHH 
The model scheme depicted in Fig 1A, and Equations 1-5, were used to describe SCHH 
data (TCA in Cells+Bile, Cells, and incubation medium) from three human livers. Data were 
analyzed as three independent data sets and were well described by the mechanistic model 
(individual fits are not shown). The mean (±S.E.M.) data and simulated mass-time profiles 
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generated using the mean of best-fit parameter estimates from the three SCHH data sets (Table 
2.2) are presented in Fig. 2.1B. After 20-min uptake, TCA Ct,Cells was 5.6 μM. The mean kinetic 
parameters and the associated variance estimated by fitting the differential Equations 1-5 to TCA 
mass-time data from three independent SCHH preparations are presented in Table 2.2. The 
estimated total CLUptake of TCA was approximately one order of magnitude greater than total 
CLBile and total CLBL estimates; TCA CLBile was approximately 2-fold greater than CLBL. These 
parameter estimates were used in the subsequent simulations. 
Sensitivity Analyses of Model Output 
To identify a model output that was sensitive to impairment in both CLUptake and CLEfflux, 
the simulated fold changes in different endpoints of the SCHH assay (at steady state) were 
plotted against the fraction of inhibition of CLUptake and CLEfflux in Fig. 2.2, where CLEfflux = 
CLBL+CLBile. The most sensitive model output to both CLUptake and CLEfflux of TCA was Ct,Cells. 
Ct,Cells decreased to 0.01-fold of baseline when CLUptake was inhibited by 99% and CLEfflux was 
not inhibited, and increased to approximately15-fold of baseline when CLEfflux was inhibited by 
99% and CLUptake was not inhibited. Other endpoints were only sensitive to either CLUptake (e.g., 
Xt,Cells+Bile) or CLEfflux (e.g., Xt,Bile, Xt,Bile/Xt,Cells and Xt,Bile/Xt,Cells+Bile) and the fold changes were 
less pronounced. Therefore, the TCA Ct,Cells was chosen as the model output in the subsequent 
simulations to reflect the altered hepatobiliary disposition of TCA in the presence of inhibitors.  
Determination of Cellular and Cytosolic Total and Unbound Concentrations of Inhibitors 
After 20-min incubation with SCHH, the total and unbound concentrations of telmisartan 
and bosentan in medium, whole cell lysates, and cytosol were measured; the results are reported 
in Table 2.3. The cytosol was isolated with ~100% recovery (based on the LDH assay; data not 
shown) and low contamination of subcellular organelles (3% recovery of the enzyme marker for 
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microsomal contamination; 5% recovery of the enzyme marker for mitochondrial 
contamination). As shown in Table 2.3, telmisartan was highly bound in the whole cell lysate 
and cytosol (fu,cell,inhibitor=0.09-0.13 and fu,cyt,inhibitor=0.05-0.08); the cytosolic unbound telmisartan 
concentrations were only 5.3-7% of the total concentrations in the cell. The unbound fraction of 
bosentan was higher than telmisartan (fu,cell,inhibitor=0.22-0.41 and fu,cyt,inhibitor=0.12); the cytosolic 
unbound bosentan concentration was 11% of the total concentration in the whole cell. More than 
one-half of the amount of telmisartan (62%-70%) and bosentan (58%-63%) in the whole cell 
lysate was recovered in the cytosol. Considering that cytosolic volume represents ~70% of the 
cellular volume (Grunberg et al., 2009), the cytosolic and cellular total concentrations were 
similar.  
Comparison of Simulated and Observed TCA Disposition in the Presence of Inhibitors 
The fold changes in the TCA Ct,Cells in the presence of inhibitors (telmisartan and 
bosentan) vs. in the absence of inhibitors were simulated and compared to experimental results 
(Table 2.4). Monte Carlo simulations were performed for 40 individuals and repeated 10 times 
using either Equation 8 or Equation 9 assuming either MRP3 or MRP4 mediated the basolateral 
efflux of TCA. The simulation results were similar and therefore, only the simulations based on 
MRP3 inhibition were presented, since MRP3 expression was reported to be higher than MRP4 
expression in human liver and hepatocytes (Vildhede et al., 2015; Wisniewski et al., 2016). In 
the prediction of telmisartan’s effect on TCA Ct,Cells, the AFE of simulations using [I]u,cell  and 
[I]u,cyt was 1.0 and 0.99, respectively. The 95% confidence interval of the simulation results 
overlapped with the range of observed data. When [I]t,cell  and [I]t,cyt were used in the simulation, 
TCA Ct,Cells was over-predicted and the AFE was 1.4 and 1.3, respectively. In the prediction of 
bosentan’s effect, the mechanistic model slightly over-predicted the fold change for TCA Ct,Cells, 
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with an AFE of 1.2-1.3, no matter which inhibitor concentration was used. According to the 
simulations (Figure S2.1), telmisartan-induced changes in TCA Ct,Cells increased as the uptake 
phase was extended. After a 30-min uptake phase, the simulated TCA Ct,Cells for telemisartan 
based on [I]t,cell was 3-fold of the simulation based on [I]u,cyt. 
Sensitivity Analyses of Model Inputs 
Since the use of [I]u or [I]t affected the simulation of TCA Ct,Cells differently for 
telmisartan and bosentan, sensitivity analysis of fu,cell,inhibitor for telmisartan and bosentan was 
performed by simulating TCA Ct,Cells using [I]t,cell of telmisartan and bosentan and various 
fu,cell,inhibitor values (0.02-1) (Table 2.3). Simulated TCA Ct,Cells at steady state were expressed as 
the mean and standard deviation of fold changes over baseline (without inhibitors) (shown in 
Fig. 2.3). The TCA Ct,Cells was sensitive to changes in fu,cell,inhibitor for telmisartan but not for 
bosentan at both the low and high dosing concentrations. At the low dosing concentration, the 
mean fold change in the TCA Ct,Cells increased from 0.8 to 2.5 when the fu,cell,inhibitor for 
telmisartan changed from 0.02 to 1; the mean fold change in the TCA Ct,Cells increased from 0.8 
to 1 when the fu,cell,inhibitor for bosentan changed from 0.02 to 1. At the high dosing concentration, 
the mean fold change in the TCA Ct,Cells ranged from 0.9 to 4 when the fu,cell,inhibitor for telmisartan 
changed from 0.02 to 1; the mean fold change ranged from 0.8 to 1.5 when the fu,cell,inhibitor for 
bosentan changed from 0.02 to 1. (Fig. 2.3).  
To explore the differential sensitivity of TCA Ct,Cells to fu,cell,inhibitor for different inhibitors, 
the TCA Ct,Cells in the presence of a set of theoretical inhibitors with various ([I]t,cell/IC50) values 
were simulated using fu,cell,inhibitor=1 and 0.02 (Fig. 2.4). For inhibitors with the same ([I]t,cell/IC50) 
value, if the inhibitor exhibited no intracellular binding (i.e., fu,cell,inhibitor=1), the simulated fold 
change in the TCA Ct,Cells was greater than when the inhibitor exhibited extensive intracellular 
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binding (i.e., fu,cell,inhibitor=0.02). As the ([I]t,cell/IC50) value increased, the difference in simulated 
TCA Ct,Cells between fu,cell,inhibitor =1 and 0.02 increased. For inhibitors with ([I]t,cell/IC50) >1, the 
predicted TCA Ct,Cells when fu,cell,inhibitor =1 was more than twice of the predicted TCA Ct,Cells 
when fu,cell,inhibitor =0.02. These relationships were the same with or without 50% inhibition of 
CLUptake (data not shown).  
Discussion 
In this study, an integrated approach was developed to predict the net effect of inhibition 
of multiple transporters on the hepatocellular disposition of the model bile acid TCA based on 
inhibition constants and SCHH data using mechanistic modeling. Importantly, the intracellular 
binding of inhibitors was considered in the simulations, and a strategy was proposed to 
determine whether it is necessary to measure the intracellular binding a priori.  
 The following assumptions were made for the mechanistic modeling. Linear kinetics was 
assumed because the unbound concentration of TCA in the medium (fu,med×1 µM, where fu,med 
refers to the unbound fraction of TCA in the medium equivalent to 0.15 in 4% BSA)(Wolf et al., 
2008) was below the Km of TCA for the uptake transporter NTCP (5-20 µM) and OATPs (5.8-
71.8 µM)  (Shitara et al., 2003; Nozawa et al., 2004; Mita et al., 2006; De Bruyn et al., 2014). In 
addition, the cellular total concentration of TCA (5.6 µM) after 20-min uptake was below the Km 
for the efflux transporters BSEP (6.2 µM) (Hayashi et al., 2005), MRP3 (30 µM) and MRP4 (7.7 
µM); if intracellular binding is taken into account, the cellular unbound concentration of TCA 
would be even lower. Passive diffusion was not included in the model because active uptake 




 To simulate the effects of inhibitors on TCA disposition, Equations 7-10 were used. Due 
to low TCA concentrations, Equations 7-10 held true regardless of the mechanisms of inhibition 
and the IC50 value was substituted for Ki. The inhibitory effects of metabolites of telmisartan and 
bosentan were assumed to be negligible. There are no literature reports about inhibitory effects 
of telmisartan metabolites on human bile acid transporters. Although a bosentan metabolite, Ro 
47-8634, was reported to be an inhibitor of rat Bsep (Ki=8.5 µM) (Fattinger et al., 2001), the 
intracellular concentration of this metabolite in human SCHH is less than 5% of bosentan 
(Matsunaga et al., 2015). In addition, the concentration of this metabolite in human plasma 
(Dingemanse et al., 2002) and feces (Weber et al., 1999) is much lower than bosentan. Both 
MRP3 and MRP4 have been reported to contribute to the basolateral efflux of TCA without 
consensus on the relative contribution. The expression of MRP3 is higher than MRP4 in human 
liver and hepatocytes; while the affinity of TCA towards MRP4 (Km=7.7 µM) (Rius et al., 2006) 
is higher than MRP3 (Km=30 µM) (Zhang et al., 2003).  Akita and colleagues reported that TCA 
was not transported to a significant degree by MRP3 (Akita et al., 2002). Therefore, two extreme 
scenarios were simulated assuming 100% contribution of either MRP3 or MRP4; the simulation 
results were similar so MRP3 was selected as the main basolateral efflux transporter for 
subsequent simulations.  
In the current study, a physiologic concentration of protein (4% BSA) was added to 
mimic the in vivo scenario. Using the mechanistic model, the estimated total CLUptake of TCA 
was 0.63 mL/min/g liver (Table 2.2) and the unbound CLUptake of TCA was 4.2 mL/min/g liver 
(calculated as total CLUptake/fu,med). This value is close to the reported unbound CLUptake (2.2 
mL/min/g liver) (Yang et al., 2015). CLBL and CLBile were similar to values reported previously 
(CLBL=0.042 mL/min/g liver and CLBile=0.14 mL/min/g liver) (Yang et al., 2015). 
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In this study, we leveraged SCHH and a mechanistic model to evaluate the net effect of 
uptake and efflux. The comparison between simulated and experimental results for telmisartan 
and bosentan provided an example of the applicability of this approach to predict the net effect of 
inhibition at multiple sites on the disposition of a model bile acid (Table 2.4). This applicability 
is important because the interplay of multiple transporters is common. Examples of dual 
inhibitors of BSEP and NTCP include the non-hepatotoxic drugs pioglitazone, telmisartan, and 
reserpine (Morgan et al., 2010; Dong et al., 2014) as well as the hepatotoxic compound 
troglitazone (Yang et al., 2014) (Morgan et al., 2010). Some compounds are dual inhibitors of 
both uptake and basolateral efflux of TCA, such as alpha-naphthylisothiocyanate (Guo et al., 
2014).  
The slight differences between model predicted and experimental results observed for 
bosentan’s effect on TCA Ct,Cells could be attributed to the model assumptions discussed earlier. 
It should be noted that inhibitor-mediated alterations in TCA Ct,Cells was not extensive due to the 
short 10-min uptake phase in this study and simultaneous inhibition of uptake and efflux. A more 
pronounced alteration in TCA Ct,Cells could be achieved by extending the uptake phase (Figure 
S2.1). However, accurate measurement of the TCA Ct,Cells after an uptake phase >30 min is 
technically challenging in sandwich-cultured hepatocytes. When Ca2+ is present during an 
extended uptake phase, the tight junctions reseal yielding a measured Xt,Cells+Bile instead of Xt,Cells 
(Pfeifer et al., 2013c).  
This is the first study to evaluate the impact of using different cellular inhibitor 
concentrations to predict transporter-mediated interactions in SCHH. Use of cytosolic 
concentrations marginally improved the prediction of telmisartan’s effects; the AFE dropped by 
≤ 0.1 when [I]cyt instead of [I]cell was used. This difference was minor because telmisartan was 
77 
 
recovered primarily in the cytosol (62-70% of the total mass) and the cytosolic concentration 
approximated the cellular concentration. The impact of using [I]cyt instead of [I]cell would likely 
be greater for drugs that are trapped in subcellular organelles, such as furamidine (Pfeifer et al., 
2013b). Different enzymatic markers were used to evaluate the purity and recovery of cytosol. 
However, membrane-anchored proteins (e.g., the endoplasmic reticulum marker glucose-6-
phosphatase) would not be able to detect whether content in the endoplasmic reticulum lumen 
had been released into the cytosol. Lumen protein markers [e.g., ERp57 (Coe et al., 2010) or 
Glucosidase II (Zuber et al., 2000)] could be measured in future studies to exclude this 
possibility. 
In DDI evaluations, [I]t,cell is used commonly to avoid false-negative predictions by 
assessing the “worst-case scenario”, but this value can lead to false-positive predictions. Pfeifer 
et al. reported that using [I]u,cell of ritonavir correctly predicted no clinical MRP2-mediated DDI 
between ritonavir and 99mTc-mebrofenin, while predictions based on [I]t,cell of ritonavir led to a 
false positive prediction of DDI liability (Pfeifer et al., 2013a). In the case of telmisartan, 
simulations using [I]t,cell and [I]t,cyt slightly overpredicted TCA Ct,Cells compared to simulations 
using [I]u,cell and [I]u,cyt. Unlike telmisartan, simulations for bosentan’s effect on TCA Ct,Cells were 
similar regardless of whether total or unbound, cellular or cytosol, concentrations of bosentan 
were employed  (Table 2.4). Sensitivity analysis revealed the differential sensitivity of TCA 
Ct,Cells to fu,cell,inhibitor  for telmisartan and bosentan (Fig. 2.3). This difference suggested that 
although it is ideal to use [I]u, it is not necessary to measure fu,cell,inhibitor and use [I]u,cell for every 
inhibitor. Simulations of a set of theoretical inhibitors showed that inhibitors with high 
([I]t,cell/IC50) values were more sensitive to changes in fu,cell,inhibitor (Fig. 2.4). For example, when 
([I]t,cell/IC50) was >1, the simulation assuming no protein binding over-predicted TCA Ct,Cells by 
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twice or more. Inhibitors with large ([I]t,cell/IC50) values either tend to accumulate in the cells or 
serve as strong inhibitors of efflux transporters. In these cases, ignoring protein binding would 
greatly impact the prediction, and thus, fu,cell,inhibitor needs to be measured. The ([I]t,cell/IC50) value 
of telmisartan was 3.6 at the 10 µM dose level and the ([I]t,cell/IC50) value of bosentan was 0.8 at 
the 8 µM dose level. This difference could explain the greater sensitivity of predicted TCA 
Ct,Cells to changes in fu,cell,inhibitor of telmisartan compared to bosentan.  
Based on the results of these studies, a framework was proposed to predict the net effect 
of drug-bile acid interactions mediated by inhibition of multiple transporters (Fig. 2.5). The 
kinetic parameters (CLUptake, CLBile, and CLBL) of the victim bile acid (e.g. TCA) are estimated by 
mechanistic modeling; in the presence of inhibitors, the clearance values are affected by [I]u,med 
or [I]cell and IC50 or Ki values. The choice of which [I]cell value to use (e.g., [I]t,cell, [I]t,cyt, [I]u,cell, 
[I]u,cyt) depends on the sensitivity of the model output to fu,cell,inhibitor, which is determined by the 
([I]t,cell/IC50) value of the inhibitor. If this value is high, the model output, Ct,Cells, is sensitive to 
changes in fu,cell,inhibitor. In these cases, it is critical to measure fu,cell,inhibitor, as demonstrated in this 
study. For inhibitors that sequester in subcellular organelles, it may be necessary to isolate 
cytosol and measure [I]u,cyt. Finally, the altered hepatocellular disposition of the victim bile acid, 
namely Ct,Cells, can be simulated using CLinhibitor (calculated using Equations 7-10). This approach 
could be applied to evaluate transporter-mediated interactions involving other victim substrates 







Table 2.1. Inhibition constants (µM) of telmisartan and bosentan against transporters involved in 
the hepatic uptake and efflux of TCA. 
Clearance Transporter Telmisartan Reference Bosentan Reference 
CLUptake 
NTCP 60 (Ki) 




(Leslie et al., 
2007) (Lepist et 
al., 2014) 
OATP1B1 0.44 (Ki) 
(Hirano et al., 
2006) 




(Lai, 2014),     
(Morgan et al., 
2013) 
23-42 (IC50) 
(Morgan et al., 
2013) (Lepist et 
al., 2014) 
CLBL 
MRP4 11-36 (IC50) 
(Sato et al., 2008) 
(Morgan et al., 
2013) 
22 (IC50) 
(Morgan et al., 
2013) 
MRP3 60 (IC50) (Morgan et al., 
2013) 
42 (IC50) 
(Morgan et al., 
2013) 












Table 2.2. Recovered estimates of d8-TCA total uptake clearance (CLUptake), basolateral efflux 
clearance (CLBL), biliary clearance (CLBile) and KFlux in the presence of 4% BSA. Estimates were 
based on the model scheme and time-course data depicted in Fig. 2.1. The model was fit to data 
generated from n=3 independent SCHH preparations (triplicate measurements) separately.   
Parameter Estimate Mean SD CV% 
CLUptake (mL/min/g liver) 0.63 0.12 20 
CLBL (mL/min/g liver) 0.034 0.011 32 
CLBile (mL/min/g liver) 0.074 0.030 36 
KFlux (min




Table 2.3. Measured total and unbound concentrations of inhibitors ([I]t and [I]u, µM) in the medium ([I]med), whole cell lysate ([I]cell), 
and cytosol ([I]cyt). SCHH were treated with telmisartan (1 or 10 µM) and bosentan (0.8 or 8 µM) for 20 min in the presence of 4% 
BSA. Data were generated from n=1 SCHH preparation. Unbound concentration and fu data were expressed as mean values obtained 
from triplicate measurements (cell lysate and cytosol) and duplicate measurements (medium) and values in parentheses represent 
ranges. Total concentrations were from single measurements. 
Inhibitor 
 
Medium  Cell lysate Cytosol 



























































14 N/Aa N/Aa 






Table 2.4. Experimentally observed and simulated alteration of TCA total concentration in Cells 
(Ct,Cells) due to telmisartan and bosentan. Observed data are presented as fold change in the 
presence compared to the absence of inhibitors. SCHH were pre-treated with telmisartan (1 and 
10 µM) or bosentan (0.8 and 8 µM) for 10 min, followed by co-incubation with d8-TCA and 
telmisartan or bosentan for 10 min. Observed data represented arithmetic  mean (range) 
measured in n=1 SCHH preparation in duplicate. Monte Carlo simulations for 40 individuals 
were performed 10 times using parameter estimates and associated variance (Table 2.2), different 
inhibitor concentrations (Table 2.3), and IC50 data (Table 2.1) assuming CLUptake was mediated 
by NTCP (70%) and OATPs (30%), CLBile was mediated by BSEP, and CLBL was governed by 
MRP3. Simulation data are presented as arithmetic mean of 10 simulations (95% confidence 
interval). Average fold errors were calculated based on Equation 11.  














Fold Change in TCA Ct,Cells 
Observation 
Simulation 

















































Average fold error 1.3 1.2 1.3 N/Aa 
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Figure 2.1. (A) Model schemes depicting disposition of d8-TCA in sandwich-cultured human 
hepatocytes (SCHH) using standard (Cells+Bile) Hanks’ balanced salt solution (HBSS) (left) and 
Ca2+-free (Cells) HBSS (right). (B) d8-TCA mass vs. time data in SCHH lysate (left) and 
incubation buffer (right). Closed symbols/solid lines represent d8-TCA in Cells + Bile or 
standard HBSS, and open symbols/dashed lines represent d8-TCA in Cells or Ca
2+-free HBSS. 
Experimental data (circles) represent the mean ± S.E.M. (n = 3 SCHH preparations in triplicate 
per group). The simulated profiles (lines) were generated from Equations 1-5 using the mean of 









Figure 2.2. Impact of impaired CLUptake and CLEfflux (CLEfflux= CLBL+ CLBile) of TCA on different model outputs: (A) TCA total 
concentration in Cells (Ct,Cells), (B) TCA total amount in Cells+Bile (Xt,Cells+Bile), (C) TCA total amount in Bile (Xt,Bile), (D) Ratio of 
the total amount of TCA in Cells to the total amount of TCA in Cells+Bile (Xt,Cells/Xt,Cells+Bile), (E) Ratio of the total amount of TCA in 
Bile to the total amount of TCA in Cells (Xt,Bile/Xt,Cells), and (F) Ratio of the total amount of TCA in Bile to the total amount of TCA 
in Cells+Bile (Xt,Bile/Xt,Cells+Bile) in SCHH. The Z-axis represents the fold change compared to baseline (shown in the color map on the 
right), based on simulations of TCA accumulation at steady state. Figures C, E, and F have been rotated to improve visibility of the 3-






Figure 2.3. Sensitivity analysis of cellular unbound fraction of inhibitor (fu,cell,inhibitor) for telmisartan and 
bosentan. Fold changes in the TCA Ct,Cells at steady state compared to baseline (without inhibitors), in 
the presence of telmisartan and bosentan were simulated based on the average IC50 values (Table 2.1), 
cellular total inhibitor concentration (Table 2.3), and different fu,cell,inhibitor values using a Monte Carlo 


















Figure 2.4. The sensitivity of the predicted TCA Ct,Cells to changes in fu,cell,inhibitor  as a function of 
([I]t,cell/IC50) values for a set of theoretical inhibitors. TCA Ct,Cells in the presence of theoretical inhibitors 
with different ([I]t,cell/IC50) values were simulated assuming fu,cell,inhibitor =1 (black bar) and fu,cell,inhibitor 
=0.02 (white bar). The fold changes of TCA Ct,Cells compared to baseline (without inhibitors) are plotted 



























Figure 2.5. Proposed framework to predict altered bile acid disposition in sandwich-cultured human 
hepatocytes (SCHH) mediated by inhibition of multiple transporters. Black solid boxes represent 
experimental observations, and black double-lines depict the simulation output, as detailed in the 
Discussion. The kinetic parameters, including uptake clearance (CLUptake), biliary clearance (CLBile), and 
basolateral efflux clearance (CLBL), of the victim bile acid (e.g. taurocholic acid) are estimated by using 
mechanistic modeling; in the presence of inhibitors, the clearance values (CLinhibitor) are estimated using 
Equations 7-10 based on inhibitor concentrations in the medium or cells ([I]cell) and IC50 or Ki values. 
The choice of which [I]cell to use depends on the ([I]t,cell/IC50) value of the inhibitor, where [I]t,cell 
represents cellular total concentration of inhibitor. If this value is high, the cellular unbound fraction of 
inhibitor (fu,cell,inhibitor) should be measured to estimate [I]u,cell, where [I]u,cell represents the cellular 
unbound concentration of inhibitor. Otherwise, [I]t,cell can be used. Finally, the altered cellular total 
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Figure S2.1. Simulated effect of telmisartan at (A) 1 μM and (B) 10 μM on TCA Ct,Cells after a 120-min 
uptake. Simulations were based on cellular total concentration ([I]t,cell), cellular unbound concentration 
([I]u,cell), and cytosolic unbound concentration ([I]u,cyt) measured in this study (Table 2.3), and 


















CHAPTER 3. Prediction of Hepatic Efflux Transporter-mediated Drug Interactions: When is it 
Optimal to Measure Intracellular Unbound Fraction of Inhibitors?3 
Introduction 
Drug interactions (DIs) due to inhibition of hepatic efflux transporters may result in increased 
hepatic exposure to drugs and endogenous compounds, which may lead to hepatotoxicity. According to 
regulatory guidance, the prediction of efflux transporter-mediated DIs is based on the half maximal 
inhibitory concentration (IC50) or inhibition constant, and the concentration of the inhibitor(EMA, 21 
June 2012; FDA/CDER, 2012). There is no consensus on which type of inhibitor concentration (total or 
unbound; plasma or intracellular) is optimal to use in the prediction. Theoretically, the intracellular 
unbound inhibitor concentration ([I]unbound,cell) would be the most relevant concentration for assessing the 
inhibition of efflux transporters. However, there is no widely accepted method to measure the 
intracellular unbound fraction of inhibitor in hepatocytes (fu,cell,inhibitor). The fu,cell,inhibitor values obtained 
from the higher-throughput method using hepatocyte or liver homogenate correlated poorly with those 
obtained from other methods that require incubation with hepatocytes(Riede et al., 2017). 
If the benefit of using [I]unbound,cell instead of intracellular total inhibitor concentration ([I]total,cell) 
to predict the inhibitory effect could be determined a priori, resources necessary for the measurement of 
fu,cell,inhibitor could be better allocated. Our previous study suggested that this benefit may vary depending 
on the characteristics of the inhibitor, such as the ([I]total,cell/IC50) value(Guo et al., 2016). In addition, 
                                                          
3This chapter has been published as Guo C, Yang K, Liao M, Xia CQ, Brouwer KR, Brouwer KLR. Prediction of hepatic efflux 
transporter-mediated drug interactions: when is it optimal to measure intracellular unbound fraction of inhibitors? J. Pharm. Sci. 
2017 Sep;106(9):2401-2406. DOI: 10.1016/j.xphs.2017.04.054. Presented in the format of the journal and reprinted by 




this benefit may depend on other factors, such as the extent of intracellular binding of the inhibitor, 
simultaneous inhibition of uptake and efflux transporters, and the experimental conditions under which 
the data were generated. For example, in most in vitro inhibition experiments, the dosing solution is 
protein-free. However, in some studies, the dosing solution contains 4% bovine serum albumin (BSA) to 
mimic protein binding in plasma (Wolf et al., 2008; Guo et al., 2016). To our knowledge, the impact of 
using [I]unbound,cell on the prediction results by considering these factors has not been evaluated 
systematically.  
To fill this knowledge gap, we simulated the effect of various theoretical inhibitors on the 
disposition of a model substrate including the abovementioned factors. Taurocholate (TCA), a 
prototypical bile acid used for transporter studies, was the model substrate. Based on the simulation 
results, a framework was developed to categorize “risk” inhibitors for which [I]unbound,cell led to a 
substantially better prediction of the inhibitory effect than [I]total,cell. For these inhibitors, the 
measurement of fu,cell,inhibitor was optimal. To demonstrate the utility of this framework, 15 experimental 
compounds were categorized. Experimental data for the inhibitory effect of five compounds (bosentan, 
ambrisentan, rosuvastatin, ritonavir, troglitazone-sulfate) were compared to the simulation results. 
Materials and Methods 
Simulation of TCA Intracellular Concentrations  
Pharmacokinetic parameters describing TCA disposition in sandwich-cultured human 
hepatocytes (SCHH) were obtained by mechanistic pharmacokinetic modeling using Phoenix 
WinNonlin, v6.3 (Certara, Princeton, NJ) (Guo et al., 2016). These kinetic parameters were used to 
simulate total cellular concentrations of TCA ([TCA]total,cell) over time using Berkeley-Madonna v.8.3.11 
(University of California at Berkeley, CA). 
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Simulation of [TCA]total,cell in the Presence of Transporter Inhibitors with Various Degrees of 
Intracellular Binding  
The steady-state [TCA]total,cell in the presence of inhibitors was simulated by using biliary 
clearance (CLBile) and basolateral efflux clearance (CLBL) in the presence of inhibitors, which were 
estimated using Eq. 1, and assuming the IC50 against CLBile (biliary IC50) and IC50 against CLBL 
(basolateral IC50) were the same. Uptake clearance (CLUptake) was assumed to be inhibited by 10%, 50% 
or 90%. Experimental conditions both in the presence and absence of 4% BSA were simulated, 
consistent with the two different approaches that are used routinely for in vitro studies.  
The effect of various theoretical inhibitors was simulated by varying the ([I]total,cell/IC50) value 
from 0.5 to 60. The effect of considering intracellular binding of inhibitors on the prediction of 
[TCA]total,cell was assessed by changing fu,cell,inhibitor  from 1 to 0.5, 0.2, 0.1, 0.02, or 0.01. The fold change 
in simulated [TCA]total,cell when fu,cell,inhibitor=1 divided by the simulated [TCA]total,cell  when 
fu,cell,inhibitor=0.5, 0.2, 0.1, 0.02, or 0.01 was calculated (Equation 2). The corresponding fu,plasma,inhibitor 
values for the assumed fu,cell,inhibitor values used in the simulations were calculated using the relationship 
reported by Jones et al. (Jones et al., 2012). This conversion was performed in order to create reference 
values that the experimental fu,plasma,inhibitor values could be compared with in the following sections.  The 
original equation was rearranged to calculate fu,plasma,inhibitor from fu,cell,inhibitor, and it was assumed that the 
concentration of binding proteins in hepatocytes was one-half of that in plasma (Poulin and Theil, 2000). 
The parameter values and simulation assumptions are summarized in Table S3.1. 
CLBile or CLBL in the presence of inhibitors = (CLBile or CLBL) / [1+ fu,cell,inhibitor × ([I]total,cell/IC50)]             
(1) 
Fold change = ([TCA]total,cell when fu,cell,inhibitor=1) / ([TCA]total,cell when fu,cell,inhibitor=0.5, 0.2, 0.1, 0.02, or 
0.01)  (2) 
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Determination of the “Risk” Inhibitors Based on the ([I]total,cell/IC50) Value and Unbound Fraction 
in Plasma  
If the fold change of [TCA]total,cell was > 2, [I]unbound,cell was considered superior to [I]total,cell when 
predicting inhibitory effects. In this case, the inhibitors were categorized as “risk” inhibitors for which 
measurement of fu,cell,inhibitor was optimal. This criterion was chosen based on the criterion used in the 
assessment of clinical DIs. Inhibitors that result in AUCi/AUC > 2 generally are considered as “high 
risk” for clinically relevant DIs, where (AUC)i represents area under the plasma drug concentration-time 
curve (AUC) of the substrate in the presence of inhibitors (Bachmann K and Ekins S, 2012). The lowest 
([I]total,cell/IC50) value that led to a fold change of [TCA]total,cell >2 was chosen as the cut-off value. A 
framework based on the ([I]total,cell/IC50) and fu,plasma,inhibitor values was proposed.  
To demonstrate the utility of this framework, 15 experimental compounds (salicylic acid, 
doxorubicin, diclofenac, telmisartan, troglitazone-sulfate, rosuvastatin, rifampicin, tolvaptan, DM-4103, 
DM-4107, sitaxentan, macitentan, ambrisentan, ritonavir, and troglitazone) were classified based on 
their ([I]total,cell/IC50) and fu,plasma.inhibitor values. [I]total,cell of these compounds were measured after 10- to 
30-min incubation with SCHH at various dosing concentrations following a 10-min pre-incubation with 
Ca2+-free Hanks’ balanced salt solution, which disrupted the tight junctions for quantification of cellular 
content (Liu et al., 1999). The IC50 and fu,plasma,inhibitor values were obtained from the literature (Table 
S3.2.). The lowest IC50 against efflux transporters was used in the calculation of ([I]total,cell/IC50) values 
in order to be conservative.  
Simulation of the Effect of Model Inhibitors on [TCA]total,cell and Comparison with Experimental 
Results 
To verify the simulation results, the effect of five model inhibitors (bosentan, ambrisentan, 
rosuvastatin, ritonavir, troglitazone-sulfate) on TCA disposition in SCHH was measured and compared 
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with the simulation results. SCHH were pre-incubated with Hanks’ balanced salt solution in the 
presence or absence of inhibitors for 10- to 30-min, followed by incubation with TCA for 10 min in the 
presence or absence of inhibitors. [TCA]total,cell at the end of incubation was measured. In addition, the 
fu,cell,inhibitor values of these inhibitors were measured as described earlier(Pfeifer et al., 2013b; Riede et 
al., 2017). Simulations of [TCA]total,cell after 10-min uptake were performed using both [I]total,cell and 
[I]unbound,cell and clearance values in the presence of inhibitors, as described previously (Guo et al., 2016). 
The average fold error (AFE) comparing the simulation with experimentally observed results was 
calculated to provide a measure of prediction accuracy, as reported previously (Guo et al., 2016).  
Results and Discussion 
Simulation of TCA Intracellular Concentrations  
Kinetic parameters describing TCA disposition in the presence or absence of 4% BSA are shown 
in Table S3.3. Simulated [TCA]total,cell reached steady state after 120-min uptake, either in the absence or 
presence of inhibitors (Yang et al., 2015). 
Simulation of [TCA]total,cell in the Presence of Transporter Inhibitors with Various Degrees of 
Intracellular Binding  
Based on a literature review of the unbound fraction measured in hepatocyte homogenate (Figure 
S3.1.), fu,cell,inhibitor =0.5 to 0.01 were selected to represent various degrees of intracellular binding of 
inhibitors. [TCA]total,cell was over-predicted using [I]total,cell compared to simulations using [I]unbound,cell. 
The extent of over-prediction was represented as the fold change calculated by Eq. 2, which was always 
≥1, as shown in Figure 3.1. The fold change increased at first and then decreased as the ([I]total,cell/IC50) 
value increased from 0.5 to 60. For example, in Figure 3.1D, when ([I]total,cell/IC50) was >1.5, the fold 
change was >2. In this case, [I]unbound,cell was the preferred measure of inhibitor concentration instead of 
[I]total,cell. These inhibitors either accumulate extensively in hepatocytes or are potent inhibitors of efflux 
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transporters. In addition, the fold change increased as the actual fu,cell,inhibitor decreased (from Figure 3.1A 
to 1E), indicating that the benefit of using [I]unbound,cell was bigger for inhibitors with greater intracellular 
binding. The fold change also was affected by the presence of BSA in the medium, shown as the 
difference between the open squares and solid circles, as well as the inhibition of uptake, which was 
assumed to be 50% in Fig. 3.1 vs. 10% and 90% in Figure S3.2 and Figure S3.3, respectively.  
Determination of the “Risk” Inhibitors Based on the ([I]total,cell/IC50) Value and Unbound Fraction 
in Plasma  
The cut-off value of ([I]total,cell/IC50) for classifying compounds as “risk” inhibitors was related to 
several factors, including fu,plasma,inhibitor, the inhibition of uptake transporters, and the presence of 4% 
BSA in the medium (Table 3.1). For inhibitors with fu,plasma,inhibitor >0.33, the fold change calculated by 
Eq. 2 was always <2. Therefore, there is no benefit in using [I]unbound,cell instead of [I]total,cell,  regardless 
of the ([I]total,cell/IC50) value. For inhibitors with greater plasma protein binding, the cut-off value of 
([I]total,cell/IC50) ranged from 1 to 4, assuming the biliary and basolateral IC50 values were the same.  
 The framework to determine the “risk” inhibitors was based on the fu,plasma,inhibitor and 
([I]total,cell/IC50) values of the inhibitors (Figure 3.2). To be conservative, the lowest ([I]total,cell/IC50) cut-
off value for inhibitors within the same fu,plasma,inhibitor  group in Table 3.1 was used in the framework. The 
cut-off value of ([I]total,cell/IC50) was higher for compounds with a larger fu,plasma,inhibitor value. Out of the 
fifteen experimental compounds, seven compounds (salicylic acid, doxorubicin, rosuvastatin, 
ambrisentan, 0.28 μM ritonavir, DM-4103, and DM-4107) were classified as “low-risk” inhibitors, due 
to the low ([I]total,cell/IC50) or high fu,plasma,inhibitor values. For these compounds, the resources necessary for 
the measurement of fu,cell,inhibitor could be better allocated. Other inhibitors fell into the “risk” category.  
This framework is limited by the assumption that biliary IC50 and basolateral IC50 were the same 
and the lowest IC50 of all efflux transporters was used to calculate the ([I]total,cell/IC50) value of the 
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inhibitor. To assess the impact of differential inhibition of basolateral and biliary efflux clearance, 
additional simulations were performed by varying the biliary IC50 or the basolateral IC50 up to 5-fold 
higher than the other IC50 value; in all cases, the lowest IC50 was used in the calculation of 
([I]total,cell/IC50). As shown in Table S3.4, when the basolateral IC50 was 5-fold higher than the biliary 
IC50, the simulated fold change in [TCA]total,cell was similar (<2-fold difference) to the original 
assumption that the IC50 values were equal. When the biliary IC50 was 5-fold higher than the basolateral 
IC50, the difference in [TCA]total,cell fold change was more obvious (>2-fold in some cases) compared to 
the original assumption. These simulations are consistent with expected changes because CLBile was the 
primary route of excretion of TCA, and therefore [TCA]total,cell was more sensitive to changes in CLBile. 
In this case, the cut-off value of ([I]total,cell/IC50) should be adjusted, as shown in Table S3.5. 
Simulation of the Effect of Model Inhibitors on [TCA]total,cell and Comparison with Experimental 
Results 
The [I]total,cell and experimentally observed fold change in [TCA]total,cell in the presence vs. 
absence of inhibitors after 10-min uptake are shown in Table S3.6. The simulated and experimentally 
observed [TCA]total,cell were compared (Table 3.2). For “low-risk” inhibitors, the AFE of the simulations 
based on [I]total,cell and [I]unbound,cell were both close to 1, indicating both simulations had good prediction 
accuracy. In contrast, for “risk inhibitors”, the AFEs of the simulations based on [I]unbound,cell were much 
closer to 1 compared to simulations based on [I]total,cell . This difference in AFEs suggests that use of 
[I]unbound,cell results in better prediction accuracy. The difference would be more pronounced at steady 
state after a longer uptake phase (Guo et al., 2016). These experimental results, albeit for a limited 






To evaluate the accuracy of the simulation results, experimental data with more inhibitors are 
needed. Ideally, [I]total,cell should be measured under the condition that the unbound medium 
concentration is similar to the clinically relevant unbound plasma concentration. By comparing the 
prediction results with the experimental data, the specificity and sensitivity of the approach could be 
calculated. In this study, a fold change of [TCA]total,cell > 2 was chosen as the criterion to select the cut-
off value of ([I]total,cell/IC50). This criterion could be adjusted based on the therapeutic window of the 
substrate and a cut-off value that gives the best specificity and sensitivity. In addition, more data are 
needed to support the relationship between fu,cell,inhibitor and fu,plasma,inhibitor. 
Conclusions 
In this study, a framework was developed to determine when it is optimal to measure fu,cell,inhibitor 
to accurately predict the effect of efflux transporter inhibitors on the disposition of TCA, a prototypical 
bile acid. When the ([I]total,cell/IC50) value of the inhibitor was > 1 to 2, depending on the extent of 
plasma protein binding, the follow-up measurement of fu,cell,inhibitor was optimal. The framework was 
developed based on simulation results and was validated with experimental data.  
In addition to bile acids such as TCA, this method could be applied to predict the disposition of 
other hepatic transporter substrates such as statins, whose therapeutic target is in the liver, or hepatotoxic 
compounds. Accurate prediction of the hepatocellular concentration of these compounds is important in 
determining their efficacy and safety.   
Professor Sugiyama’s research has contributed significantly to the field of pharmacokinetic 
modeling and simulation, including the role of transporters in drug disposition and transporter-mediated 
drug interactions. Advances in this field have laid the foundation for this work and will guide the 
refinement and application of tools to more precisely predict transporter-mediated DIs. 
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Table 3.1. Cut-off value of ([I]total,cell/IC50) to categorize “risk” inhibitors for compounds with various 
degrees of plasma protein binding. Compounds were categorized as “risk” inhibitors” when 


























2 1.5 1.5 
50 
Yes 2 1.5 1 1 
No 4 2 1.5 1.5 
90 
Yes 2 1.5 1 1 



















Table 3.2.  Experimentally observed and simulated alteration of [TCA]total,cell due to inhibitors. 
Sandwich-cultured human hepatocytes were pre-incubated with Hanks’ balanced salt solution in the 
presence or absence of inhibitors [bosentan (0.8 µM), ambrisentan (100 µM), rosuvastatin (2 µM), 
ritonavir (0.28, 2.8, and 28 µM), or troglitazone-sulfate (0.1 and 0.5 µM)], followed by co-incubation 
with TCA in the presence or absence of inhibitors for 10 min without BSA (except bosentan). The 
categorization of the inhibitors was based on the classification system in Fig. 3.2. Simulations of 
[TCA]total,cell in the presence of inhibitors were performed using [I]total,cell or [I]unbound,cell. Average fold 
error (AFE) of the simulation results compared to experimental observations (shown in Table S3.6) were 






AFE Compared With Observation 
Simulations based on: 
[I]total,cell                   [I]unbound,cell 
Bosentana 0.8 Low-risk 0.1 1.3 1.2 
Ambrisentan 100 Low-risk 0.067 b 1.1 0.97 
Rosuvastatin 2 Low-risk 0.13 c 0.98 0.95 
Ritonavir 
0.28 Low-risk 0.006d 1.1 0.93 
2.8 and 28 Risk 0.006 d 1.7 1.0 
Troglitazone-
sulfate 
0.1 and 0.5 Risk 0.0032 b 2.9 1.1 
aexperimental and simulated data were obtained from a previous study with 4% BSA in the dosing 
solution (Guo et al., 2016) 
b obtained by incubating SCHH with the compounds, followed by isolating the cytosol and measuring 
unbound fraction in cytosol using equilibrium dialysis, as reported earlier (Pfeifer et al., 2013b) 
c obtained from a previous study, where rosuvastatin was incubated with suspended human hepatocytes 
at 4 °C. The fu,cell,inhibitor was calculated as the medium unbound concentration divided by the total 
cellular concentration, assuming uptake transporters were not active at 4°C and concentration 
equilibrium of the unbound drug was achieved between the medium and hepatocytes (Riede et al., 
2017).  
d obtained from a previous study, where ritonavir was incubated with suspended human hepatocytes at a 
high concentration that blocked the active transport and metabolism. The fu,cell,inhibitor  was calculated as 
the medium unbound concentration divided by the total cellular concentration, assuming the medium 







Figure 3.1. Fold change in simulated [TCA]total,cell when fu,cell,inhibitor=1 vs. 0.5, 0.2, 0.1, 0.02, or 0.01, 
assuming the uptake was inhibited by 50%, and biliary IC50 and basolateral IC50 were the same. Open 
squares: in the absence of 4% BSA; solid circles: in the presence of 4% BSA. The red horizontal line 
represents the fold change of 2. The inset table shows the corresponding fu,plasma,inhibitor for each 






Figure 3.2. A framework to categorize “risk” inhibitors for which the measurement of fu,cell,inhibitor is 
optimal. The black solid line represents cut-off values of ([I]total,cell/IC50) for inhibitors with different 
fu,plasma,inhibitor values shown in Table 3.1; the lowest ([I]total,cell/IC50) cut-off value for inhibitors within the 
same fu,plasma,inhibitor  group was used. Drugs that fall into the upper left quadrant above the solid line (grey 
shaded area) are classified as “low-risk” inhibitors. Drugs that fall into the lower right quadrant (white 
area) are considered as “risk” inhibitors and fu,cell,inhibitor should be measured. The color codes represent 
data from Takeda Pharmaceuticals (red), unpublished in-house data (brown), and publications by Life 
Technologies (Kimberly Freeman  et al., 2009) (green), Qualyst Transporter Solutions (Lepist et al., 
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Table S3.1. Assumptions or parameter values used to simulate [TCA]total,cell in the presence of 
theoretical inhibitors with various degrees of intracellular binding. 
Assumptions and Parameters Values 
Concentration of BSA in uptake buffer (%) 0, 4 
Inhibition of uptake transporters (%) 10, 50, 90 
fu,cell,inhibitor 
1, 0.5, 0.2, 0.1, 0.02, 
0.01 



















Table S3.2. Inhibition constants against TCA efflux transporters and unbound fraction in human plasma 
of inhibitors (fu,plasma,inhibitor) for 15 experimental compounds. The lowest IC50 against efflux transporters 









Salicylic acid N/A N/A 1500 
0.05 (Johnson and 
Livingston, 1997) 
Doxorubicin 133 N/A 19 
0.344 (Terasaki et al., 
1984; Morgan et al., 
2013) 
Diclofenac N/A N/A 0.006 
0.0033 (El-Sheikh et al., 
2007; Obach et al., 
2008) 
Telmisartan 16 60 11 
0.004 (Obach et al., 2008; 
Morgan et al., 2013; 
Guo et al., 2016) 
Rosuvastatin 133 27 N/A 
0.12 (Obach et al., 2008; 
Morgan et al., 2013) 
Troglitazone-
sulfate 
0.23 N/A 8 0.002 a (Funk et al., 2001) 
Ritonavir 1.74 11.1 34 
0.015 (Morgan et al., 2013; 
Patterson et al., 
2013) 
Troglitazone 1.3 31 61 
0.002 (Izumi et al., 1996; 
Morgan et al., 2013; 
Yang et al., 2014) 
Rifampicin 10.5 69 42 
0.2 (Izumi et al., 1996; 
Obach et al., 2008; 
Morgan et al., 2013) 
Tolvaptan 31 >50 >50 
0.01 (Shoaf et al., 2014; 
Slizgi et al., 2016) 
DM-4103 4.15 45 4.3 0.01 a (Slizgi et al., 2016) 
DM-4107 119 61 38 0.01 a (Slizgi et al., 2016) 
Sitaxentan 25 N/A N/A 
0.01 (Ray et al., 2009; 
Dhaun et al., 2007) 
Macitentan 11.9 N/A N/A 
0.001 (Lepist et al., 2014; 
Sidharta et al., 2015) 
Ambrisentan 288 N/A N/A 0.01 (Kenna et al., 2015) 
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BSEP: bile salt export pump; MRP: multidrug resistance-associated protein 
IC50 values determined using inside-out membrane vesicles were obtained from the literature.  

























Table S3.3. Kinetic parameters of TCA in sandwich-cultured human hepatocytes in the presence and 
absence of 4% BSA. Estimates were based on the model scheme published previously (Guo et al., 
2016). The model was fit to data generated from n = 3 independent sandwich-cultured human hepatocyte 
(SCHH) preparations (triplicate measurements) separately. The mean and CV% of estimated parameters 
from the three SCHH preparations are shown.   
Parameters 
With 4% BSA Without 4% BSA 
Mean a CV% Mean CV% 
CL
Uptake 
(mL/min/g liver) 0.63 20 8.1 25 
CL
BL 
(mL/min/g liver) 0.034 32 0.042 45 
CL
Bile 





) 0.018 8 0.049 12 
Uptake clearance (CLUptake); basolateral efflux clearance (CLBL); biliary clearance (CLBile); rate constant 
that describes the flux from bile networks into the medium (KFlux) 

















Table S3.4. Fold change in simulated [TCA]total,cell  when fu,cell,inhibitor =1 vs. 0.5, 0.2, 0.1, 0.02, or 0.01, 
assuming the uptake was inhibited by 50%. Simulations were performed for three scenarios: A) the 
basolateral IC50 was 5-fold higher than the biliary IC50, which was used to calculate the ([I]total,cell/IC50);  
B) the basolateral and biliary IC50 were the same; C) the biliary IC50 was 5-fold higher than basolateral 
IC50, which was used to calculate ([I]total,cell/IC50). 
fu,cell,inhibitor = 1 vs. 0.5 
 


















0 1.00 1.00 1.00 1.00 1.00 1.00 
0.5 1.14 1.20 1.09 1.12 1.17 1.07 
0.8 1.19 1.28 1.12 1.17 1.24 1.10 
1 1.22 1.33 1.14 1.19 1.27 1.12 
1.5 1.28 1.41 1.19 1.24 1.33 1.16 
2 1.33 1.48 1.22 1.27 1.37 1.18 
4 1.43 1.57 1.33 1.33 1.41 1.27 
8 1.50 1.53 1.46 1.36 1.37 1.35 
10 1.51 1.48 1.49 1.36 1.34 1.37 
20 1.45 1.31 1.54 1.31 1.23 1.38 
40 1.31 1.17 1.44 1.23 1.14 1.32 
60 1.23 1.12 1.35 1.17 1.10 1.26 
fu,cell,inhibitor = 1 vs. 0.2 


















0 1.00 1.00 1.00 1.00 1.00 1.00 
0.5 1.25 1.36 1.15 1.22 1.31 1.13 
0.8 1.37 1.54 1.22 1.32 1.45 1.19 
1 1.44 1.65 1.26 1.38 1.53 1.23 
1.5 1.58 1.89 1.35 1.49 1.71 1.30 
2 1.70 2.10 1.44 1.58 1.83 1.37 
4 2.04 2.58 1.70 1.80 2.11 1.57 
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8 2.37 2.77 2.08 1.97 2.16 1.81 
10 2.44 2.69 2.22 2.00 2.12 1.89 
20 2.47 2.24 2.57 1.97 1.84 2.07 
40 2.16 1.72 2.54 1.78 1.52 2.02 
60 1.90 1.50 2.32 1.62 1.37 2.16 
fu,cell,inhibitor = 1 vs. 0.1 


















0 1.00 1.00 1.00 1.00 1.00 1.00 
0.5 1.29 1.42 1.17 1.26 1.36 1.15 
0.8 1.44 1.66 1.26 1.39 1.55 1.22 
1 1.53 1.80 1.31 1.46 1.66 1.27 
1.5 1.73 2.14 1.43 1.62 1.91 1.36 
2 1.90 2.44 1.54 1.75 2.10 1.45 
4 2.43 3.30 1.91 2.11 2.61 1.73 
8 3.06 3.95 2.48 2.45 2.89 2.11 
10 3.24 3.98 2.71 2.53 2.90 2.24 
20 3.53 3.53 3.41 2.62 2.60 2.62 
40 3.23 2.63 3.71 2.42 2.09 2.73 
60 2.85 2.15 3.52 2.19 1.80 2.62 
fu,cell,inhibitor = 1 vs. 0.02 


















0 1.00 1.00 1.00 1.00 1.00 1.00 
0.5 1.33 1.48 1.19 1.30 1.41 1.17 
0.8 1.50 1.75 1.29 1.44 1.64 1.25 
1 1.62 1.94 1.35 1.53 1.77 1.31 
1.5 1.87 2.38 1.50 1.74 2.10 1.42 
2 2.11 2.81 1.64 1.92 2.38 1.53 
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4 2.93 4.27 2.14 2.49 3.26 1.91 
8 4.18 6.08 3.02 3.23 4.20 2.50 
10 4.65 6.56 3.42 3.49 4.45 2.74 
20 6.01 7.41 4.90 4.15 4.81 3.57 
40 6.59 6.76 6.31 4.35 4.41 4.27 
60 6.38 5.89 6.74 4.20 3.94 4.47 
fu,cell,inhibitor = 1 vs. 0.01 


















0 1.00 1.00 1.00 1.00 1.00 1.00 
0.5 1.33 1.48 1.19 1.30 1.42 1.17 
0.8 1.51 1.77 1.30 1.45 1.65 1.26 
1 1.63 1.95 1.36 1.55 1.79 1.31 
1.5 1.90 2.41 1.51 1.76 2.13 1.43 
2 2.14 2.86 1.65 1.95 2.43 1.54 
4 3.02 4.42 2.18 2.56 3.38 1.94 
8 4.40 6.52 3.12 3.39 4.48 2.57 
10 4.95 7.16 3.55 3.70 4.81 2.84 
20 6.71 8.62 5.25 4.59 5.47 3.79 
40 7.87 8.68 7.08 5.09 5.46 4.71 










Table S3.5. Adjusted cut-off values of ([I]total,cell/IC50) to categorize “risk” inhibitors when the biliary 
IC50 was 5-fold higher than the basolateral IC50, assuming the uptake was inhibited by 50%. Compounds 
were categorized as “risk” inhibitors” when ([I]total,cell/IC50) was equal to or greater than the cut-off 
value.  
Presence of 
4% BSA in 
medium 
fu,plasma,inhibitor = 
>0.33 0.33-0.11 0.11-0.053 0.053-0.01 0.1-0.005 
Yes Low-
risk 
8 4 4 4 
No 20 8 4 4 
The cut-off values were chosen based on the simulated fold changes in [TCA]total,cell that was closest to 2 
(Table S3.4). Scenario C (5-fold higher biliary IC50) was the primary focus since the simulated fold 




















Table S3.6.  Experimentally measured [I]total,cell and fold change in [TCA]total,cell in the presence of 
inhibitors. Sandwich-cultured human hepatocytes were pre-incubated with Hanks’ balanced salt solution 
in the presence or absence of the inhibitors [ambrisentan (100 µM), rosuvastatin (2 µM), ritonavir (0.28, 
2.8, and 28 µM), or troglitazone-sulfate (0.1 and 0.5 µM)] for 10-30 min, followed by incubation with 
TCA for 10 min in the presence or absence of inhibitors for 10 min without BSA. [I]total,cell and 
[TCA]total,cell were measured. Fold changes in the measured [TCA]total,cell in the presence vs. absence of 






Fold change in 
[TCA]total,cell 
Ambrisentan 100 125 a 0.5 a 
Rosuvastatin 2 7.1 0.92 
Ritonavir 
0.28 1.54 c 1.0 b 
2.8 22.4 c 0.76 b 
28 158 c 0.35 b 
Troglitazone-sulfate 
0.1 16 1.0 
0.5 113 0.65 
a data obtained from (Lepist et al., 2014) 
b data obtained from  (McRae et al., 2006) 















Figure S3.1. Distribution of unbound fraction measured in hepatocyte homogenate (fu,hepatocytes). 
Hepatocellular binding data for 30 compounds were obtained from the literature. Data were included if 
the unbound fraction was measured in human or rat hepatocyte homogenate using equilibrium dialysis; 
hepatocytes were incubated with compounds before (Guo et al., 2016; Pfeifer et al., 2013b) or after 
















Figure S3.2. Fold change in simulated [TCA]total,cell when fu,cell,inhibitor = 1 vs. 0.5 (A), 0.2 (B), 0.1 (C) 
0.02 (D), 0.01 (E), assuming the uptake was inhibited by 10%, and CLBile and CLBL were inhibited to the 
same extent. The red horizontal line represents the fold change of 2. Open squares: in the absence of 4% 





Figure S3.3. Fold change in simulated [TCA]total,cell  when fu,cell,inhibitor = 1 vs. 0.5 (A), 0.2 (B), 0.1 (C) 
0.02 (D), 0.01 (E), assuming the uptake was inhibited by 90%, and CLBile and CLBL were inhibited to the 
same extent. The red horizontal line represents the fold change of 2. Open squares: in the absence of 4% 
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CHAPTER 4. Modeling and Simulation-Guided Study Design for Ki Estimations against Bile Acid 
Efflux Clearance Values in Hepatocytes 
Introduction 
Transporter-mediated drug interactions have important implications for drug efficacy and safety. 
Inhibition of bile acid efflux transporters has contributed to the hepatotoxicity of many drugs such as 
troglitazone (TGZ) and bosentan (Smith, 2003; Chojkier, 2005). Clinical drug interaction liabilities 
depend on the potency and the mechanism of inhibition as well as substrate (victim) and inhibitor 
(perpetrator) concentrations at the site of inhibition (FDA/CDER, 2012). The inhibition potency is 
represented by the inhibition constant (Ki) or half-maximal inhibition concentration (IC50) values, which 
are typically obtained from in vitro systems such as transfected cell lines or inside-out membrane 
vesicles derived from cells that express the protein of interest at high levels. Currently, robust 
predictions of transporter-mediated drug interactions remain challenging (Pan et al., 2016). Relatively 
poor model performance could be due to high uncertainty or variability in IC50 estimates, biased 
information generated from overexpressed transporter systems (Balakrishnan et al., 2007), a default 
assumption of competitive inhibition, and/or incomplete characterization of the transport mechanism of 
victim compounds, as discussed below. In addition, ambiguity in the relevant inhibitor concentration 
also contributes to poor model predictions.  
Large inter-laboratory variability in Ki or IC50 values has been reported for efflux transporters 
such as, P-glycoprotein (P-gp) (Bentz et al., 2013) (Ellens et al., 2013) (Lee et al., 2014) and bile salt 
export pump (BSEP) (Kis et al., 2009; Morgan et al., 2013). The variability may be associated with the 
experimental protocol, the data analysis method, the in vitro systems that express transporters at non-
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physiologically relevant levels, and inter-individual differences in the conduct of the experiment (Kis et 
al., 2009). In an effort to reduce the variability in P-gp IC50 estimates using different methods, a 
modeling-based approach was reported that showed the potential for pharmacokinetic (PK) modeling to 
improve the estimation of in vitro inhibition potency (Kishimoto et al., 2016). In addition, whole cell 
systems with physiologically-relevant transporter expression levels are important for generating quality 
data that can be translated to in vivo.  
The inhibition mechanism (e.g., competitive vs. non-competitive) also affects the impact of 
transporter inhibition. Simulations revealed that noncompetitive inhibition of BSEP resulted in greater 
bile acid accumulation and potential hepatotoxicity (Woodhead JL et al., 2014). Conventionally, in order 
to identify the inhibition mechanism and estimate Ki of the inhibitor, in vitro systems are incubated with 
at least five different substrate concentrations in the presence of at least five different inhibitor 
concentrations (Ring et al., 2014). These experiments are resource- and labor-intensive. Therefore, it is 
highly desirable to develop a more efficient method that requires fewer inhibitor and substrate 
concentrations to identify the inhibition mechanism.  
Another prerequisite for accurate model prediction is the complete understanding of transport 
mechanisms of victim substrates, including which transporters are involved in the disposition and their 
relative contribution to the overall clearance. These details may not be fully characterized for many 
compounds. For example, the basolateral efflux of taurocholic acid (TCA) may be mediated by 
multidrug resistance-associated protein 3 (MRP3), MRP4 (Zhang et al., 2003; Rius et al., 2006) and 
organic solute transporter α/β (OSTα/β) (Ballatori et al., 2008; Soroka et al., 2010). The relative 
contribution of each of these transporters is unknown in healthy or diseased hepatocytes. Therefore, it 
may be more useful to derive the Ki for a clearance pathway (e.g., biliary or basolateral efflux), which 
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represents a composite Ki for multiple transporters in the same clearance pathway, rather than the Ki for 
individual transporters.   
In light of these knowledge gaps, a novel approach to estimate Ki values combining model-based 
analysis and data from sandwich-cultured hepatocytes (SCH) was developed in this study. SCH 
represent a physiologically-relevant whole-cell system that maintains the functionality of multiple 
transporters and biliary networks (LeCluyse et al., 2000; Yang et al., 2016). In vitro studies using SCH 
can be resource-intensive, especially considering the limited availability of high quality, transporter 
competent human hepatocytes. Therefore, a framework was developed to assist the experimentalist in 
planning the studies in such a way as to obtain robust identification of model parameters, minimize the 
number of required experiments, and optimize the use of resources. Although modeling and simulation 
have been used to minimize the experimentation for determining Ki and the inhibition mechanism for 
CYP enzymes (Kakkar et al., 2000), this approach has not been reported for transporter studies, which 
oftentimes require a whole-cell system and are more complicated. 
In this study, the objective was to provide an optimized study design for, and assess the 
practicality of, the following hypotheses using modeling and simulation techniques: (1) Ki values for a 
model inhibitor against the biliary and basolateral efflux clearance values of a model bile acid substrate 
can be estimated simultaneously using data from rat sandwich-cultured hepatocytes and PK modeling. 
(2) The inhibition mechanism against the biliary clearance value of the model bile acid can be identified 
using a single dose of the inhibitor and substrate. TCA was used as the model bile acid because it is a 
commonly used substrate for in vitro bile acid transport studies and is thought to be metabolically stable 
(Hofmann and Hagey, 2008). Troglitazone sulfate (TS), the major metabolite of TGZ, was chosen as the 
model inhibitor because TS is a metabolically stable compound and a strong inhibitor of multiple bile 




The overall workflow of methods is shown in Figure 4.1 and Table 4.1.  
Estimation of TCA Kinetic Parameters 
In Step #1, individual mass-time data for TCA disposition in rat SCH from a previous study was 
used to estimate TCA kinetic parameters (Yang et al., 2015). In the study by Yang et al., rat SCH from 
three hepatocyte lots were cultured in 6-well plates, pre-incubated for 10 min in Ca2+-containing 
(standard) or Ca2+-free Hanks’ balanced salt solution (HBSS), and the uptake of 3H-TCA (1 µM) in 
standard HBSS and efflux of 3H-TCA in standard and Ca2+-free HBSS in rat SCH were quantified. The 
total amount of TCA in Cells+Bile, Cells, and the efflux buffers (standard HBSS and Ca2+-free HBSS) 
were measured. A mechanistic PK model (scheme depicted in Figure 4.2) was fit to the data from 
individual hepatocyte lots using Phoenix WinNonlin 7.0 (Certara USA, Inc., Princeton, NJ). Differential 
Equations 1 to 9 described changes in TCA amount over time. Kinetic parameters for TCA in control rat 
SCH were estimated, including CLUptake,TCA, Vmax,BL,TCA, Vmax,Bile,TCA, and KFlux,TCA. The definition and 
fixed values of variables and parameters are listed in Table 4.2. The Michaelis-Menten constants for 
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Establishment of the TS-TCA Interaction Model  
To simulate the TS-TCA interaction, the disposition and interaction of TS and TCA were 
described by a PK model shown in Figure 4.2. The disposition of TS in rat SCH was simulated using 
differential equations and mean kinetic parameters of TS described in a previous study (Lee et al., 
2010). The rate constants of TS were converted to clearance values and summarized in Table 4.4. In the 






 were estimated by Equations 10-12 to 
reflect noncompetitive inhibition of CLint,BL,TCA
TS





 based on the current understanding of inhibition mechanisms shown in Table 4.3. This 
PK model was defined as Model #1. The definition and fixed values of variables and parameters used in 
Equations 10-12 are shown in Table 4.2. Vmax,BL,TCA, Vmax,Bile,TCA, and CLUptake,TCA values were fixed at 
values estimated in Step #1. Simulations were performed using Phoenix WinNonlin 7.0 (Certara USA, 
































                                                                                                                        (12) 
Evaluation of the TS-TCA Interaction Model  
To evaluate the predictive performance of the TS-TCA interaction model, TCA disposition in 
individual rat SCH pre-incubated with TGZ from the study by Yang et al. (Yang et al., 2015) was 
compared with the corresponding simulation results. Briefly, rat SCH (n=3 hepatocyte lots) were pre-
incubated with TGZ (10 µM) for 30 min in standard HBSS; then, rat SCH were incubated for 10 min in 
standard or Ca2+-free HBSS, followed by uptake of 3H-TCA (1 µM) in standard HBSS and efflux of 3H-
TCA in standard and Ca2+-free HBSS, all in the absence of TGZ (Figure S4.1). Simulations were 
performed as described in Step #2 using TCA parameters for each hepatocyte lot (Table 4.6). Since the 
CLUptake,TCA
TS
value in these hepatocytes could not be explained by Equation 12 (Yang et al., 2015) and 
KFlux,TCA
TS was unknown, they were fixed to the estimates in the published study (Yang et al., 2015) for 
the simulations. Most intracellular TGZ was converted to TS during the pre-incubation phase (Figure 
S4.1), and therefore, the inhibitory effect of TGZ was not considered in the simulations.  
Optimization of Study Design 
Simulations using PK Model #1 were conducted using various dosing schemes (Table 4.5) to 
assess whether data could be generated for reliable estimation of Ki values (within 2-fold of reference 
value) and to identify the inhibition mechanism for CLint,Bile,TCA, as described below. The various dosing 
schemes were selected to include different doses and timing of TS and TCA co-incubation. Restrictions 
on the dosing schemes were described in the Discussion section. Under each dosing scheme, the amount 
of TCA and TS in the Cells+Bile (standard HBSS) and Cells (Ca2+-free HBSS) during the uptake and 
efflux phases, and the amount of TCA and TS in the incubation buffer during the efflux phase were 
simulated, using mean values of TCA and TS kinetic parameters (Table 4.4 and Table 4.6). The 
sampling scheme was optimized so that the number of samples was sufficient for parameter estimation, 
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but ≤10 from a practical perspective. Sampling points that were critical for the estimation of Ki,BL and 
Ki,Bile were identified based on the partial derivative of a predicted function (Xt,Cells,TCA, Xt,Cells+Bile,TCA, 
Xt,Buffer,TCA) with respect to each parameter plotted against time. The model was most sensitive to 
changes in a particular parameter when the derivative was near a maximum or minimum value 
(Gabrielsson and Weiner, 2007). Simulated data taken at the critical sampling time points were used for 
subsequent model fitting to estimate Ki values in Step #5 using PK Model #1.  
In order to test if the competitive inhibition mechanism of TS against CLint,Bile,TCA could be 
statistically distinguished from noncompetitive inhibition, the data set simulated by using PK Model #1 
(described by Equations 10-12, competitive inhibition of CLint,Bile,TCA
TS
) was fit by both Model #1 and 
Model #2 (the same as Model #1 except that inhibition of CLint,Bile,TCA
TS
 was assumed to be 













                                                                         (13) 
If Model #1 described the data better than Model #2, it indicated that the correct inhibition 
mechanism could be identified. The best-fit model was identified by the Akaike’s Information Criterion 
(AIC) value, CV% for the Ki,Bile estimate, and visual inspection of the predictions relative to the 
observations.  
Assessment of the Optimized Study Design in Different Hepatocyte Lots 
The best identified study design (i.e., dosing and sampling scheme) was developed based on 
simulated data using mean parameter values. The utility of this study design was assessed when inter-
individual variability was incorporated into the kinetic profiles of TCA and TS. First, using the selected 
study design, the TS-TCA interaction was simulated using TCA kinetic parameters for three different 
hepatocyte lots shown in Table 4.6. These simulated data were used for model fitting to estimate Ki 
values and compare the fitting results using Model #1 and Model #2. In addition, each of the seven 
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kinetic parameters describing TCA and TS disposition (shown in Figure 4.2) was varied by 2-fold (0.5X 
and 2X) around the mean value, while all other parameters were held constant. Fourteen different sets of 
data were simulated using these theoretical parameter values and PK Model #1. These simulated data 
were used for model fitting to estimate Ki values. The study design was selected if Ki,BL and Ki,Bile 
estimates were within 2-fold (i.e., <100% difference) of the reference values.   
To assess the impact of 2-fold variability in Ki on the simulation results, sensitivity analysis of 
Ki,Bile and Ki,BL was performed by varying each of these parameters by 2-fold while all other kinetic 
parameters were held constant, using the optimal dosing scheme.  
Results 
Estimation of TCA Kinetic Parameters  
The PK model of TCA adequately described the data from the three individual rat SCH lots, with 
modest but consistent over-prediction of the amount in the cells (Figure 4.3). Vmax,BL,TCA and 
Vmax,Bile,TCA values for the individual data sets were precisely estimated (CV% values were ≤21%). The 
CV% for the mean kinetic parameters of TCA varied from 19% and 70% (Table 4.6).  
Evaluation of the TS-TCA Interaction Model 
Predictions based on the TS-TCA interaction model were generally in accordance with the 
observed TCA disposition in TGZ pre-treated rat SCH from three different rat hepatocyte donors 
(Figure 4.4). There was modest but consistent over-prediction of the amount of TCA in the Cells and 
some under-prediction of the amount of TCA in Standard HBSS for Lot=1.  
Optimization of Study Design and Assessment in Different Hepatocyte Lots 
Among the dosing schemes shown in Table 4.5, only dosing scheme 4 and its corresponding 
optimal sampling schemes could generate data for reliable Ki estimates in different hepatocyte lots.  
When the number of samples was constrained to ≤10, other dosing schemes failed to provide reliable Ki 
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estimates in some of the hepatocyte lots assessed. In dosing scheme #4, Cells are pre-incubated with 
standard or Ca2+-free HBSS for 10 min. Following pre-incubation, cells are dosed with 2 µM of TCA in 
standard HBSS (uptake phase). After a 20-min TCA uptake phase, 50 µM of TS is added into the TCA-
containing incubation buffer for an additional 10-min TCA uptake phase. After the uptake phase, cells 
are washed for 1 min and then incubated with fresh standard or Ca2+-free HBSS containing 50 µM of TS 
for 20 min (efflux phase) (Figure 4.5). For dosing scheme 4, important sampling times based on Figure 
4.6 included the amount of TCA and TS in cell lysate during the uptake (20, 25, 30 min) and efflux (1, 
3, 5, 7, 9, 17, and 19 min) phases, and the amount of TCA and TS in the incubation buffer during the 
efflux phase (1, 3, 5, 7, 9, 17, and 19 min).  
The model fitting results using Model #2 were compared with the results using the correct 
inhibition mechanism (Model #1). Although AIC values generated by Model #1 were lower than those 
from Model #2 (Table 4.7), both models were able to describe the data equally well based on visual 
inspection of the generated curves (Figure 4.7). Therefore, data generated using this current study 
design cannot distinguish the correct inhibition mechanism from other mechanisms.  
The variation in both TCA and TS clearance values may affect the identifiability of Ki using the 
current study design. This is because for different TCA PK profiles, the sensitive regions shown in 
Figure 4.6 may differ, or may even be beyond the end of the experiment. In that case, this study design 
may not be suitable for some hepatocyte lots. This question was addressed in Step #5 and shown in 
Table 4.7 and Figure 4.8. For the three hepatocyte lots, the differences between the Ki estimates and 
reference values were within 100% when the correct inhibition mechanism was assumed (Model #1). 
The CV% for all the parameter estimates in Table 4.7 were very small, although the parameters 
estimated using the two models were substantially different. For the 14 hypothetical hepatocyte lots, 
which were generated when the seven kinetic parameters describing the disposition of TCA and TS were 
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varied by 2-fold, the differences between the estimated Ki values and reference values were within 100% 
(Figure 4.8). In all cases, the estimated Ki,Bile values were greater than the reference values. In general, 
the estimated Ki,BL values were also greater than the Ki,BL reference values.  
Based on Figure 4.9, a 2-fold change in Ki around the reference values (i.e. 0.11-0.46 µM for 
Ki,Bile and 4-16 µM for Ki,BL) had minimal impact on the predicted Ct,Cells,TCA and Ct,Cells+Bile,TCA. 
Discussion 
This study generated options for an optimal study design for collecting mass-time data in rat 
SCH to estimate Ki of TS against biliary and basolateral efflux clearance values of TCA. Through 
modeling the interaction between TS and TCA, both Ki values in different hepatocyte lots were 
estimated simultaneously and limitations on accuracy were evaluated. This study highlighted how 
existing bile acid kinetic data could be leveraged by using modeling and simulation to try to develop 
efficient experimental protocols for the quantitative analysis of bile acid PK data in SCH.  
The optimization and assessment of the study design were based on simulated data using pre-
existing knowledge of the kinetic parameters of TCA and TS, and the inhibition potency. Assumptions 
that were made for the modeling and simulation are listed in Table 4.1. The justification for, and 
limitations of, these assumptions are discussed below.  
Assumptions about Km and Ki values were based on the current knowledge of TCA transport 
mechanisms shown in Table 4.3. Km values were fixed to literature values obtained from membrane 
vesicles expressing human or rat transporters. Km values may be affected by the expression level of the 
transporters (Shirasaka et al., 2008). Transporters other than BSEP and MRP4 may be involved in TCA 
biliary excretion and basolateral efflux, respectively. Therefore, the Km values fixed in this study may 
not represent the true Km value in rat SCH. In addition, the uptake and basolateral efflux mechanisms of 
TCA were assumed to be the same for rat and human because data generated with the rodent proteins 
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were not available. Michaelis-Menten equations were used to describe efflux clearance values in order 
to estimate Ki and identify inhibition mechanisms for efflux clearance pathways. Linear uptake of TCA 
was assumed because Ct,Buffer,TCA was much lower than the Km for NTCP, and the estimation of Ki and 
identifying the inhibition mechanism for CLUptake, TCA were not the objective of this study.  
It was assumed that TCA did not affect the disposition of TS. Based on current knowledge 
(Table 4.3), the dosing concentration of TCA proposed in this study (2 µM) would not affect the uptake 
of TS. The inhibitory effect of TCA on Bcrp and basolateral efflux transporters of TS is unknown.  
Noncompetitive inhibition of TS against CLint,BL,TCA was assumed based on previously published 
MRP4 membrane vesicle studies with [3H]-dehydroepiandrosterone sulfate as the substrate (Yang et al., 
2014). It is not clear if a substrate-dependent inhibition mechanism exists and if the potential 
involvement of other hepatic basolateral efflux transporters could affect the inhibition mechanism. In the 
study by Yang et al., the maximum Ct,Cells,TCA for hepatocyte Lots #1-3 was <1 µM (Figure 4.4); these 
concentrations are much lower than Km,BL,TCA (7.7 μM). Thus, CLint,BL,TCA would be expected to be in the 
linear range and the mechanism of inhibition should have a minimal effect on the prediction results. 
With higher Ct,Cells,TCA, it might be possible to differentiate the inhibition mechanisms.   
Despite the uncertainty in the assumptions mentioned above, this TS-TCA interaction model 
could be parameterized to give good agreement between predicted and experimental data in the presence 
of TGZ (Figure 4.4).  
As shown in Figure 4.8, using the current study design, the accuracy in Ki estimates was 
modestly sensitive to the variability in TCA and TS kinetics. In all cases, estimated Ki,Bile values were 
higher than the reference value. This may have occurred because Cu,Cells,TS was much higher than the 
reference value for Ki,Bile, (0.23 μM) when samples were taken. As shown in Figure 4.10, using the 
optimized dosing scheme (#4), Cu,Cells,TS was 0.6 μM at the first sampling point (25 min of uptake 
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phase). As shown in Figure 4.9, Ct,Cells,TCA and Ct,Cells+Bile,TCA were relatively insensitive to changes in 
Ki,Bile (0.11-0.46 µM) and Ki,BL (4-16 µM), indicating the potential challenge in accurately assessing the 
Ki values in the proposed experiment. Adding additional inhibitor doses should be considered to 
improve the accuracy of Ki estimation.  
There was ambiguity in determining the mechanism of inhibition using the current protocol. 
None of the dosing schemes assessed in this study were able to clearly differentiate competitive and 
noncompetitive inhibition against CLint,Bile,TCA. As shown in Figure 4.7, the optimal study design could 
not identify the inhibition mechanism in three hepatocyte lots. Therefore, in subsequent studies, only 
Model #1 was considered. One possible explanation for the challenge in distinguishing the inhibition 
mechanism is that the intracellular concentrations of TCA and TS did not span a broad enough range, or 
there was no/minimal overlap when the inhibitor and substrate were both within the critical 
concentration range. For reliable estimation of Ki values, generally Cu,Cells,TS needs to range from 0 to the 
Ki value (0.23 μM and 8 μM) or higher. Conventionally, Cu,Cells,TS that generates approximately 50-80% 
inhibition is considered the most informative region to determine Ki (Murphy, 2004). A later study 
showed that Ki estimates based on five inhibitor concentrations that ranged from 0 to the Ki value were 
sufficient (Zheng and Polli, 2010). To distinguish the inhibition mechanism for CLint,Bile,TCA, it is 
desirable that Ct,Cells,TCA spans from 1/5
th to 5-fold of the  Km,Bile,TCA (9.7 μM)(Ring et al., 2014). The 
timeframe when these criteria were met is shaded in blue and red in Figure 4.10. In dosing scheme 2 
and 3, there was sufficient overlap between the blue and red shaded areas for an average hepatocyte lot. 
When experimental and inter-donor variabilities are considered, this overlap might be difficult to 
achieve. Another possible explanation for the inability to distinguish the inhibition mechanism is that for 
each substrate concentration, there was only one inhibitor concentration present at that time point, since 
the intracellular concentrations of TCA and TS were dynamic. This is different from the traditional 
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approach to determining the mechanism of inhibition in which the inhibitor and substrate concentration 
at the site of interaction are static, and for each substrate concentration, there are 5 inhibitor 
concentrations. For future studies, two additional inhibitor and substrate dose levels should be included 
to obtain information about the inhibition mechanism. 
The best currently available study design was identified after examining multiple dosing 
schemes, as shown in Table 4.5. Only dosing scheme 4 was able to generate data that met the following 
criteria:  moderate accuracy of Ki estimates (<2-fold difference) with a reasonable number of sampling 
points (≤ 10) in hepatocyte lots with variable kinetic profiles of TCA and TS. The dosing schemes were 
designed based on the following considerations. The length of the efflux phase in standard and Ca2+-free 
HBSS is limited by 25 min because cell viability begins to decrease after prolonged exposure to Ca2+-
free HBSS (Swift et al., 2010). TS is a potent inhibitor of Ntcp and shows high intracellular binding. 
Thus, obtaining sufficient Cu,Cells,TS without diminishing TCA uptake is challenging. To address that 
issue, in dosing scheme 4, TS was added into the system in the middle of the TCA uptake phase to allow 
for TCA accumulation in the Cells, which is important for measuring efflux clearance values.  
In conclusion, using the best study design identified, Ki values of TS against TCA biliary and 
basolateral efflux clearance values in rat SCH could be estimated moderately accurately using a single 
dose of TS and TCA. This optimal study design could not distinguish competitive and noncompetitive 
inhibition mechanisms; this may require additional dose levels of TS and TCA. Modeling and 
simulation were helpful in utilizing known PK information for TCA and TS to facilitate the design of 






Table 4.1. Summary of each step in the Methods and Results. The definition of kinetic parameters are shown in Table 4.2.  
Step Data Input Assumptions Modeling & Simulation 
1. Estimate TCA 
kinetic 
parameters 
 TCA PK profile in control 
rat SCH (n=3 hepatocyte 
lots) a   
 Km,Bile,TCA and Km,BL,TCA c 
 Km,Bile,TCA=Km of TCA for rat Bsep 
 Km,BL,TCA=Km of TCA  for human MRP4  
 Linear uptake and nonlinear efflux 
clearances 
Estimate CLUptake,TCA, 
Vmax.BL,TCA and Vmax,Bile,TCA  in 
each control rat SCH (Table 





 TS PK parameters in  rat 
SCH b 
 TCA PK parameters 
estimated in Step #1 
 Ki,Bile, Ki,BL, and Ki,Uptake c 
 Ki,Bile=Ki of TS against Bsep; Ki,BL=Ki of TS 
against MRP4; Ki,Uptake=Ki of TS against 
Ntcp 




TS , and noncompetitive inhibition 
of CLint,BL,TCA
TS  
 No effect of TCA on TS disposition  
Simulate the effect of TS on 
TCA disposition using TCA 
clearance values calculated by 
Eqs. 10-12 and model structure 





TCA PK profile in rat SCH 






  values (n=3 
hepatocyte lots) a     
 During pre-incubation, all the TGZ was 





 values in SCH 
pre-incubated with TGZ cannot be described 
by Eq. 12; therefore, literature values were 
used a 
 Simulate the effect of TGZ 
pre-incubation on TCA 






values reported a 
 Compare simulated data with 
experimental observations a 
(Fig. 4.4) 
4. Optimize the 
study design 
 Mean values of TCA (Step 
#1) and TS parameters in 
control rat SCH b   
 Various dosing schemes 
 
The study design is considered to be 
“optimal” if it can generate data for reliable 
estimation of Ki values (within 2-fold of 
reference value) in an average hepatocyte lot 
 Simulate TS effect on TCA 
disposition using various 
dosing schemes (Table 4.5) 
 Fit the TS-TCA interaction 
model to the simulated PK 
profiles  
 Optimize the sampling 







a (Yang et al., 2015) 
b (Lee et al., 2010) 
c Table 4.3
 Select the optimal study 
design (Fig. 4.5) 
5. Assess the 








 TCA PK parameters from 3 
different lots of control rat 
SCH estimated in Step #1 
 Mean values of TCA (Step 
#1) and TS PK parameters  
b 
The study design is optimal if it can generate 
data for reliable estimation of Ki values 
(within 2-fold of reference value) in different 
lots of SCH with variable TCA and TS PK 
profiles 
 Simulate TCA PK profiles 
using the optimized study 
design in 3 different lots of  
rat SCH  
 Simulate TCA PK profiles 
when TCA and TS PK 
parameters are varied by 2-
fold around the mean value 
 Fit the TS-TCA interaction 
model to each of the 
simulated PK profiles (Fig. 
4.7, 4.8, Table 4.7) 
 Assess whether the optimized 
protocol remains optimal in 








Table 4.2. Definition of variables and parameters in Equations 1-12. 
Category Name Definition 
Dependent 
variables 
Ct,Cells,TCA Total concentration of TCA in the Cells 
Ct,Buffer,TCA Total concentration of TCA in the Buffer 
Xt,Cells,TCA Total amount of TCA in Cells 
XCells+Bile,TC
A 
Total amount of TCA in Cells+Bile 
Xt,Bile,TCA Total amount of TCA in Bile 
Cu,Cells,TS 
Unbound intracellular concentration of TS, which equals the 
product of the total intracellular concentration and the intracellular 
unbound fraction a 
Cu,med,TS 
Unbound medium concentration of TS, which is equivalent to the 
total concentration due to the absence of protein in the medium 
Superscript
s 
“+” and “-“ 
Ca2+-containing (standard) HBSS and Ca2+-free HBSS, 
respectively 
“TS” Parameter values in the presence of TS 
Kinetic 
parameters 
CLUptake,TCA Uptake clearance of TCA, assumed to be linear 
CLint,BL,TCA 
Intrinsic basolateral efflux clearance of TCA, assumed to be 
nonlinear (Michaelis-Menten)  
CLint,Bile,TCA 
Intrinsic biliary clearance of TCA, assumed to be nonlinear 
(Michaelis-Menten)  
KFlux,TCA 
First-order rate constant that describes the flux of TCA from bile 
networks into the medium b  
Vmax,BL,TCA Maximum velocity for CLint,BL,TCA 
Vmax,Bile,TCA Maximum velocity for CLint,Bile,TCA 
Km,BL,TCA TCA concentration at one-half Vmax,BL,TCA, fixed at 7.7 μM
 c  
Km,Bile,TCA TCA concentration at one-half Vmax,Bile,TCA, fixed at 9.7 μM 
d 
CLUptake,TS Uptake clearance of TS, assumed to be linear 
CLint,BL,TS Intrinsic basolateral efflux clearance of TS, assumed to be linear  





Volume of cellular compartment, fixed depending on the protein 
content of each preparation e 
VBuffer Volume of buffer compartment, fixed at 1.5 mL/well 
Kwash 
Wash term to remove TCA at the end of the uptake phase, 
activated for 1 min and fixed at 5x104 min-1  
Xdose,TCA 
Total amount of TCA added in the incubation buffer, which is the 
product of dosing concentration of TCA and VBuffer 






Ki,BL Ki of TS on CLint,BL,TCA, fixed at 8 μM 
g 
Ki,Bile Ki of TS on CLint,Bile,TCA, fixed at 0.23 μM 
h   
a set at 0.003, assumed to be the same as the intracellular unbound fraction of TS in human 
hepatocytes (Guo et al., 2017; Riccardi et al., 2018) 
b(Lee et al., 2010; Pfeifer et al., 2013; Yang et al., 2015) 
cassumed to be the same as the Km for human MRP4 determined in membrane vesicles (Table 
4.3) 
dassumed to be the same as the Km for rat Bsep determined in membrane vesicles (Table 4.3) 
eranged from 5.5-7.6 µL/well for hepatocyte Lot#1-3 cultured in 6-well plates. An average value 
of 6.4 µL/well was used for simulation. 
fassumed to be the same as the IC50 of TGZ for rat Ntcp (Table 4.3) 
gassumed to be the same as the Ki of TS for human MRP4 determined in membrane vesicles 
(Table 4.3) 















Table 4.3. Parameter values describing the interaction of TCA and TS with human or rat bile 
acid and TS transporters. The inhibition mechanism was assumed to be competitive for all 
parameters unless indicated otherwise. 






NTCP (Km=5-20 μM, 70% of 
total clearance) 
OATP1B (Km=5.8-72 μM, 








Inhibitor OATP1B1 (Ki=11.4 µM)
b   
TS 
Inhibitor 
Ntcp (IC50=2.3 μM) 
c, 









Substrate OATP1B1 and OATP1B3 d  Bcrp i 
a (Shitara et al., 2003; Nozawa et al., 2004a; Mita et al., 2006) 
b (Gui et al., 2009) 
c Assumed to be the same as TGZ (Marion et al., 2007) 
d (Nozawa et al., 2004b) 
e (Rius et al., 2006) 
f (Yang et al., 2015) 
g (Hayashi et al., 2005) 
h (Funk et al., 2001) 






Table 4.4. Kinetic parameters of TS in rat SCH cultured in 6-well plates.  
Kinetic Process Rate constant (min-1) a Clearance (µL/min/6 well) b CV (%) 
CLUptake,TS 0.004 6 36 
CLint,BL,TS 0.018 0.11 39 
CLint,Bile,TS 0.035 0.21 21 
a published by (Lee et al., 2010) 
b Efflux clearance values were calculated as the product of the rate constant and 6.4 (µL/well), 
which is VCells; Uptake clearance values were calculated as the product of the rate constant and 



















Table 4.5. Different dosing schemes assessed in this study. The time period that each compound 
was present in the incubation system is noted in parentheses. A 1-min wash phase was included 







TCA     5 µM (0-20min) 
TS 10 µM (10-20min) 10 µM (21-41min) 
2 
TCA 5 µM (0-20 min)  
TS  50 µM (21-41 min) 
3 
TCA 5 µM (0-30min)  
TS 50 µM (20-30 min) 50 µM (31-51min) 
4 
TCA       2 µM (0-30min) 
















Table 4.6. Parameter estimates (CV%) of TCA obtained by fitting PK Model #1 to the published 
data from control rat SCH (Yang et al., 2015). Data from three different rat hepatocyte donors are 
designated as Lots 1-3.  
Parameter Unit Lot=1 Lot=2 Lot=3 Mean CV (%) 
CLUptake,TCA μL/min/well 15 (14%) 11 (6.5%) 6.4 (10%) 11 41 
Vmax,BL,TCA  pmol/min/well 34 (2.9%) 15 (2.7%) 8.1 (9.3) 19 70 
Km,BL,TCA  μM 7.0 (FIXED) 7.0 N/A
a 
Vmax,Bile,TCA pmol/min/well 17 (21%) 12 (9.3%) 16 (9.5%) 15 19 
Km,Bile,TCA  μM 9.7 (FIXED) 9.7 0 
KFlux,TCA min
-1 0.071 (15%) 0.057 (10%) 0.057 (14%) 0.053 N/Aa 

















Table 4.7. Best-fit parameters (μM) for TS and associated AIC values for competitive (Model 
#1) or noncompetitive (Model #2) inhibition of CLint,Bile,TCA using the simulated TCA profile 
from three different lots of hepatocytes.   



















Ki,BL Estimate 6.7 5.9 13.0 14.4 13.6 15.3 8 
 CV (%) 0.63 0.67 2.9 5.4 6.6 7.9  
Ki,Bile Estimate 0.46 0.59 0.40 0.65 0.41 0.58 0.23 
 CV (%) 0.70 0.73 2.4 4.1 3.7 5.6  


















Figure 4.1. Workflow of the methods. The definition of kinetic parameters are shown in Table 
4.2. Green and blue boxes represent data input and modeling & simulations, respectively. If Step 
#5 shows that the optimized study design is not useful different hepatocyte lots, Step #4 will be 
repeated for a different dosing scheme.   
 
 
a (Yang et al., 2015) 
b Published data as shown in Table 4.3 
c (Lee et al., 2010) 
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Figure 4.2. Model schemes depicting the disposition of TCA and interaction of TS and TCA in 
rat SCH. The model structure for TCA in standard HBSS and Ca2+-free HBSS was adapted from 
a previous study (Guo et al., 2016). The model structure for TS in Ca2+-free HBSS was adapted 
from a previous study (Lee et al., 2010). CLUptake, CLint,BL, and CLint,Bile represent the uptake 
clearance, intrinsic basolateral efflux clearance, and intrinsic biliary clearance, respectively. KFlux 
represents the flux from bile networks into the medium. CLint,BL,TCA and CLint,Bile,TCA are inhibited 













Figure 4.3. Observed (symbols) and model-fitted (solid lines) TCA amount vs. time in control 
rat SCH. Data from three different rat hepatocyte donors (Lots=1-3) are presented in black, blue, 












Figure 4.4. Observed (symbols) and model-simulated (solid lines) TCA amount vs. time in rat 
SCH after 30-min pre-incubation with TGZ. Data from three different rat hepatocyte donors 













Figure 4.5. Optimal dosing and sampling scheme to generate data for the estimation of Ki,BL and 
Ki,Bile for TS using TCA as the substrate in rat SCH. Sampling time points include 20, 25, and 30 





















Figure 4.6. Model-predicted partial derivative plots of TCA amount in different compartments  
with respect to Ki,Bile (red line, left y-axis) and Ki,BL (black line, right y-axis) vs. time for TS-TCA 
interaction model using the mean kinetic parameters and the optimal dosing scheme (#4). Yellow 














Figure 4.7. Observed (symbols) vs. model-fitted (solid lines) amount of TCA in different 
compartments. (A) Modeling fitting using PK Model #1 (noncompetitive inhibition against 
CLint,BL,TCA
TS
 and competitive inhibition against CLint,Bile,TCA
TS
); (B) Model fitting using PK Model 
#2 (noncompetitive inhibition against CLint,BL,TCA
TS
 and CL int,Bile,TCA
TS
)The optimal study design 
was used to generate the data. The yellow, red and blue bars at the top represent the uptake phase 






Figure 4.8. Sensitivity of Ki,BL and Ki,Bile estimates to changes in TCA and TS kinetic 
parameters. Each of TCA and TS kinetic parameter was varied by 2-fold (0.5X, gray bars; 2X, 
black bars) of the mean value while all other kinetic parameters were held constant. The 
difference between the estimated Ki values using PK Model #1 and the reference values (8 μM 


































Figure 4.9. Sensitivity of TCA profiles to changes in Ki,Bile (blue) and Ki,BL (orange). Simulations 
were performed using the optimal study design and PK Model #1; Ki,Bile and Ki,BL were changed 





















Figure 4.10. Intracellular concentrations of total TCA (red lines) and unbound TS (blue lines) 
vs. time simulated using the four different dosing schemes presented in Table 4.5 based on PK 
Model #1. Mean kinetic parameters of TCA and TS were used for the simulation. The red shaded 
area represents the timeframe when TCA concentrations was greater than 5-fold of Km,Bile,TCA 
(9.7 μM).  The blue shaded area represents the timeframe when TS concentrations were greater 












Figure 4.11. Workflow showing how to integrate the prior information and modify the proposed 
study design to estimate Ki values of inhibitors. 
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Figure S4.1. Simulated unbound concentration of TGZ and TS in Cells over time using the 
protocol published by Yang et al (Yang et al., 2015). Briefly, rat SCH (n=3 hepatocyte lots) were 
pre-incubated with TGZ (10 µM) for 30 min in standard HBSS; then, rat SCH were incubated for 
10 min in standard or Ca2+-free HBSS, followed by uptake of 3H-TCA (1 µM) in standard HBSS 
and efflux of 3H-TCA  in standard and Ca2+-free HBSS, all in the absence of TGZ. Kinetic 

















CHAPTER 5. FXR Agonists Obeticholic Acid and Chenodeoxycholic Acid Increase Bile 
Acid Efflux in Sandwich-Cultured Human Hepatocytes: Functional Evidence and 
Mechanisms4 
Introduction 
Farnesoid X Receptor (FXR) is a nuclear receptor that regulates genes involved in the 
homeostasis of bile acids (Lefebvre et al., 2009). Bile acids are signaling molecules that 
modulate hepatic metabolic and transporter function (Dawson et al., 2009), inflammation (Allen 
et al., 2011) as well as lipid, glucose and energy homeostasis (Staels and Kuipers, 2007; Thomas 
et al., 2008; Lefebvre et al., 2009). Therefore, FXR is a promising novel drug target to treat 
metabolic and chronic liver diseases, such as non-alcoholic steatohepatitis (NASH) and primary 
sclerosing cholangitis (Wagner et al., 2011; Trivedi et al., 2016; Fiorucci et al., 2007; Jiang et al., 
2007). The first-in-class FXR agonist, obeticholic acid (OCA), has been approved for the 
treatment of primary biliary cholangitis (PBC). FXR is activated by various bile acids; 
chenodeoxycholic acid (CDCA) and conjugated CDCA species are the most potent natural 
agonists. OCA is an analog of CDCA, with 100-fold higher FXR activation potency (median 
effective concentration is 99 nM for OCA vs. 8.3 µM for CDCA) (Soisson et al., 2008; Markham 
and Keam, 2016).  
                                                          
4This chapter has been published as C Guo, C LaCerte, JE Edwards, KR Brouwer, and KLR Brouwer (2018) FXR 
Agonists Obeticholic Acid and Chenodeoxycholic Acid Increase Bile Acid Efflux in Sandwich-Cultured Human 
Hepatocytes: Functional Evidence and Mechanisms, J Pharmacol Exp Ther, DOI: 
https://doi.org/10.1124/jpet.117.246033. Reprinted with permission of the American Society for Pharmacology and 
Experimental Therapeutics and is presented in the style of that Journal. All rights reserved.  
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Activation of FXR protects against the toxic accumulation of bile acids by decreasing 
bile acid synthesis and regulating bile acid transport (Adorini et al., 2012).  For example, FXR 
activation by CDCA increased mRNA expression of bile acid efflux transporters including the 
bile salt export pump (BSEP) (Yu et al., 2002; Modica et al., 2010), multidrug resistance-
associated protein 2 (MRP2) (Liu et al., 2014; Modica et al., 2010), and organic solute 
transporter (OSTα/β) (Liu et al., 2014; Modica et al., 2010; Boyer et al., 2006) in hepatic cell 
lines and primary human hepatocytes. Sandwich-cultured human hepatocytes (SCHH) are a 
physiologically-relevant model that maintains transporter function, morphology and regulatory 
machinery (LeCluyse et al., 2000; Yang et al., 2016), and therefore is an ideal system to study 
the regulation of bile acid transporters after non-acute (>24 hr) treatment of hepatocytes with 
FXR agonists. Recent studies revealed that OCA and CDCA treatment of SCHH for 72 hr 
increased mRNA expression of OSTα/β and BSEP with minor changes in MRP3, MRP4, and 
sodium taurocholate cotransporting polypeptide (NTCP) (Jackson et al., 2016; Zhang et al., 
2017).  
Unlike drug metabolizing enzymes, changes in gene expression of transporters do not 
always translate to changes in protein expression (Ahlin et al., 2009; Thompson et al., 2017) 
and/or function (Ohtsuki et al., 2012). This discrepancy may be explained by the prominent role 
of post-transcriptional regulation of hepatic transporters and the importance of transporter 
localization in determining transporter function (Gu and Manautou, 2010; Schonhoff et al., 2013; 
Wang et al., 2002; Chandra et al., 2005; Zhang et al., 2005).  
Due to discrepancies between gene expression and transporter function, direct functional 
evidence for FXR agonist-mediated induction of bile acid efflux transporters (i.e., OSTα/β and 
BSEP) is lacking.  One of the challenges in quantitative assessment of hepatic transporter 
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function is the multiplicity of transporters expressed on the basolateral and canalicular 
membranes of hepatocytes, and the concurrent uptake and efflux of bile acids. Studies showed 
reduced intracellular accumulation of deuterium-labeled taurocholic acid (d8-TCA), a 
prototypical bile acid, after treatment of SCHH with OCA and CDCA (Jackson et al., 2016; 
Zhang et al., 2017). Since d8-TCA was added exogenously and the synthesis rate of TCA does 
not play a role, this change could be due to increased efflux or decreased uptake of d8-TCA. On 
the basolateral membrane of human hepatocytes, NTCP, and to a much lesser extent the organic 
anion-transporting polypeptides (OATPs), contribute to TCA uptake. MRP3, MRP4, and 
OSTα/β are responsible for the basolateral efflux of TCA from human hepatocytes to the 
sinusoidal blood (Seward et al., 2003; Zhang et al., 2003; Rius et al., 2006; Ballatori et al., 2008; 
Soroka et al., 2010). To deconvolute these processes, a more sophisticated method, such as 
pharmacokinetic (PK) modeling is needed. To assess the function of the canalicular transporter 
BSEP, TCA biliary excretion can be quantified in SCHH using B-CLEAR® technology.   
In the present study, mechanistic PK modeling of data obtained from SCHH using B-
CLEAR® technology and our previously published basolateral efflux protocol (Pfeifer et al., 
2013; Yang et al., 2015; Guo et al., 2016) was utilized to characterize the functional changes in 
bile acid transporters that occur with FXR activation. Changes in the basolateral uptake 
clearance, intrinsic basolateral efflux clearance, and intrinsic biliary clearance of an exogenously 
administered model bile acid, d8-TCA, were evaluated in SCHH after 72-hr treatment with OCA 
and CDCA to reflect the transporter function. In order to identify the transporters that might be 
responsible for alterations in the overall clearance, the protein expression of TCA uptake and 
efflux transporters was assessed by immunoblot analysis. 
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Materials and Methods 
Materials 
BioCoatTM cell culture plates and Matrigel® were obtained from BD Biosciences (San 
Jose, CA). QualGroTM medium was obtained from Qualyst Transporter Solutions (Durham, NC). 
d8-TCA was obtained from Toronto Research Chemicals (ON, Canada). Pierce bicinchoninic 
acid protein assay was obtained from Thermo Fisher Scientific (Waltham, MA).  
Primary antibodies for OSTα, OSTβ, BSEP, and NTCP were purchased from Abcam 
(Cambridge, MA). Primary antibodies for MRP3 and MRP4 were obtained from Cell Signaling 
Technology (Danvers, MA) and Everest Biotech (Ramona, CA), respectively. The primary 
antibody for ATPase and all the secondary antibodies were purchased from Santa Cruz 
Biotechnology (Dallas, TX). Other reagents for immunoblot were obtained from Bio-Rad 
(Hercules, CA) or Thermo Fisher Scientific unless stated otherwise.   
Hepatocyte Culture and FXR Agonists Treatment 
Transporter CertifiedTM cryopreserved human hepatocytes [HC3-26, HUM4122C/D, 
HUM4119C, and HUM8246 purchased from Xenotech (Kansas City, KS), Lonza (Basel, 
Switzerland), and Thermo Fisher Scientific, respectively] were obtained from two Caucasian 
females, one Asian male, and one African American female donor, respectively (age range: 30-
43 years; body mass index range: 22-39). Hepatocytes were seeded at a density of 0.4-0.5×106 
cells/well in 24-well BioCoatTM plates and cultured in a sandwich configuration (overlaid with 
Matrigel®) in QualGroTM Induction Medium as previously reported (Swift et al., 2010). On Day 
2 of culture, SCHH were treated with OCA (1 µM), CDCA (100 µM), or vehicle control for 72 
hr. The dose of OCA was selected based on the maximum plasma concentration of OCA at 
steady state (~0.7-1 µM) (Edwards et al., 2016). In addition, based on the dose-gene expression 
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relationships published previously, the maximal effect on the induction of downstream genes 
was achieved at 1 µM OCA and 100 µM CDCA (Jackson et al., 2016; Zhang et al., 2017). 
Previous studies using the same lots of human hepatocytes (Jackson et al., 2016; Zhang et al., 
2017), and a study using different lots of human hepatocytes (Yang et al., 2016), demonstrated 
that neither OCA (1 µM) nor CDCA (100 µM) affected the viability of SCHH.  The medium was 
changed every 24 hr. 
d8-TCA Uptake and Efflux in SCHH 
On Day 5 of culture (at the end of 72-hr treatment), uptake of d8-TCA in Ca
2+-containing 
(standard) Hanks’ balanced salt solution (HBSS) and efflux of d8-TCA in standard and Ca
2+-free 
HBSS were performed (n=3 donors, HC3-26, HUM4122C, and HUM4119C, measured in 
triplicate), as described previously (Guo et al., 2016; Yang et al., 2015). Briefly, SCHH were 
pre-incubated with standard or Ca2+-free HBSS for 10 min. Incubation with Ca2+-free HBSS 
disrupts the tight junctions which seal the canalicular networks, allowing the contents in the bile 
canaliculi to be released into the medium (B-CLEAR® technology)(Liu et al., 1999). Following 
pre-incubation, SCHH were dosed with 2.5 µM of d8-TCA in standard HBSS containing 4% 
bovine serum albumin (BSA) for 20 min (uptake phase). The presence of BSA (Fraction V, 
Thomas Scientific, NJ) during the uptake phase mimics the effect of protein binding in vivo. 
After the uptake phase, the cells were washed for 1 min and incubated with fresh protein-free 
standard or Ca2+-free HBSS for 15 min (efflux phase). The total amount of d8-TCA in Cells+Bile 
(standard HBSS) and Cells (Ca2+-free HBSS) during the uptake phase (2, 5, 10, and 20 min) and 
the efflux phase (2, 5, 10, and 15 min), and the total amount of d8-TCA in the incubation buffer 
during the efflux phase (2, 5, 10, and 15 min), were determined by liquid chromatography–mass 
spectrometry as reported previously (Guo et al., 2016).  
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Model-independent parameters describing the overall hepatobiliary disposition of TCA in 
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BRI=
AmountBuffer during efflux phase
 AmountCells at end of 20- min uptake
  ×100%                                                             (3) 
CLapp,Bile represents the in vitro apparent biliary clearance calculated at 10 min during the 
uptake phase. The biliary excretion index (BEI), determined at 10 min during the uptake phase, 
represents the fraction of compound accumulated in the bile compartment relative to the total 
accumulation of compound in Cells+Bile. The Buffer Recovery Index (BRI), determined at 2 
min during the efflux phase, represents the fraction of compound effluxed from Cells and fluxed 
from bile canaliculi into the buffer relative to the total accumulation in Cells at the end of the 20-
min uptake phase. 
PK Modeling of TCA Disposition in SCHH 
A mechanistic PK model (scheme depicted in Fig. 5.1) incorporating linear clearance 
processes (Guo et al., 2016; Yang et al., 2015) was modified and fit to the TCA total mass-time 
data in Cells+Bile, Cells, standard HBSS, and Ca2+-free HBSS using Phoenix WinNonlin 7.0 
(Certara USA, Inc., Princeton, NJ). A mixed proportional and additive error model was used to 
account for residual error. Parameter estimates from a previous report were used as initial 
estimates for the control group (Guo et al., 2016). Data from the same hepatocyte donor exposed 
to different treatments were modeled together. Various model structures were tested. The best-fit 
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model was selected based on Akaike’s Information Criterion, the precision of parameter 
estimates, the degree of bias in the residual error, and visual inspection of the predicted curves 
relative to the observed data. The following kinetic parameters were estimated: total uptake 
clearance (CLUptake), total intrinsic basolateral efflux clearance (CLint,BL), total intrinsic biliary 
clearance (CLint,Bile), and the rate constant describing flux from bile networks into the medium 
(KFlux) due to periodic contraction of bile canalicular networks (Oshio and Phillips, 1981; Lee et 
al., 2010). The mean values and coefficient of variation (CV%) of parameter estimates from the 
three donors were calculated. Differential eqs 4 to 8 were used to describe the changes in the 
amount of TCA with respect to time in different compartments in this model.  
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where Ct,Cells represents the total intracellular concentration, and was calculated as Xt,Cells/VCells; 
VCells represents cellular volume and was calculated and fixed using the protein content of each 
hepatocyte preparation and a value of 7.4 μL/mg protein (Pfeifer et al., 2013; Yang et al., 2015); 
“+” and “-" refer to Ca2+-containing (standard HBSS) and Ca2+-free HBSS, respectively; Xt,Cells, 
Xt,Cells+Bile, and Xt,Bile represents total amount in Cells, Cells+Bile, and Bile, respectively; Ct,Buffer 
represents the total concentration in Buffer; VBuffer was set as a constant (0.3 mL); CLu,Uptake 
represents unbound uptake clearance; CLu,int,BL represents unbound intrinsic basolateral efflux 
clearance; CLu,int,Bile represents unbound intrinsic biliary clearance. The fu,buffer represents 
unbound fraction in buffer containing 4% BSA; fu,buffer was set at 0.15 (Wolf et al., 2008) during 
the 20-min uptake phase, and set at 1 during the 15-min efflux phase because BSA was present 
only in the uptake phase. The fu,cell represents unbound fraction in hepatocytes, and was assumed 
to be 0.15. CLUptake was calculated as fu,buffer × CLu,Uptake; CLint,BL and CLint,Bile were calculated as 
fu,cell × CLu,int,BL and fu,cell × CLu,int,Bile, respectively. To mimic the 1-min wash between the uptake 
and efflux phase, KWash was activated for 1 min using an if-then statement. KWash was fixed at 
5×104 min-1, which was sufficient to eliminate the d8-TCA from the buffer compartment. Protein 
concentrations were measured by the bicinchoninic acid assay. 
Immunoblots 
At the end of 72-hr treatment (Day 5 cultures), SCHH (n=3 hepatocyte donors, 
HUM4122D, HC3-26, and HU8246) were washed with PBS, and the membrane protein was 
extracted using ProteoExtract® Native Membrane Protein Extraction Kit (Millipore Sigma, 
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Burlington, MA). Membrane proteins (12 µg, without boiling) were mixed with loading buffer 
containing 50 mM dithiothreitol and resolved on NuPAGE 4 to 12% Bis-Tris gel or 7% Tris-
Acetate gel and the proteins were transferred to polyvinylidene fluoride membranes. After 
blocking in 5% nonfat milk in Tris-buffered saline with Tween 20 (TBST) for 1 hr, blots were 
incubated with the following primary antibodies diluted in 5% BSA (Sigma-Aldrich, St. Louis, 
MO): OSTα, (1:500), OSTβ (1:500), MRP3 (1:1000), MRP4 (1:200), BSEP (1:1000), NTCP 
(1:1500) overnight at 4 °C or with primary antibody for ATPase (1:500) for 3 hr at room 
temperature. Then the blots were probed with horseradish peroxidase-conjugated anti-rabbit 
(OSTs, BSEP, MRP3, NTCP, ATPase) or anti-goat IgG secondary antibody (MRP4) for 1 hr at 
room temperature (1:7000). Signals were detected by using the Amersham ECL Select Western 
Blotting Detection Reagent (GE Healthcare Bio-Sciences, Pittsburgh, PA) or Clarity Max ECL 
Substrate (Bio-Rad, Hercules, CA) with a BioRad ChemiDoc XRS+ system. Densitrometric 
analysis was performed using Image-J 1.6.0 (NIH, MD, US).  
Data Analysis 
Statistical analysis was performed on the clearance values and immunoblot results using 
GraphPad Prism (V6.01, La Jolla, CA). One-way ANOVA with Bonferroni’s test was used to 
correct for multiple comparisons with the control group. 
 
Results 
Uptake and Efflux of d8-TCA in SCHH 
OCA and CDCA treatment markedly decreased the total amount of TCA in hepatocytes, 
the hepatocyte plus bile compartment, and the efflux buffer (Fig. 5.2). The BRI (%), representing 
the fraction of accumulated TCA in hepatocytes that undergoes efflux into buffer, was increased 
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from 27-36% in control to 50-53% and 47-78% in OCA- and CDCA-treated SCHH, 
respectively. The CLapp,Bile of TCA ranged from 0.62-1.2 µL/min per milligram protein in control 
SCHH, but was decreased to 0.35-0.81 and 0.097-0.41 µL/min per milligram protein by OCA 
and CDCA treatment, respectively. However, the BEI (%) in control SCHH (63-71%) was 
similar to values after OCA (63-74%) and CDCA (46-71%) treatment. 
PK Modeling of d8-TCA Disposition in SCHH 
 Observed mass-time profiles of TCA from individual donors were plotted against the 
predicted mass-time profiles generated by using the best-fit parameters based on the mechanistic 
model (Fig. 5.2). The estimated clearance values of TCA in individual hepatocyte donors and the 
mean values calculated from the individual donors are presented in Table 5.1. The mechanistic 
model revealed that CLint,Bile was approximately 3-fold higher than CLint,BL in the control 
hepatocytes, consistent with previous report (Guo et al., 2016). The CV% of the estimated 
parameters from model fitting were acceptable (< 65%, Table 5.1), indicating good precision of 
the model fitting. The fold change in each parameter in treated hepatocytes compared to control 
hepatocytes is shown in Fig 5.3. OCA and CDCA treatment significantly increased CLint,BL by > 
6-fold, and CLint,Bile by ~2-fold. Changes in CLUptake were not statistically significant. 
Protein Expression of TCA Transporters  
To investigate which transporters might have contributed to the changes in TCA 
disposition, immunoblot analysis of major bile acid transporters was performed using SCHH 
from three hepatocyte donors. As shown in Fig. 5.4, OCA treatment increased the average 
expression of OSTα and OSTβ to 260% and 1100% of control, respectively. CDCA treatment 
increased the average expression of OSTα and OSTβ to 280% and 1300% of control, 
respectively. The average BSEP expression was modestly upregulated to 185% and 165% of 
170 
 
control by OCA and CDCA. Changes in MRP3, MRP4, and NTCP protein expression were 
negligible (<25% changes). The changes in OSTα and OSTβ expression were statistically 
significant while the changes in other proteins were inconclusive. 
 
Discussion 
To our knowledge, this study is the first direct demonstration of functional induction of 
bile acid efflux transporters in response to FXR agonists, revealed by mechanistic PK modeling 
results. The combination of mechanistic PK modeling and molecular analysis provided a 
comprehensive data set for understanding the mechanisms of OCA- and CDCA-mediated 
alterations in hepatic bile acid transporters. Increases in the basolateral efflux clearance and 
biliary clearance were consistent with a pronounced upregulation of OSTβ protein expression, 
and a smaller increase in BSEP protein expression, respectively (Figure 5.5).  
This study demonstrated the advantages of PK modeling in assessing changes in 
concurrent clearance pathways in a whole cell system. Quantitative assessment of basolateral 
bile acid efflux transporter function is challenging since plasma/medium bile acid concentrations 
reflect the net effect of synthesis and metabolism, as well as uptake and efflux. A recent report 
quantified the transport kinetics of a bile acid tracer [N-methyl-11C] cholylsarcosine (11C-CSar), 
which is similar to glycocholic acid, in human blood and liver using positron emission 
tomography (PET) (Orntoft et al., 2017). Based on a kinetic model, the rate constant for 
basolateral efflux of 11C-CSar was higher in cholestatic patients compared to healthy subjects. 
Similarly, in this mechanistic PK modeling study, concurrent clearance pathways of TCA in 
hepatocytes were de-convoluted; CLint,BL and CLint,Bile of TCA were increased by FXR agonist 
treatment. This information may have been overlooked by merely calculating model-independent 
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parameters. Although BRI showed a 2-fold increase, indicating increased basolateral efflux, it 
underestimated the magnitude of change compared to the model-estimated 6-fold increase in 
CLint,BL. After FXR agonist treatment, BEI remained the same and CLapp,Bile decreased, while 
model-estimated CLint,Bile increased by 2-fold. In this case, BEI and CLapp,Bile measured at a single 
time point failed to reflect the modest changes in biliary excretion because these model-
independent parameters are also affected by basolateral uptake and efflux.  
The FXR agonist-induced changes in transporter protein expression (greater induction of 
OSTβ and OSTα than BSEP) were consistent with the increases in TCA clearance (greater 
increase in CLint,BL than CLint,Bile), which would be expected for plasma membrane-localized 
proteins. In addition, alterations in protein expression agreed with previously published gene 
expression data in SCHH. OCA treatment (1 µM, 72 hr) increased OSTα, OSTβ, and BSEP 
mRNA in SCHH by 6.4-, 43-, and 4.6-fold, respectively (Zhang et al., 2017), while CDCA 
treatment (100 µM, 72 hr) increased OSTα, OSTβ, and BSEP mRNA by 3.1-, 21-, and 2.2-fold, 
respectively (Jackson et al., 2016).  No marked changes in the mRNA expression of MRP3, 
MRP4, or NTCP were observed in previous studies (Jackson et al., 2016; Zhang et al., 2017), 
consistent with the present protein expression data. Therefore, the increase in bile acid efflux was 
likely due to the induction of OSTβ and to a lesser extent to OSTα induction. Protein expression 
of NTCP remained unchanged in FXR agonist-treated SCHH, consistent with no statistically 
significant changes in CLUptake in CDCA-treated SCHH.  
OSTα/β is expressed in many other organs including the intestine, kidneys, and testis, and 
it can transport a variety of endogenous compounds in addition to bile acids, such as estrone 3-
sulfate, prostaglandin E, dehydroepiandrosterone 3-sulfate, and drugs like digoxin (Soroka et al., 
2010). Therefore, up-regulation of OSTα and OSTβ may affect the disposition of various 
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endogenous and exogenous compounds, and may have significant physiological implications and 
affect pharmacotherapy. The heterodimeric OSTα/β is a facilitated transporter that can 
translocate organic solutes across the basolateral membrane in either direction in vitro (Ballatori 
et al., 2005). In vivo, it is the primary bile acid efflux transporter in the intestine (Soroka et al., 
2010). Lower expression of OSTα and OSTβ in transfected COS cells decreased OSTα/β-
mediated transport (Sultan et al., 2017). OSTβ is required for the maturation and stability of 
OSTα (Dawson et al., 2010). The baseline gene expression level of OSTα is 3-7-fold higher than 
OSTβ in human liver tissue (Ballatori et al., 2005; Ballatori et al., 2009). Since 
heterodimerization of the two subunits is required for transport function, greater induction of 
OSTβ might be needed for maximal function of OSTα/β. Like other basolateral efflux 
transporters, OSTα/β is expressed at much lower levels in healthy human hepatocytes. Under 
cholestatic conditions, basolateral efflux transporters are often up-regulated to serve as alternate 
excretory pathways for bile acids (Zollner et al., 2003; Chai et al., 2012). In the present study, 
OCA and CDCA treatment both increased the CLint,BL of TCA more than 6-fold relative to 
control, resulting in clearance values that were slightly greater than the CLint,Bile. An increase in 
CLint,BL may exert a hepatoprotective effect by decreasing the hepatocellular accumulation of bile 
acids.  
The marked induction of OSTα, OSTβ, and to a lesser extent BSEP, but not MRP3, 
MRP4, or NTCP, as shown by immunoblotting, could be explained by the differential regulatory 
mechanisms of these transporters. SLC51A, SLC51B (genes encoding OSTα and OSTβ, 
respectively) and ABCB11 (gene encoding BSEP) are direct target genes for FXR 
(Ananthanarayanan et al., 2001; Yu et al., 2002; Landrier et al., 2006; Lee et al., 2006; Lefebvre 
et al., 2009). The FXR pathway was functional in SCHH and activated by OCA (1 µM) and 
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CDCA (100 µM) treatment, as shown by the following changes in other FXR target genes: 
decreased gene expression of CYP7A1, the synthesizing enzyme for bile acids, and increased 
gene expression of small heterodimer partner (SHP) (Zhang et al., 2017) (Jackson et al., 2016), 
similar to findings reported by Liu et al.  (2014). However, MRP3 is regulated by retinoic acid 
receptor, pregnane X receptor, constitutive androstane receptor (CAR), and liver receptor 
homolog-1 (Inokuchi et al., 2001; Teng et al., 2003; Chen et al., 2007; Geier et al., 2007).  MRP4 
is regulated primarily by CAR (Geier et al., 2007; Assem et al., 2004). Although rat Ntcp is a 
target gene of FXR (Denson et al., 2001), gene expression of human NTCP was minimally 
affected by FXR agonists. Gene expression of NTCP remained unchanged in human liver slices 
after CDCA treatment (100 µM, 24 hr) (Jung et al., 2007) and in SCHH after CDCA (100 µM, 
72 hr) and OCA treatment (1 µM, 72 hr) (Jackson et al., 2016; Zhang et al., 2017). A slight 
decrease (30%) in NTCP mRNA was reported in human hepatocytes after CDCA treatment (100 
µM, 48 hr) (Liu et al., 2014). Our results, together with these literature reports, showed that 
NTCP protein expression and function do not appear to be markedly affected by OCA and 
CDCA treatment of SCHH at the concentrations utilized in the present study.  
One assumption of the current PK model was that KFlux was the same across different 
treatment groups. KFlux is dependent on the contraction of bile canaliculi driven by the actin 
network (Watanabe et al., 1985). Since there is no evidence that FXR regulates actin function, 
KFlux was fixed to control values to avoid over-parameterization.  
In conclusion, FXR agonists OCA and CDCA increased bile acid efflux in SCHH, which 
contributed to reduced hepatocellular concentrations of d8-TCA. OSTα/β appeared to be the 
major transporter responsible for the increase in intrinsic basolateral efflux clearance of d8-TCA. 
These cellular effects, together with the suppression of bile acid synthesis (Jackson et al., 2016; 
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Zhang et al., 2017), provide the mechanistic rationale for FXR as a therapeutic target for the 
treatment of cholestatic diseases by reducing bile acid burden in hepatocytes. These results will 
enhance our understanding of the FXR-dependent mechanisms of OCA, and its impact on bile 
acid homeostasis. 
Table 5.1. Parameter estimates of TCA CLint,BL, CLint,Bile, CLUptake, and KFlux. Estimates and the corresponding CV% were obtained by 
fitting the model to the time-course data from individual SCHH preparations (Figure 5.2) based on the model scheme depicted in 
Figure 5.1. Mean values of these three individual estimates were calculated. Donor 1, 2 and 3 represent HUM4119C, HUM4122C, and 
HC3-26, respectively.  
  CLint,BL CLint,Bile CLUptake KFlux 
  (µL/min per milligram protein) (min-1) 
Treatment Donor Estimate CV% Estimate CV% Estimate CV% Estimate CV% 
Control 
1 0.29 33 0.80 14 1.6 6.4 0.048 7.3 
2 0.25 52 0.80 15 0.95 5.8 0.046 12 
3 0.19 58 0.70 16 1.4 4 0.037 11 
Mean 0.24 N/A b 0.77 N/A 1.3 N/A 0.044 N/A  
OCA 
1 1.7 32 1.3 12 1.9 18 0.048 a N/A 
2 1.6 41 1.3 14 1.04 24 0.046 a N/A 
3 1.4 38 1.5 12 1.54 17 0.037 a N/A 
Mean 1.6 N/A 1.4 N/A 1.5 N/A 0.044 a N/A 
CDCA 
1 1.7 40 1.1 16 1.03 25 0.048 a N/A 
2 1.6 64 1.4 24 0.54 36 0.046 a N/A 
3 1.3 56 1.5 24 0.79 24 0.037 a N/A 
Mean 1.6 N/A 1.3 N/A 0.78 N/A 0.044 a N/A 
a KFlux values in treated SCHH were fixed to the values in control SCHH from the same hepatocyte donor. 











Figure 5.1. Model structure depicting TCA disposition in SCHH in standard HBSS and Ca2+-
free HBSS. Cu,Cells and Cu,Buffer represent unbound concentration in the cells and buffer, 
























Figure 5.2. Predicted and observed amount of TCA in different matrices from three different 
SCHH donors. Black, orange, and blue colors represent control-, OCA-, and CDCA-treated 
groups, respectively, for observed (circles) and predicted (solid lines) data. Experimental data 
represent the mean ± S.D. (triplicate measurements). The fitted mass vs. time profiles were 






Figure 5.3. Fold change in CLint,BL, CLint,Bile and CLUptake in OCA- and CDCA-treated SCHH 
compared to control. Data represent mean ± S.D. (n = 3 hepatocyte donors, as detailed in Table 




































Figure 5.4. Effect of OCA and CDCA treatment of SCHH on the protein expression of OSTα, 
OSTβ, MRP3, MRP4, BSEP, and NTCP. (A) Immunoblots from three independent studies using 
three hepatocyte donors are shown. ATPase was used as the loading control for each blot. Donor 
1, 2, and 3 represent HU8246, HUM4122D, and HC3-26, respectively. Each protein was 
analyzed on a separate membrane except that BSEP and NTCP shared the same membrane and 
the same ATPase bands. (B) Quantitative analyses conducted by calculating the relative densities 
of each protein normalized by the density of ATPase (mean and S.D. expressed as % of control; 

















Figure 5.5.  The effect of FXR agonists on bile acid clearance and protein expression of bile acid 
transporters in SCHH. Different colors represent the fold change in clearance values 
(arrowheads; CLUptake, CLint,BL, CLint,Bile) and protein levels of transporters (circles; OSTα/β, 
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CHAPTER 6. Summary and Future Directions 
This dissertation research has focused on developing methods to improve the 
understanding and prediction of drug interactions with hepatic bile acid transporters. Inhibition 
or induction of bile acid transporters can lead to altered hepatic bile acid disposition, and 
therefore, may exert hepatotoxic or hepatoprotective effects. The effect of a drug on bile acid 
transporters is often multifactorial, including simultaneous inhibition and/or induction of uptake 
and efflux transporters, and may involve transport mechanisms that are poorly characterized. 
Therefore, the linkage between the function of individual bile acid transporters in the presence of 
a drug, and the overall impact on bile acid disposition in hepatocytes, remains to be studied. To 
better understand this linkage, “bottom-up” and “top-down” modeling approaches were used 
(Figure 6.1).  A series of studies was conducted utilizing in vitro systems, primarily rat and 
human sandwich-cultured hepatocytes (SCH), as well as in silico tools, including mechanistic 
pharmacokinetic (PK) modeling and simulation. Aims #1 and #2 focused on inhibitory 
interactions, and Aim #3 studied induction-type interactions. Taurocholic acid (TCA) was used 
as the model bile acid substrate to evaluate bile acid transporter function due to the wealth of 
data generated using TCA as the substrate. A number of model transporter inhibitors and 
inducers were used. Bosentan, telmisartan, and troglitazone sulfate (TS) were selected as 
inhibitors of multiple bile acid transporters. Obeticholic acid (OCA) and chenodeoxycholic acid 




In Aim #1, a framework was developed to predict the net effect of inhibiting multiple 
transporters on bile acid disposition in human SCH. Individual transporter inhibition data [e.g., 
half maximal inhibition concentration (IC50)] and relevant inhibitor concentrations were 
integrated by using mechanistic PK modeling. The applicability of this framework was 
demonstrated by predicting the effect of bosentan and telmisartan on TCA disposition using 
unbound inhibitor concentrations (Chapter 2). To further assess the relevant inhibitor 
concentration in predicting the effect of hepatic efflux transporter inhibition, a method to 
determine the benefit of using the unbound versus total intracellular inhibitor concentration was 
proposed. This method was developed based on simulation results and evaluated with 
experimental data from human SCH (Chapter 3). In this Aim, a “bottom-up” approach was used 
to predict the overall bile acid disposition in hepatocytes using individual transporter inhibition 
data. 
The translation of inhibition data generated in systems transfected with individual 
transporters to drug-bile acid interactions in the whole cells has its limitations, as discussed in 
Chapter 1 and 2. Therefore, it may be useful to derive the inhibition constant (Ki) for a clearance 
pathway (e.g., biliary or basolateral efflux), which is a composite Ki for multiple transporters in 
the same clearance pathway. In Aim #2, options for optimal study design in rat SCH were 
evaluated to provide a dataset for estimating Ki values for TS against the biliary and basolateral 
efflux clearance values of TCA simultaneously using a “top-down” PK modeling approach 
(Chapter 4).  
In Aim #3, the induction of bile acid efflux transporters by FXR agonists, OCA and 
CDCA, was studied in human SCH. Basolateral efflux and biliary clearance values of TCA, 
determined by mechanistic PK modeling, were increased by FXR agonists, which provided 
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direct functional evidence of transporter induction. Immunoblot analysis suggested that organic 
solute transporter α/β (OSTα/β) may be the main transporter responsible for the increase in the 
basolateral efflux clearance of TCA (Chapter 5). In this Aim, a “top-down” approach was used 
to deconvolute the changes in each clearance pathway using the overall bile acid disposition 
data. 
This dissertation has made a number of contributions in advancing the prediction and 
evaluation of drug interactions mediated by hepatic bile acid transporters. An overview of the 
experimental findings, the implications, and future directions for each chapter are discussed in 
the following sections.  
 
Prediction of Altered Bile Acid Disposition Due to Inhibition of Multiple Transporters: An 
Integrated Approach Using Sandwich-Cultured Hepatocytes, Mechanistic Modeling and 
Simulation (Chapter 2) 
Inhibition of bile acid efflux transporters may increase the hepatic accumulation of toxic 
bile acids, leading to liver toxicity (Morgan et al., 2010; Kock et al., 2014). However, translating 
inhibitory potency data to clinical risks is challenging (Dawson et al., 2012). The simultaneous 
inhibition of multiple transporters (Aleo et al., 2017) and the relevant inhibitor concentration 
need to be considered. The purpose of Chapter 2 was to develop a framework to predict altered 
bile acid disposition in the context of transporter interplay and relevant inhibitor concentrations. 
The kinetic parameters for deuterium-labeled TCA (d8-TCA) in the presence of albumin in 
human SCH were characterized by PK modeling (Table 2.2). Based on kinetic parameters of d8-
TCA and the inhibition potency of telmisartan and bosentan, the effect of these inhibitors on the 
disposition of d8-TCA was predicted and compared with experimental observations (Table 2.4). 
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The prediction accuracy using different measures of inhibitor concentrations, including cellular 
total ([I]total,cell) or unbound concentrations ([I]unbound,cell), and cytosolic total ([I]total,cyt) or 
unbound concentrations ([I]unbound,cyt) (Table 2.3), was assessed. Finally, a framework was 
proposed to predict bile acid disposition in human hepatocytes by integrating transporter 
inhibition data and PK parameters of the bile acid (Figure 2.5).  
A previously published protocol was adopted to estimate kinetic parameters for TCA and 
a few modifications were made to better represent the in vivo scenario. First, instead of 3H-TCA, 
d8-TCA was used due to the high specificity of mass spectrometry-based quantification without 
interference from potential TCA metabolites, though the metabolism of TCA has been reported 
to be negligible (Hofmann and Hagey, 2008). In addition, 4% bovine serum albumin (BSA), 
approximating the plasma albumin concentration in humans, was added into the uptake buffer to 
represent the physiologically relevant condition. The impact of protein on the uptake process was 
mimicked, including the availability of unbound drug, the equilibrium between binding with the 
albumin and uptake transporters for TCA, and the potential interaction between albumin and 
transporters at the functional level (albumin-facilitated uptake) (Poulin and Haddad, 2013). In 
addition, the presence of albumin could limit the uncertainty arising from TCA binding to the 
experimental apparatus. Because of these benefits, the addition of protein in transport assays has 
gained more popularity in recent years (Riccardi et al., 2016; Kikuchi et al., 2017; Mao et al., 
2018).   
A strength of Chapter 2 was to leverage modeling and simulation to assist in the selection 
of sensitive model output and critical model input, and to explore the underlying rules for 
experimental findings. Sensitivity analysis of the model output showed that the total TCA 
concentration in Cells (Ct,Cells) was the most sensitive experimental readout to the impairment in 
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both uptake and efflux clearance values (Figure. 2.2). Without this quantitative analysis, TCA 
amount in Cells+Bile could have been selected since it is most commonly measured. However, 
the amount in Cells+Bile was sensitive only to inhibition of uptake clearance; if one were relying 
solely on this value, the inhibitory effect of efflux clearance values might have been overlooked. 
Theoretically, the cytosolic unbound concentration of inhibitors is most relevant for the 
inhibition of efflux transporters and therefore, intracellular unbound fraction (fu,cell,inhibitor) might 
be an important model input and worth collecting. Accordingly, the comparison between 
simulated and experimental observations indicated that the measurement of fu,cell,inhibitor for 
telmisartan was critical for accurately predicting its effect on TCA disposition, while it was less 
critical for bosentan (Table 2.4). Accordingly, sensitivity analysis was used to explore the 
underlying rules. Sensitivity analysis revealed that fu,cell,inhibitor was a critical input only for 
inhibitors with higher ([I]total,cell/IC50) values, such as telmisartan (Figure 2.3, Figure 2.4). In the 
case of inhibitors with lower ([I]total,cell/IC50) values, resources needed for the measurement of 
fu,cell,inhibitor could be better allocated elsewhere.  
An advantage of the framework shown in Figure 2.5 is the ability to integrate 
information readily available for many inhibitors and interpret this information together with 
TCA kinetics characterized in this study. Inhibition potency against individual bile acid 
transporters can be accessed through public databases (e.g. UCSF transportal, TP-search) and 
published studies (Morgan et al., 2010; Dong et al., 2013; Morgan et al., 2013; Dong et al., 2015; 
Aleo et al., 2017). Intracellular inhibitor concentrations can be estimated using partition 
coefficient values.  
Some model assumptions were necessary due to the lack of knowledge regarding the 
transport characteristics of the substrate and inhibitors. Since the relative contribution of each 
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basolateral efflux transporter to the overall basolateral efflux clearance of TCA was unknown, 
two extreme scenarios were simulated assuming 100% contribution of either MRP3 or MRP4. 
Although the simulation results were similar in this study, this assumption could become an issue 
in certain populations in which OSTα/β plays a more important role in the basolateral efflux of 
TCA, as shown in Chapter 5. This limitation could be addressed by a novel approach to obtain Ki 
estimates against biliary and basolateral efflux clearance pathways proposed in Chapter 4.  If it is 
necessary to characterize the contribution of each transporter towards the total clearance, RNA 
interference (RNAi) or Clustered Regularly Interspaced Short Palindromic Repeats 
(CRISPR)/CRISPR-associated 9 (Cas9) could be used to modulate gene expression in the human 
SCH (Yue et al., 2009; Dorr et al., 2017; Sosicka et al., 2017), although optimization of these 
techniques in human SCH would be needed.  
In the process of predicting the inhibitor effect, the intracellular concentration of 
inhibitors was assumed to be static. Although this assumption is reasonable for screening 
purposes and is possible to achieve in vitro, the portal vein and hepatic concentration of drugs in 
vivo are rarely static. If a better representation of the in vivo scenario is critical, dynamic models 
of inhibitors could be incorporated in the simulation process. The kinetic parameters for some 
commonly used inhibitors are already available in the literature, including bosentan and 
telmisartan, which were published after the work described in Chapter 2 had been completed (Li 
et al., 2014; Matsunaga et al., 2016). For other inhibitors, the kinetic parameters need to be 
obtained through a PK modeling approach.   
The small change in TCA Ct,Cells observed in this study (Table 2.4) was due primarily to 
the short uptake period (10 min) and the simultaneous inhibition of uptake and efflux 
transporters. These results suggest that the current standard protocol may not be optimal to detect 
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the effect of dual inhibition of both uptake and efflux transporters. A simulation-based study 
design, such as that shown in Chapter 4, would be helpful to develop a dosing scheme that may 
lead to more extensive alterations in TCA Ct,Cells. Alternatively, compounds that caused a more 
extensive increase in TCA Ct,Cells in human SCH could be used as model inhibitors, such as 
glyburide or cyclosporine A (Ansede et al., 2010). In addition, experimental data from additional 
hepatocyte donors would be helpful to evaluate the simulation results more thoroughly, and to 
characterize the inter-individual variability, which will be helpful for Monte Carlo simulations. 
Outcomes of the research detailed in Chapter 2 serve as the basis for some ideas 
regarding additional studies. From a practical perspective, the cost of human hepatocytes 
required to generate time-course data is not trivial. To maximize the use of human hepatocytes, 
imaging techniques could be used to quantify drug disposition in vitro. Studies by De Bruyn et 
al. showed that a bile acid derivative N-(24-[7-(4-N,N-dimethylaminosulfonyl-2,1,3-
benzoxadiazole)]amino-3α,7α,12α-trihydroxy-27-nor-5β-cholestan-26-oyl)-2'-
aminoethanesulfonate (tauro-nor-THCA-24-DBD) was a useful fluorescent probe to study 
NTCP/Ntcp-, OATP1B1/1B3- and BSEP/Bsep-mediated transport. In addition, they 
demonstrated that the fluorescence of tauro-nor-THCA-24-DBD in different compartments (i.e., 
intracellular and bile canaliculi) of rat and human SCH could be quantified by real-time confocal 
imaging (De Bruyn et al., 2014) without destruction of hepatocytes at each time point. Since at 
least eight time points are needed for PK modeling, this real-time imaging technique could result 
in a significant cost savings (at least eight times fewer hepatocytes consumed). However, this 
approach assumes that the probe is metabolically stable. 
The modeling approach developed in Chapter 2 could be applied to characterize the 
kinetic properties of other endogenous transporter substrates, or in other cellular models. Toxic 
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bile acids could be studied as substrates, since the disposition of these bile acid species may be 
more directly relevant to hepatotoxicity and the PK characteristics of various bile acids is likely 
different. One example is the differential effect of troglitazone on the disposition of TCA and 
CDCA species in rat SCH (Marion et al., 2011). Differences in PK properties among various bile 
acid species using transfected cell lines has been published (Notenboom et al., 2018). In addition 
to bile acids, the mechanistic PK modeling approach could be applied to coproporphyrin (CP) I 
and III, the endogenous probes for organic anion transporting polypeptide 1B and multidrug 
resistance-associated protein 2. Current PK models for CP I did not include basolateral efflux 
clearance due to the lack of knowledge about this clearance pathway (Barnett et al., 2017; Guo et 
al., 2018). In addition, the framework to predict bile acid disposition in human SCH developed in 
Chapter 2 could be applied to other holistic cell systems, such as HepaRG cells or the HepatoPac 
model.  However, the cellular models must be polarized and the functionality of transporters and 
other proteins involved in hepatobiliary drug disposition (e.g., metabolic enzymes, nuclear 
receptors, trafficking proteins) must be well maintained in order to recover physiologically-
relevant parameter estimates.  
The prediction of bile acid disposition in human SCH would be of higher impact if the 
results could be scaled to in vivo. In vitro-in vivo extrapolation of bile acids has been limited by 
the unknown scaling factors discussed in Chapter 1. Scaling factors may be compound-specific 
and can be estimated accurately when in vivo data are available (Jones et al., 2012). Clinical PK 
studies of bile acids, albeit limited, may be useful for the extrapolation of in vitro data, such as 
the PK profile of [N-methyl-11C]cholylsarcosine (11C-CSar), a bile acid tracer similar to 
glycocholic acid (Orntoft et al., 2017), and OCA, an analogue of the endogenous bile acid 
CDCA (Edwards et al., 2016). Alternatively, scaling factors can be generated based on the 
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abundance of individual bile acid transporters determined by mass spectrometry in human SCH 
and human liver tissues. This approach has been used to predict the in vivo PK of nine groups of 
bile acids, such as CDCA and its conjugates (Notenboom et al., 2018).  
 
Prediction of Hepatic Efflux Transporter-Mediated Drug Interactions: When Is It Optimal 
to Measure Intracellular Unbound Fraction of Inhibitors? (Chapter 3) 
Studies in Chapter 2 showed that the impact of using [I]unbound,cell instead of [I]total,cell to 
predict the transporter inhibitor effect varies depending on the characteristics of the inhibitor, 
specifically the ([I]total,cell/IC50) value. As an extension of Chapter 2, the objective of Chapter 3 
was to determine when it is optimal to measure fu,cell,inhibitor to accurately predict the effect of 
efflux transporter inhibitors on the disposition of TCA. These inhibitors were referred to as 
“risk” inhibitors in Chapter 3.  Based on simulation results (Figure 3.1), an approach was 
proposed to classify “risk” inhibitors determined by the plasma unbound fraction (fu,plasma,inhibitor) 
and ([I]total,cell/IC50) values of the inhibitors was proposed. The cut-off value of ([I]total,cell/IC50) 
was greater for compounds with higher fu,plasma,inhibitor values (Figure 3.2). Experimental data 
were provided to demonstrate the utility of this approach (Table 3.2). For “low-risk” inhibitors, 
the simulations based on [I]total,cell and [I]unbound,cell were similarly close to experimental 
observations, which was not the case for “risk inhibitors”.  
Compared to simulations using [I]unbound,cell, the TCA Ct,Cells was over-predicted using 
[I]total,cell, which may lead to false-positive predictions of drug-drug interactions (DDIs). The 
extent of over-prediction increased at first and then decreased as the ([I]total,cell/IC50) value 
became larger. Thus, for extremely strong or weak inhibitors, the differentiating power of using 
[I]unbound,cell versus [I]total,cell was smaller compared to inhibitors with moderate inhibition potency. 
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In addition, the benefit of using [I]unbound,cell was bigger for inhibitors with greater intracellular 
binding, which generally also show higher plasma protein binding. For compounds with lower 
protein binding, the difference between [I]total,cell and [I]unbound,cell would be smaller, resulting in a 
smaller difference in the prediction results using these two types of inhibitor concentrations.  
The value of understanding the importance of using [I]unbound,cell is to avoid unnecessary 
collection of fu,cell,inhibitor data. Out of the fifteen experimental compounds, seven compounds 
were classified as “low-risk” inhibitors. For these compounds, the resources necessary for the 
measurement of fu,cell,inhibitor could be better allocated elsewhere. Accurate measurement of 
fu,cell,inhibitor may be labor- and resource-intensive. Although the measurement of fu,cell,inhibitor is 
higher-throughput using the homogenization method (Riccardi et al., 2018), fu,cell,inhibitor values 
measured using the homogenization method were generally lower than those obtained using 
other methods that are less efficient, such as the steady-state accumulation at 4 °C (temperature 
method)(Riede et al., 2017) and the “cytosol isolation” method that was used in Chapter 2 
(Pfeifer et al., 2013). In the “cytosol isolation” method, human SCH are first incubated with the 
inhibitors, and then homogenized gently to avoid breaking the subcellular organelles. Following 
that, the cytosol of human SCH homogenate is isolated by differential centrifugation and the 
unbound fraction in the cytosol is measured.  
Some necessary assumptions were made for the simulations. First, a quantitative 
relationship between intracellular and plasma protein binding was assumed based on the equation 
reported by Jones et al. (Jones et al., 2012). This assumption was needed since fu,plasma,inhibitor 
values are more readily available than fu,cell,inhibitor values. The determining factors for classifying 
“risk” inhibitors need to be easily accessible so this classification approach will be a useful 
predictive method and can save experimental resources a priori. If this assumed relationship is 
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inaccurate, the cut-off values might be slightly different. It would be ideal if a quantitative 
relationship can be established between fu,cell,inhibitor and other easier-to-measure parameters, such 
as physicochemical properties, chemical structures, etc. Other assumptions have been addressed 
by additional simulations shown in the Supplement of Chapter 3, including equal biliary IC50 and 
basolateral IC50 and the percentage of uptake inhibition.  
           In Chapter 3, it was assumed that a 2-fold difference between the simulation results is a 
reasonable criterion to determine that the [I]unbound,cell-based simulations are superior to the 
[I]total,cell-based simulations. Although an AUC ratio of 2 is generally used as an indicator of 
moderate clinical DDIs (FDA/CDER, 2012), this 2-fold criteria is arbitrary. For future studies, 
more experimental data will be needed to validate the simulation results, and to optimize this 
criterion by using a receiver operating characteristic (ROC) curve. In a ROC curve, the specificity 
(false positive rate) and sensitivity (true positive rate) are plotted on the x- and y-axis. The best 
cut-off value should provide the highest area under the ROC curve (Maiuri et al., 2017). The 
tolerance for risk should be considered as well.  
One question that came up during the peer review process was whether the medium 
concentration of inhibitors could be used as a substitute for the cellular concentration. This 
approach is acceptable if the cell membrane does not present a diffusional barrier. Alternatively, 
the intracellular concentration could be estimated from the medium concentration using the 
partition coefficient values. Currently, it is still challenging to predict hepatocyte accumulation 
without experimentation.  
Even though more experimental data are needed, Chapter 3 provides a first step towards 
bridging the gaps to determine the relevant inhibitor concentration a priori. In addition, the 
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experimental paradigm developed in Chapter 3 could be applied to additional substrates, such as 
drugs and toxic bile acids.  
 
Modeling and Simulation-Guided Study Design for Ki Estimations against Bile Acid Efflux 
Clearance Values in Hepatocytes (Chapter 4) 
As discussed in Chapter 1 and 2, the utility of individual transporter Ki values will be 
compromised if the transport mechanism of the substrate is not well characterized. Therefore, the 
concept of the Ki or IC50 against a clearance pathway instead of a specific transporter was 
proposed in Chapter 4. Traditional methods to estimate Ki values using transfected systems 
require several concentrations of the inhibitor and the substrate.  A more efficient model-based 
approach to enable Ki estimations against biliary and basolateral efflux clearance values 
simultaneously using a physiologically-relevant system would be advantageous. Chapter 4 
evaluated options for an optimal study design in rat SCH based on modeling and simulation, and 
used TS and TCA as the model inhibitor and substrate, respectively (Figures 4.1, 4.5). A PK 
model describing the interaction between TS and TCA was evaluated by experimental data 
(Figure 4.4) and used for the simulation. Using the proposed study design, the generated data 
were suitable for moderately accurate estimation of TS Ki values against biliary and basolateral 
efflux clearance, which were within 2-fold of the reference values, in different hepatocyte lots 
(Figure 4.8, Table 4.7).  
This is the first time the concept of a Ki against a clearance pathway in SCH was 
proposed using intracellular unbound inhibitor concentration and modeling-based analysis. 
Compared to conventional methods and individual transporter Ki values, there are several 
advantages of the approach developed in Chapter 4. The Ki values can be used directly in whole-
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body mechanistic models to predict the inhibitor-substrate interactions, even if the transporters 
involved in the substrate disposition are not fully characterized.  In conventional methods, five 
concentrations for the substrate and inhibitor are added into the incubation buffer to create a 
dynamic range of concentrations for both compounds at the site of interaction. Similarly, a 
concentration range for both compounds was achieved in the proposed protocol by allowing the 
substrate and inhibitor to accumulate in the cells over time. Additionally, the proposed method 
requires measuring the intracellular unbound concentration of TS to account for the intracellular 
binding, which is relevant to in vivo conditions. Chapter 4 also demonstrated the advantages of 
using modeling and simulation to optimize the experimental design so that data input for the PK 
model is sufficient for reliable parameter estimation.  
A similar concept was reported previously; the IC50 values of cyclosporine A were 
estimated against the uptake and efflux clearance of the phenylglucuronide metabolite of 
mycophenolic acid (Matsunaga et al., 2015). However, this study used the medium concentration 
of the inhibitor and did not measure the intracellular unbound concentration, which is crucial to 
obtain an accurate estimate of the Ki or IC50 against the efflux clearance, and to translate these 
values to in vivo. 
Future experiments using this optimized study design will be helpful to assess the utility 
of this protocol, especially in the presence of experimental error. Several practical issues should 
be considered including the potential cytotoxicity of the inhibitor and the lowest limit for 
quantification for the substrate (i.e., TCA) and the inhibitor (i.e., TS). In Chapter 4, maximum 
velocity values for TCA efflux were estimated using data from a published study where TCA 
was dosed at 1 μM. This was not the ideal experimental condition to estimate nonlinear PK 
parameters, since the intracellular concentration of TCA was <1 μM, which is much lower than 
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the Michaelis-Menten constants for TCA efflux clearance. In future studies, TCA should be 
dosed at 5 μM, which would generate higher intracellular concentrations and provide more 
accurate estimates of the maximum velocity.  
The framework proposed in Chapter 4 could be applied to design experiments for other 
inhibitors, in addition to TS. The necessary prior information and modifications in this study 
design are shown in Figure 4.11. This approach could be extended to estimate Ki for both the 
parent drug and metabolites. Transporter inhibition assays by metabolite(s) may not be evaluated 
routinely. However, some metabolites are potent inhibitors of BSEP, such as TS (Funk et al., 
2001) and DM-4103, a metabolite of tolvaptan (Slizgi et al., 2016). In the present study, 
troglitazone was metabolized to TS rapidly, which made quantification of the troglitazone Ki 
challenging. The Ki information for metabolites could be especially useful in the early stages of 
drug discovery and development, when large amounts of pure metabolites are generally 
unavailable for traditional transporter assays.  
Finally, the utility of the overall Ki for the clearance value can be evaluated against the 
“individual transporter IC50” values by incorporating inhibition potency data into mechanistic 
models, including physiologically-based PK models and systems pharmacology models, such as 
DILIsym®, to predict troglitazone-mediated hepatotoxicity. The Ki value and inhibition 
mechanism of TS against TCA biliary clearance is an important model input for the prediction of 






FXR Agonists Obeticholic Acid and Chenodeoxycholic Acid Increase Bile Acid Efflux in 
Sandwich-Cultured Human Hepatocytes: Functional Evidence and Mechanisms (Chapter 
5) 
FXR is a nuclear receptor that is expressed at high levels in the liver and intestine and 
regulates bile acid homeostasis (Lefebvre et al., 2009). That mechanism contributed to the 
therapeutic rationale for FXR agonists being developed to treat cholestatic liver disease, such as 
primary sclerosing cholangitis, and chronic liver disease, such as non-alcoholic steatohepatitis 
(NASH) (Fiorucci et al., 2007; Wagner et al., 2011; Nevens et al., 2016). FXR agonists, OCA 
and CDCA, increased mRNA expression of bile acid efflux transporters in human SCH after 72 
hr treatment (Jackson et al., 2016; Zhang et al., 2017). The purpose of Chapter 5 was to 
characterize the effects of OCA and CDCA treatment on the function and protein expression of 
bile acid transporters in human SCH. PK modeling of d8-TCA data showed that the intrinsic 
basolateral efflux clearance (CLint,BL) and intrinsic biliary clearance (CLint,Bile) of TCA were 
significantly increased by OCA (1 µM) and CDCA (100 µM) treatment for 72 hr, with minimal 
change in the uptake clearance (CLUptake) (Figure 5.3, Table 5.1). Immunoblotting was 
performed to assess protein expression of individual transporters. Results showed that the 
expression of OSTα and OSTβ in FXR agonist-treated human SCH was significantly induced, 
with only modest changes in other TCA transporters (Figure 5.4). Therefore, OSTα/β appeared 
to be the major transporter responsible for the increase in CLint,BL of d8-TCA.  
It is challenging to study transporter induction, as suggested by the limited number of 
publications on transporter induction. With the assistance of PK modeling, Chapter 5 addressed 
some of these challenges and provided, for the first time, clear functional evidence for bile acid 
efflux transporter induction in human SCH. Furthermore, quantifying the function of efflux 
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transporters, especially those on the basolateral membrane, is challenging due to the concurrent 
uptake processes. PK modeling can deconvolute these processes, and also provide high 
granularity in the quantification; even modest changes can be detected. Without time-course data 
and the assistance of mathematical/PK modeling, such changes could have been overlooked, as 
shown by the minor changes in model-independent parameters calculated from data at a single 
time point (e.g. biliary excretion index and buffer recovery index). Most of the published 
literature reporting transporter induction is at the mRNA level. However, changes in gene 
expression of transporters may not translate to changes in protein expression (Ahlin et al., 2009; 
Thompson et al., 2017) and/or function (Ohtsuki et al., 2012). Clinical evidence for drug-
mediated transporter induction is very limited, although there are reports of disease-related up-
regulation of transporters. For example, the mRNA and protein level of OSTβ were increased in 
the livers of NASH and PBC patients (Malinen et al., 2018), which may be due to increased bile 
acids in the liver (Lake et al., 2013). This is consistent with increased OSTβ protein levels in 
human SCH after exposure to CDCA reported in Chapter 5. The protein expression (Hardwick et 
al., 2011) and function of MRP3 were increased in NASH patients (Ferslew et al., 2015). 
Findings in Chapter 5 bridged the gap between mRNA and function data for the FXR agonist-
mediated induction of bile acid efflux transporters. 
The quantification of functional changes in transporters shown in this study can be 
helpful to predict clinical outcomes and optimize pharmacotherapy. For example, the changes in 
transporter function can be used as key data input for whole-body mechanistic PK models to 
predict clinical liabilities for DDIs or drug-induced liver injury as a result of induction of 
OSTα/β. OSTα/β transports various endogenous and exogenous substrates such as digoxin 
(Soroka et al., 2010; Malinen et al., 2018) and rosuvastatin (Schwarz, 2012). Digoxin has a 
203 
 
narrow therapeutic window (Ehle et al., 2011) and rosuvastatin is a potential co-medication with 
OCA in NASH patients (Kargiotis et al., 2014). A recent clinical study showed a modest increase 
in the systemic exposure of rosuvastatin in healthy subjects taking oral daily doses of 25 mg 
OCA (1.3-fold increase compared to control) (Edwards et al., 2017), which may be related to the 
induction of OSTα/β and increased hepatic basolateral efflux of rosuvastatin. In this clinical 
study, no obvious changes in digoxin systematic exposure were observed (1.1-fold increase 
compared to control).  If these functional data were unavailable and gene data (43-fold increase 
in OSTβ) were used instead to predict DDI liability, the DDI risk might be overpredicted. 
This study was designed to mimic the in vivo scenario. There was no wash-out phase 
between the FXR agonist treatment and the uptake of TCA. Thus, a caveat of this study design 
was that the induction of transporters may be masked by the concurrent inhibition of transporters 
by OCA and/or CDCA. Although the actual induction in transport might be higher than what was 
observed, the study design was deemed most relevant to the in vivo situation, where induction 
and inhibition may occur simultaneously.  
Although CLint,Bile was increased by ~1.5 fold after OCA and CDCA treatment, there 
were no significant changes in the total level of BSEP protein. This apparent discrepancy 
between function and protein data could be explained by the localization and trafficking of 
BSEP. Transporters must be expressed on the plasma membrane to be functional (Wang et al., 
2002; Chandra et al., 2005; Zhang et al., 2005). After being synthesized in the Golgi, BSEP is 
transiently sequestered in an intracellular vesicle pool en route to the canalicular membrane 
(Kipp and Arias, 2000; Van et al., 2000). As a mechanism of short-term regulation, BSEP can be 
cycled between the membrane and the intracellular pools of vesicles (Kipp et al., 2001; Wustner 
et al., 2001; Hoekstra et al., 2004). Therefore, although there was no change in the total protein 
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level, the amount of BSEP expressed on the plasma membrane might be increased. To prove this 
hypothesis, isolation of plasma membrane (Lee et al., 2008; Kweon et al., 2016) followed by 
immunoblotting analysis could be considered for future investigations. In addition, it would be 
ideal to use the same hepatocyte lots for the functional study and protein quantification. 
However, due to the limited availability of quality human hepatocytes, one of the three 
hepatocyte lots used for the functional study, HUM4199C, was no longer available when the 
immunoblotting studies were conducted.  
The OCA- and CDCA-associated changes in d8-TCA disposition were believed to be a 
result of FXR activation, since multiple FXR target genes were altered (Jackson et al., 2016; 
Zhang et al., 2017). To provide more definitive evidence for this cause effect relationship, 
additional studies could be considered. For example, if co-exposure of an FXR antagonist or 
FXR knockdown in human SCH (through RNAi or CRISPR) decreased the effect of OCA or 
CDCA on increasing the efflux of d8-TCA, this would establish the FXR-dependence of the 
observed changes.  
In the implementation of PK modeling, the rate constant describing the flux of compound 
from bile canaliculi to the medium (KFlux) was fixed at the value from control human SCH to 
avoid over-parameterization. In addition, the effect of OCA and CDCA on KFlux was unknown. 
A recent publication showed that the cholestatic drugs cyclosporine A and chlorpromazine 
changed the bile canalicular volume in HepaRG cells (Kaschek et al., 2018), indicating that KFlux 
could be altered by some compounds.  
The findings of Chapter 5 laid the foundation for some future studies that could expand 
the impact of this research.  In vivo evidence is needed to prove transporter induction in response 
to FXR agonists. Biomarkers for OSTα/β, such as plasma bile acids, could be informative. 
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However, the bile acid profile is affected by bile acid synthesis and metabolism rates, which are 
regulated by FXR. Since OSTα/β is also expressed in the intestine, which is another important 
organ that governs bile acid disposition, the overall impact of OSTα/β induction on systemic bile 
acid exposure in vivo needs to be assessed by a whole-body physiologically-based PK model. 
Due to the challenges in quantifying bile acid kinetics in humans, quantitative intravital 
microscopy of fluorescent bile salts, such as cholylglycyl amidofluorescein and cholyl-lysyl-
fluorescein, in rats could provide an estimate of bile acid transport clearance values (Ryan et al., 
2018). However, the species difference needs be considered when interpreting bile acid data 
from rodents.  
There are many other FXR agonists under development for the treatment of chronic liver 
diseases, including synthetic FXR agonists and herbal medicines (Gao et al., 2017; Kong et al., 
2018). The paradigm used in Chapter 5 can serve as an in vitro tool to prioritize FXR agonists 
based on their induction effect on bile acid transporters, which is part of the therapeutic rationale 
for FXR agonists to treat cholestatic liver diseases. In addition to FXR, other nuclear receptors 
are exploited as drug targets and may regulate transporter function. For example, liver X receptor 
(LXR) is being developed as a potential therapeutic target for neurodegenerative diseases, such 
as Alzheimer's disease (Xu et al., 2013). A recent study using human SCH showed that an LXR 
agonist increased the protein level of P-glycoprotein and decreased the protein level of organic 
cation transporter 1 and organic anion transporter 2 (Ito and Brouwer, 2018) Alterations in the 
function of these transporters can be proven using the PK modeling approach in Chapter 5.  
Concluding Remarks 
The field of drug metabolism and transport research has generated abundant experimental 
data over the past few decades. This field is evolving towards an era when in silico tools will be 
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leveraged to integrate and interpret available in vitro and in vivo data, to predict untested 
scenarios, to facilitate the optimization of study designs, and to identify knowledge gaps. This 
dissertation research showcased these diverse applications by combining a physiologically-
relevant cellular model and PK modeling, with a focus on bile acid transporter-mediated drug 
interactions. It is of great interest to obtain quality in vitro data in an effective and efficient 
fashion. The approaches developed in this research can be added into a toolbox that can be used 



















Figure 6.1. Summary of the in vitro and in silico tools used in this dissertation research and the 
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Figure 2.1. d8-TCA mass vs. time data in SCHH lysate and incubation buffer 
 
Amount in Cells+Bile (pmol/mg pro) 
Time (min) Donor 1 Donor 2 Donor 3 Mean CV% S.E.M. 
2 13 20 14 16 25 2 
5 31 43 43 39 18 4 
10 63 73 66 67 8 3 
20 95 120 106 107 12 7 
23 103 99 73 92 18 10 
26 90 60 68 73 21 9 
31 100 70 65 65 24 11 
36 81 52 48 60 30 10  
Amount in Cells (pmol/mg pro) 
Time (min) Donor 1 Donor 2 Donor 3 Mean CV% S.E.M. 
2 5.3 3.6 2.8 3.9 33 1 
5 10 13 15 13 19 1 
10 23 16 30 23 29 4 
20 33 47 48 42 20 5 
23 30 27 23 26 14 2 
26 23 12 22 19 31 4 
31 13 28 23 18 35 4 
36 5.4 7.2 7.6 6.7 18 1  
Amount in Standard HBSS (pmol/mg pro) 
Time (min) Donor 1 Donor 2 Donor 3 Mean CV% S.E.M. 
23 10 13 13 12 15 1 
26 17 13 11 14 24 2 
31 22 22 21 21 3 0 
36 28 24 23 25 12 2  
Amount in Ca2+-free HBSS (pmol/mg pro) 
Time (min) Donor 1 Donor 2 Donor 3 Mean CV% S.E.M. 
23 12 19 10 14 34 3 
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26 23 22 12 19 31 3 
31 26 36 17 27 35 5 













































Figure 2.4. The sensitivity of the predicted TCA Ct,Cells to changes in fu,cell,inhibitor  as a function of 
([I]t,cell/IC50) values 
 
[I]t,cell/IC50 fu,cell,inhibitor=0.02 fu,cell,inhibitor=1 
0.5 1 1.5 
1 1 2 
2 1 2.9 
4 1.1 4.5 
8 1.2 7 
20 1.4 11 
40 1.8 13 
































Table 2.3. Measured unbound fraction (fu) and unbound concentrations ([I]u) of telmisartan and 
bosentan in the medium, cell lysate, and cytosol. Data were from triplicate measurements except 
that measurements from the medium were duplicates.  
   





1 2 1 2 3 1 2 3 
fu 
Telmisartan 
1 0.014 0.0098 0.15 0.16 0.099 0.056 0.050 0.053 
10 0.022 0.018 0.068 N/A 0.12 0.098 0.090 0.052 
Bosentan 
0.8 0.029 0.048 0.34 0.48 N/A 0.12 N/A 0.12 




1 0.014 0.0098 2.4 2.5 1.6 0.90 0.80 0.85 
10 0.22 0.18 2.7 N/A 4.8 3.4 3.1 1.8 
Bosentan 
0.8 0.023 0.039 0.66 0.93 N/A 0.21 N/A 0.21 
8 0.47 0.44 3.1 4.5 N/A N/A N/A N/A 





























Table 2.4. Experimentally observed TCA Ct,Cells in the presence and absence of telmisartan and 
bosentan. Data were from duplicate measurements.  
Inhibitor Dosing concentration (µM) TCA Ct,Cells (pmol/mg protein) 
Bosentan 
0 22.0 23.6 
0.8 19.0 21.0 
8 18.8 18.2 
Telmisartan 
0 28.8 28.1 
1 26.9 24.6 



































Figure 4.3. Observed TCA amount vs. time in control rat SCH, provided by Yang et al. (Yang et 
al., J Pharmacol Exp Ther, 2015).  
  
Amount in Cells+Bile (pmol/well) 
Time (min) Lot=1 Lot=2 Lot=3 Mean S.E.M. 
2 21.3 18.7 13.4 17.8 4.0 
5 34.8 34.6 23.2 30.9 6.6 
10 51.1 46.6 36.2 44.6 7.6 
15 63.1 63.4 45.7 57.4 10.1 
20 77.5 75.1 55.0 69.2 12.4 
23 55.2 54.5 55.9 55.2 0.7 
24.5 45.6 52.1 49.6 49.1 3.3 
26 38.1 40.1 42.4 40.2 2.2 
31 28.2 33.3 33.7 31.7 3.1 
36 27.3 28.2 28.5 28.0 0.6 
protein (mg/well) 1 0.73 0.8 0.8 
 
Vcell (µL/well) 7.59 5.54 6.07 6.40 
 
 
Amount in Cells (pmol/well) 
Time (min) Lot=1 Lot=2 Lot=3 Mean S.E.M. 
2 4.7 4.0 3.2 4.0 0.8 
5 4.5 6.1 3.4 4.7 1.4 
10 7.9 10 6.9 8.3 1.6 
15 8.9 9.5 9.4 9.3 0.3 
20 11.6 9.5 10.4 10.5 1.1 
23 3.1 4.2 3.2 3.5 0.6 
24.5 2.0 4.4 3.0 3.1 1.2 
26 1.0 1.7 1.9 1.5 0.5 
31 0.7 1.5 0.9 1.0 0.4 
36 0.4 0.5 0.4 0.4 0.1  
Amount in standard HBSS (pmol/well) 
Time (min) Lot=1 Lot=2 Lot=3 Mean S.E.M. 
23 18.4 16.2 10.3 15.0 4.2 
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24.5 23.3 26.0 16.2 21.8 5.1 
26 28.3 29.2 19.7 25.7 5.2 
31 39.9 43.5 24.8 36.1 9.9 
36 49.0 51.3 33.3 44.5 9.8  
Amount in Ca2+-free standard HBSS (pmol/well) 
Time (min) Lot=1 Lot=2 Lot=3 Mean S.E.M. 
23 7.3 9.7 4.5 7.2 2.6 
24.5 7.7 9.8 4.9 7.5 2.5 
26 6.6 8.4 6.0 7.0 1.2 
31 10.8 13.0 6.7 10.2 3.2 
































Figure 4.4. Observed TCA amount vs. time in rat SCH after 30-min pre-incubation with TGZ, 
provided by Yang et al. (Yang et al., J Pharmacol Exp Ther, 2015).  
  
Amount in Cells+Bile (pmol/well) 
Time (min) Lot=1 Lot=2 Lot=3 Mean S.E.M. 
2 6.6 3.3 3.3 4.4 1.9 
5 7.2 5.6 6.4 6.4 0.8 
10 10.9 7.1 7.6 8.5 2.1 
15 11.7 8.9 9.4 10.0 1.5 
20 15.0 10.1 11.9 12.3 2.5 
23 8.5 4.3 4.2 5.7 2.5 
24.5 4.1 3.6 4.2 4.0 0.3 
26 5.6 2.6 3.6 3.9 1.5 
31 4.0 1.5 2.0 2.5 1.3 
36 2.0 1.1 1.3 1.5 0.5 
Protein (mg/well) 1 0.73 0.8 0.8 
 
Vcell (µL/well) 7.6 5.5 6.1 6.4 
 
 
Amount in Cells (pmol/well) 
Time (min) Lot=1 Lot=2 Lot=3 mean SEM 
2 3.3 1.9 1.7 2.3 0.9 
5 2.9 1.4 2.9 2.4 0.9 
10 3.3 1.8 3.4 2.8 0.9 
15 4.5 3.0 3.7 3.7 0.8 
20 5.5 3.0 4.8 4.4 1.3 
23 1.0 0.6 0.7 0.8 0.2 
24.5 0.6 0.4 0.7 0.6 0.2 
26 0.9 0.2 0.4 0.5 0.4 
31 0.3 0.1 0.1 0.2 0.1 
36 0.2 0 0 0.1 0.1       
 
Amount in standard HBSS (pmol/well) 
Time (min) Lot=1 Lot=2 Lot=3 Mean S.E.M. 
23 5.0 3.5 3.5 4.0 0.9 
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24.5 6.7 4.4 4.7 5.3 1.3 
26 9.0 6.1 6.0 7.0 1.7 
31 11.3 6.5 6.7 8.2 2.7 
36 10.6 7.1 7.1 8.3 2.0       
 
Amount in Ca2+-free standard HBSS (pmol/well) 
Time (min) Lot=1 Lot=2 Lot=3 Mean S.E.M. 
23 3.1 2.0 2.4 2.5 0.6 
24.5 4.1 2.0 4.5 3.5 1.3 
26 4.8 3.0 4.0 3.9 0.9 
31 4.4 2.6 5.7 4.2 1.6 































Figure 4.7. Observed amount of TCA in different compartments generated by using the optimal 
study design.  
 
 
Amount in Cells+Bile (pmol/well) Amount in Cells (pmol/well) 
Time 
(min) 
Lot=1 Lot=2 Lot=3 
 
Lot=1 Lot=2 Lot=3 
20 127 170 98 
 
65 118 50 
25 48 97 58 
 
4.9 53 20 
30 26 50 33 
 
1.8 21 10 
32 20 37 26 
 
0.45 13 7.0 
34 15 27 20 
 
0.11 7.5 4.9 
36 12 20 16 
 
0.028 4.2 3.4 
38 9.4 15 12 
 
0.0076 2.4 2.4 
40 7.4 11 10 
 
0.0024 1.3 1.7 
48 2.8 4.0 3.6 
 
0.00059 0.14 0.44 
50 2.2 3.1 2.8 
 
0.00059 0.089 0.32 
Time 
(min) 
Amount in standard HBSS 
(pmol/well) 
Amount in Ca2+-free standard HBSS 
(pmol/well) 
32 3.0 6.5 3.6 
 
0.48 3.9 1.4 
34 7.4 16 9.3 
 
0.82 9.3 3.5 
36 11 23 14 
 
0.90 12 5.0 
38 13 28 17 
 
0.92 14 6.0 
40 15 32 20 
 
0.93 15 6.8 
48 20 39 26 
 
0.93 17 8.0 
50 20 40 27 
 









Figure 5.2. Observed amount of TCA in different matrices from three different SCHH donors. 
The protein content for HUM4119C, HUM4122C, and HC3-26 was 0.14, 0.173, and 0.185 mg 
protein/well, respectively.  
In control SCHH 
 
Amount in Cells+Bile (pmol/mg pro) 
Time (min) HUM4119C HUM4122C HC3-26 Mean S.D. 
2 11.5 9.37 14.4 11.8 2.5 
5 23 17.6 23.8 21.5 3.4 
10 40.7 27.5 47.3 38.5 10.1 
20 63.4 35.7 72.2 57.1 19.0 
23 48.7 28.8 55.7 44.4 14.0 
26 40.3 26.1 54.1 40.2 14.0 
31 35.1 18.7 45.1 33.0 13.3 
36 31 16.8 41.6 29.8 12.4 
 
Amount in Cells (pmol/mg pro) 
2 6.17 3.8 5.56 5.2 1.2 
5 9.34 5.72 8.67 7.9 1.9 
10 14.7 10.1 13.6 12.8 2.4 
20 25 15.8 22.9 21.2 4.8 
23 16.7 12 17.4 15.4 2.9 
26 14.2 11.2 15 13.5 2.0 
31 11.1 5.23 8.51 8.3 2.9 
36 7.74 3.73 4.92 5.5 2.1 
 
Amount in Standard HBSS (pmol/mg pro) 
23 8.97 6.42 6.2 7.2 1.5 
26 12.9 9.79 10.2 11.0 1.7 
31 15 11.9 13.9 13.6 1.6 
36 20.5 14.4 17.6 17.5 3.1 
 
Amount in Ca2+-free HBSS (pmol/mg pro) 
23 5.81 3.37 4.65 4.6 1.2 
26 9.74 6.92 10.1 8.9 1.7 
31 13.9 7.49 10.2 10.5 3.2 
226 
 
36 17.3 10.6 12.4 13.4 3.5 
In OCA-treated SCHH 
  Amount in Cells+Bile (pmol/mg pro) 
Time (min) HUM4119C HUM4122C HC3-26 Mean S.D. 
2 14.4 7.37 12.3 11.4 3.6 
5 23.1 11 19.4 17.8 6.2 
10 34.1 15.6 26.1 25.3 9.3 
20 45.6 26 39.3 37.0 10.0 
23 29.5 16.2 26.1 23.9 6.9 
26 28.1 21 27.8 25.6 4.0 
31 25.2 13 24.1 20.8 6.7 
36 19.2 9.24 18.2 15.5 5.5 
 
Amount in Cells (pmol/mg pro) 
2 11.5 5.31 6.78 7.86 3.2 
5 11.2 5.7 6.65 7.85 2.9 
10 11.3 5.82 6.68 7.93 2.9 
20 14.4 8.32 9.54 10.8 3.2 
23 5.08 2.7 2.71 3.5 1.4 
26 3.51 2.35 2.39 2.8 0.7 
31 1.95 1.19 1.14 1.4 0.5 
36 1.26 0.729 0.757 0.9 0.3 
 
Amount in Standard HBSS (pmol/mg pro) 
23 7.67 4.2 4.76 5.5 1.9 
26 10.7 6.69 10.3 9.2 2.2 
31 16.9 7.35 12.7 12.3 4.8 
36 18.7 9.77 14.9 14.5 4.5 
 
Amount in Ca2+-free HBSS (pmol/mg pro) 
23 4.99 2.81 3.58 3.8 1.1 
26 6.39 3.88 5.55 5.3 1.3 
31 9 4.73 6 6.6 2.2 
36 9.69 4.46 6.91 7.0 2.6 
227 
 
In CDCA-treated SCHH 
 
Amount in Cells+Bile (pmol/mg pro) 
Time (min) HUM4119C HUM4122C HC3-26 Mean S.D. 
2 7.01 3.0 5.56 5.19 2.0 
5 10.7 4.68 9.27 8.22 3.1 
10 15.1 5.87 15.5 12.2 5.4 
20 21.5 9.75 23.5 18.3 7.4 
23 12.5 6.50 15.9 11.6 4.8 
26 9.44 5.48 13.8 9.57 4.2 
31 8.46 3.67 9.61 7.25 3.2 
36 6.97 2.79 7.63 5.80 2.6 
 
Amount in Cells (pmol/mg pro) 
2 4.65 2.29 2.62 3.19 1.3 
5 6.06 2.82 3.65 4.18 1.7 
10 6.15 3.14 4.03 4.44 1.5 
20 8.51 4.36 5.65 6.17 2.1 
23 3.59 1.82 2.15 2.52 0.9 
26 2.23 1.69 1.57 1.83 0.4 
31 1.63 0.86 0.869 1.12 0.4 
36 0.89 1.2 0.644 0.91 0.3 
 
Amount in Standard HBSS (pmol/mg pro) 
23 4.24 2.04 4.39 3.56 1.3 
26 6.92 3.02 8.3 6.08 2.7 
31 9.74 3.92 10.3 7.99 3.5 
36 13.5 4.9 12 10.1 4.6 
 
Amount in Ca2+-free HBSS 
23 2.7 1.38 1.97 2.02 0.7 
26 4.6 2.02 2.86 3.16 1.3 
31 4.66 2.54 3.41 3.54 1.1 





Figure 5.3. Fold change in CLint,BL, CLint,Bile and CLUptake in OCA- and CDCA-treated SCHH 
compared to control. 
 Treatment HUM4119C HUM4122C HC3-26 
CLint,BL 
Control 1.2 1.0 0.77 
OCA 7.1 6.8 5.7 
CDCA 7.1 6.8 5.4 
CLint,Bile 
Control 1.0 1.0 0.91 
OCA 1.7 1.7 2.0 
CDCA 1.4 1.8 1.9 
CLUptake 
Control 1.2 0.73 1.0 
OCA 1.5 0.79 1.2 




































Figure 5.4. Effect of OCA and CDCA treatment of SCHH on the protein expression of OSTα, 
OSTβ, MRP3, MRP4, BSEP, and NTCP. The absolute quantity was normalized by the quantity 
of ATPase. 
OSTα (approximate M.W. 37 kD) 














Hu 8246 0.703 84 2.24 269 3.04 365 
HUM4122D 1.01 122 1.91 229 2.10 252 
HC3-26 0.783 94 2.44 293 2.08 250 
OSTβ (approximate M.W. 19kD) 














Hu 8246 1.46 80 19.4 1058 25.5 1392 
HUM4122D 1.83 100 17.7 967 18.9 1031 
HC3-26 2.20 120 25.5 1390 29.6 1617 
MRP3 (approximate M.W. 140kD) 














Hu 8246 1.57 104 1.63 108 1.96 130 
HUM4122D 0.92 61 1.48 98 1.43 95 
HC3-26 2.05 136 1.54 102 1.61 107 
MRP4 (approximate M.W. 150kD) 














Hu 8246 0.853 89 1.31 136 1.05 109 
HUM4122D 0.609 63 0.96 100 0.963 100 
HC3-26 1.42 148 0.95 99 0.937 98 
BSEP (approximate M.W. 146kD) 
















Hu 8246 0.186 35 0.393 74 0.46 87 
HUM4122D 0.563 107 0.88 167 0.575 109 
HC3-26 0.834 158 1.68 318 1.58 300 
NTCP (approximate M.W. 38kD) 














Hu 8246 0.204 94 0.268 123 0.240 111 
HUM4122D 0.172 79 0.232 107 0.259 119 
HC3-26 0.275 127 0.303 140 0.331 152 
 
 
